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Abstract 
 
Colorectal cancer (CRC), the second leading cause of cancer mortality in the UK, is 
on the rise. Cancer research often focuses on the molecular biology of a tumour, 
whereas the importance of the biology and condition of the tumour host - the 
patient - has been underappreciated. The aim of my thesis was to examine the 
assumption that a systemic (S) and local inflammatory response (IR) is related to the 
host Body Composition (BC) and also associated with clinical outcomes in patients 
treated for CRC. Chapter 4 concluded that specific BC profiles such, as the 
presence of myopenia was an independent predictor of poor survival. Chapter 5 
determined the role of the neutrophil to lymphocyte ratio as a prognostic marker 
for patients with CRC undergoing curative resection. Chapter 6 used CT image 
analysis to confirm a strong relationship between SIR and muscle depletion in 
patients with CRC. In Chapter 7, laparoscopy and moderate preoperative SIR 
favoured preservation and restoration of muscle mass, postoperatively in patients 
treated for CRC. In Chapter 8.1 through flow cytometry analysis, it was shown that, 
in a selected group of CRC patients when compared to healthy controls, the 
circulating DCs were more activated and potentially lymph node homing. Chapter 
8.2 built on this knowledge and confirmed associations between the DC phenotype 
and the disease and host’s BC characteristics. Chapter 9 examined the relationship 
of local IR with BC and its prognostic utility for CRC outcomes. Results suggested 
that CCR7 positive cell density at the tumor margin might be a novel prognostic 
biomarker to predict outcomes in patients with CRC. Overall this thesis highlights 
the importance of determining the BC profile and the IR of patients undergoing CRC 
treatment and this may lead to early identification of high-risk patients, allowing early 
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optimisation and ultimately improving their outcomes.   
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Chapter 1 
1! Introduction 
1.1! Colorectal Cancer 
1.1.1! Epidemiology of Colorectal Cancer 
 
The project Global Cancer Control (GLOBOCAN) published in 2012 is the most 
recent report with regards cancer incidence and mortality worldwide (Ferlay et al., 
2015).  According to this report, there were 14.1 million new cases and 8.2 million 
deaths from cancer in 2012. Cancer now causes more deaths than all stroke or 
ischaemic heart disease according to the World Health Organization (WHO.) 
(WHO., 2012) 
Colorectal cancer (CRC) is the third most common cancer in the world with over 
1.36 million new cases in 2012; with the 55% of the new cases seen in Australasia, 
Western Europe and North America. The African nations have the lowest incidence 
although countries with a rapid “westernization” of diet and lifestyle have seen a 
substantial increase in the number of new cases of CRC. Worldwide, CRC accounts 
for more than 650,000 deaths (8.5 % of the total) each year, making it the fourth 
commonest cause of cancer death. More deaths (52% of the annual due to CRC) are 
seen in the less developed regions of the world, reflecting a poorer prognosis in 
these regions. 
In the United Kingdom (UK), CRC is the fourth most common cancer: third most 
common cancer in men after prostate and lung cancer, third most common cancer 
in women after breast and lung. Around 42,000 people are diagnosed with CRC 
every year. The incidence rates in the UK are estimated to be the 20th (males) and 
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17th (females) highest in the Europe (CRUK, 2011). Between 1971 and 2010, 
incidence rates of bowel cancer increased by 36% for men and 15% for women. For 
men, this increase was more marked during the 1970s and 1980s. For women, there 
has been a gradual overall increase since 1971(Coleman et al., 2004). 
Each year the disease accounts for over 16,200 deaths making CRC the second most 
common cause of cancer death in the UK (CRUK, 2011). Despite the increasing 
incidence of CRC, mortality from colorectal cancer has fallen across all age groups 
since the 1970‟s. Between 1971 and 2010, it decreased by 38% for men and 51% for 
women. Five-year survival estimates for those diagnosed with colon cancer in 
1971−1975 and followed up to 1995 were 26% for men and 25% for women. 
Survival estimates for the same period for those diagnosed with rectal cancer were 
27% for males and 29% for women (Coleman et al., 2004). The corresponding 
figures for those diagnosed with colon cancer in 2006−2010 and followed up to 2011 
were 55% for men and 56% for women, and 55% for men and 58% for women 
diagnosed with rectal cancer (Quaresma, Coleman, & Rachet, 2015). In 2006 the 
National Health Service introduced a new screening programme for the early 
detection of CRC and this has to be taken into account alongside the new diagnostic 
and therapeutics developments for cancer when trying to explain the epidemiological 
changes.  
 
1.1.2! Molecular Pathogenesis of CRC 
 
CRC is a diverse disease, which can develop from different pathological precursors. 
CRCs develop from apparently normal mucosa into a premalignant state (polyp) and 
 26 
from there they can progress to a malignant state.  There are at least three major 
molecular pathways driving this process; (1) the chromosomal instability (CIN) or 
suppressor pathway, (2) the microsatellite instability (MSI) or mutator pathway and 
the (3) methylator (CIMP+) pathway. Each of these pathways is characterized by 
genomic instability, distinct molecular signatures and involves different mechanisms 
of carcinogenesis (Worthley, Whitehall, Spring, & Leggett, 2007). 
1.1.2.1! Chromosomal instability 
 
Vogelstein et al in 1988 were amongst the first to describe a series of key molecular 
events that occur in the progression for adenoma to adenocarcinoma (Vogelstein et 
al., 1988). This “adenoma –carcinoma” sequence model is associated with the most 
common category of genomic instability the CIN (accumulation of numerical or 
structural chromosomal abnormalities-aneuploidy), activation of oncogenes such as 
the adenomatous polyposis gene (APC) and the k-Ras and mutation of the tumour 
suppressor gene p53 (Grady, 2004). Among the earliest events in this pathway are 
deletions of the adenomatous polyposis coli (APC) gene. Germline mutation on one 
of the APC allele genes is present in patients with Familial Polyposis Syndrome 
(FAP).  The frequency of APC mutation in early adenomas is up to 80% and it is 
present in 60% of the colon and 82% of the rectal cancers (Jass, Whitehall, Young, & 
Leggett, 2002). K-ras mutations are present in up to 40% of the CRC and result in 
further growth and progression of the adenoma (Leslie, Carey, Pratt, & Steele, 
2002). Loss of the tumour suppressor gene p53 is often part of the final transition to 
adenocarcinoma and invasive disease. It is now accepted that a small minority of 
CRCs carries all the molecular abnormalities of the CIN pathway. This original 
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model may be too simplistic and recent evidence suggests that several steps can be 
overruled by other genetic events (Staton et al., 2007).  
1.1.2.2! The microsatellite instability pathway  
 
Microsatellites are repetitive sequences of DNA distributed throughout the human 
genome and their transcribed proteins have a vital role in reviewing and repairing 
DNA following replication. MSI is the other important form of genomic instability 
and is associated with defective DNA mismatch repair machinery. MSI is observed in 
the majority of Hereditary Non-polyposis Colon Cancer (German et al.) tumours 
and is also present in up to 10-20% of sporadic colorectal cancers (German et al., 
2006; Poynter et al., 2008). The phenotypic characteristics of CRC with MSI have 
been widely studied and include mucinous or poor differentiation, prominent host 
immune response, a circumscribed growth pattern, histologic heterogeneity, and 
right-sided location (Poynter et al., 2008). The clinical implications of determining the 
MSI status of colorectal cancer are described in more detail below. 
1.1.2.3!  CpG island methylator phenotype (CIMP+) pathway 
 
More recently epigenetic factors have been implicated as a third carcinogenic 
pathway. DNA methylation is observed throughout the genome and more 
specifically when cytosine and guanosine are seen in pair (CpG). CpG islands can be 
found within the promoter of many strategic genes and in cancer the promoter 
sequence methylation can lead into silencing of the gene transcription. A subset of 
colorectal tumours exhibit hypermethylation and are referred to as CpG island 
methylator phenotype (CIMP+) lesions (J. P. Issa, 2004) .  
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CIMP+ colorectal tumours display certain clinicopathological features, including 
proximal tumour location, poor differentiation, high frequency of BRAF mutations 
and lack of p53 or APC mutations, seen in the CIN tumours (van Rijnsoever, Grieu, 
Elsaleh, Joseph, & Iacopetta, 2002; Weisenberger et al., 2006).   
1.1.3! Aetiology and Risk Factors 
 
Colorectal cancer is a multifactorial disease. Genetic variations, environmental 
exposures, diet and inflammatory conditions of digestive tract are all involved in the 
development of CRC. About 75% of the cases are sporadic CRC with no clear 
evidence of an inherited disorder. The remaining 25 % of the patients with CRC have 
a family history of CRC that suggests a heritable component, common exposures in 
the family or a combination of both. However an inherited genetic aberration 
accounts for only less that 5% of all CRC patients. (Brenner, Kloor, & Pox, 2014) 
 
 
Figure 1-1 Colorectal cancer cases arising in various family risk settings  
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Demographic, behavioral and environment factors have been associated with 
increased risk of sporadic CRC but very few have been confirmed as causative. 
Numerous epidemiological studies from around the world show geographical 
variation with significantly higher risk in affluent societies and prospective cohort 
data have linked certain dietary habits and western lifestyle factors to CRC. Several 
other host and environmental elements have been considered and investigated as 
risk and preventive factors but still no clear associations with the incidence of CRC 
have been found. (Johnson et al., 2013) 
The factors described below are those that have been commonly linked with an 
increased risk of CRC. 
 
1.1.3.1! General factors 
 
1.1.3.1.1! Age 
 
For the great majority of people, the main factor that increases a person’s risk for 
CRC is increasing age. Risk increases dramatically after age 50 years; nearly 90% of 
all CRCs are diagnosed after this age (CRUK, 2011). With increasing age the 
possibility of an exposure to other risk factors or the possibility of chromosomal 
anomalies to happen are increased. At the ends of the chromosomes are areas of 
DNA called telomeres, which protect the genetic data. Each time a cell divides, the 
telomeres get shorter and thus with age they get too “short” so the cell can no 
longer divide; it becomes inactive or it dies. However in cancer; the cancerous cells 
escape death by making more telomerase enzyme, which prevents the telomeres 
from reducing in length (Hoeijmakers, De Leeuw, Kenis, & De Vries, 2007).  
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1.1.3.1.2! Race 
 
Several studies especially from the United States have showed an association 
between race and CRC incidence.  Data form the Surveillance Epidemiology End 
Results (SEER) Program of the National Cancer Institute demonstrated that the 
incidence of colorectal cancer in Caucasian men and women is considerably low 
compared to African Americans. The reasons for this association are not completely 
clear, as genetic and social economic reasons such as access to diagnosis and 
treatment have been implied.  
1.1.3.1.3! Gender 
 
The role of gender in the development of CRC remains unclear. In a study by Wei et 
al using data from 2 prospective cohort databases from the United States the 
incidence of CRC in men and women was reported as equal (Wei et al., 2004). 
However results from the GLOBOCAN report in 2012 suggested that the incidence 
and mortality of colorectal cancer in populations over 65 years old are higher in 
women than those in men (Ferlay et al., 2015). Explanations for the increased 
incidence and also the worse survival rate of CRC among older women have been 
based on the fact that a higher proportion of right-sided colon cancer is reported 
than in men (Hansen & Jess, 2012).  Differences between right- and left-sided colon 
cancers are possibly due to variances in genetic nature, life style, and/or dietary 
patterns. MSI-high, CIMP-high, and BRAF mutation are often observed in right-sided 
colon cancer with poorer outcomes compared to the left CRCs (Lee et al., 2015). 
Estrogen exposure is a protective factor against MSI, while the lack of estrogen in 
older women increased the risk of MSI-high colon cancer according to a study case-
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control study examining sex, reproductive factors, and hormone exposure related 
with MSI in colon cancer (Slattery et al., 2001).  
 
1.1.3.2! Lifestyle factors 
 
As discussed in paragraph 1.1.1 over 50 % of the new cases of CRC each year are 
found in Western countries and also countries with rapid westernization of their 
societies and lifestyle such as Japan have seen a substantial increase in CRC 
incidence.  Migrant studies have indicated that the disease of CRC is particularly 
sensitive to changes in the lifestyle and this has led to the consideration of the 
western lifestyle as a risk factor for CRC. Incidence rates reach those of the host 
country within one or two generations, and even within the migrating generation 
(Potter, Slattery, Bostick, & Gapstur, 1993). Several studies have tried to identify 
different components of a Western lifestyle as risk factors of CRC but still an 
intergrated picture is still missing.  
1.1.3.2.1! Diet 
 
The role of diet as a risk factor for colorectal cancer has been widely explored. 
Burkitt based on the infrequency of CRC in Africa several decades ago suggested 
that the high-fiber diet of Africans was protective against CRC (Burkitt, 1971). Since 
then dietary fiber has been hypothesized to prevent CRC by diluting or adsorbing 
fecal carcinogens, reducing colonic transit time, altering bile acid metabolism, 
reducing colonic pH, or increasing the production of short-chain fatty acids 
(Kritchevsky, 1995). This belief has been tested by several large prospective studies 
with contradictory results (Aune et al., 2011). Recent metanalysis from Johnson et al 
concluded that increased consumption of fruit and vegetables significantly decreases 
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CRC risk whereas a trend of greater risk was found with increased intake of 
processed meat servings.  Also a significant positive correlation between red meat 
consumption and CRC was reported. (Johnson et al., 2013) 
1.1.3.2.2! Inactive lifestyle  
 
CRC has been one of the most studied cancers in relation to physical activity. The 
majority of the studies concluded that individuals who have increased physical 
activity either on duration, frequency or intensity can reduce the colon cancer risk 
development by 30 to 40 per cent regardless of the body mass index (BMI) (Wolin 
et al., 2007). It is not yet clear whether there is an impact of physical activity on the 
development of rectal cancer, adenomas or polyp recurrence. Physical exercise may 
protect against colon cancer and tumour development through its role in energy 
balance, hormone metabolism, insulin regulation and the maintenance of a healthy 
body composition (BC). Also physical activity has been associated with a number of 
inflammatory and immune factors that may influence colon cancer risk. (Samad, 
Taylor, Marshall, & Chapman, 2005) 
1.1.3.2.3! Smoking 
 
Cigarette smoking is associated with an increased risk of a number of malignancies 
including lung, stomach, kidney, bladder and pancreas. Cigarette smoke contains 
various carcinogens, which can cause DNA changes that can cause permanent 
destruction to colorectal mucosa (Hoffmann, Djordjevic, & Hoffmann, 1997; K. 
Huang et al., 2006). The mucosa of the digestive track is exposed to these 
carcinogens through the circulation or direct luminal contact after ingestion of saliva 
(Luchtenborg, White, Wilkens, Kolonel, & Le Marchand, 2007). In the majority of 
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the epidemiologic studies, active smoking has been consistently related to an 
increased risk of colorectal adenomas, and the relationship between smoking and an 
increased risk of CRC is reported consistently (Johnson et al., 2013). 
1.1.3.2.4! Alcohol  
 
Alcohol consumption is one of the most important and known risk factors for 
human cancers. Acetaldehyde and free radicals, the main products of alcohol 
metabolism, are carcinogenic and mutagenic as they bind to DNA and proteins, 
destruct folate and can cause secondary hyper proliferation. Recent metanalysis from 
Fedirko et al concluded that alcohol consumption is associated with an increase in 
risk for CRC for intakes of >1 drink/day (Fedirko et al., 2011).  
 
1.1.3.3! Genetics 
 
1.1.3.3.1! Family history of CRC  
 
It is estimated that 30% of CRC risk may be explained by heritable factors 
(Lichtenstein et al., 2000). These CRC cases include well-characterized genetic 
syndromes characterized by a Mendelian manner of progression but also CRC cases 
with a strong family history but without the presence of any identifiable genetic 
syndromes. Recent advances using genome-wide association study (GWAS) have 
facilitated the identification of multiple CRC related single nucleotide polymorphisms 
(SNPs). These genetic variants are believed to be strongly associated with the 
increase risk of CRC in individuals with strong family history. (K. Zhang, Civan, 
Mukherjee, Patel, & Yang, 2014)  
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1.1.3.3.2! Inherited syndromes 
 
Hereditary forms of CRC are highly valued models for the study of the pathogenesis 
and progression of CRC. In these forms important genes such as the APC or the 
DNA repair genes are inactivated by a monoallelic first hit in the germ line and a 
somatic second hit and lead to the tumour development. The two most common 
forms of hereditary CRC are the HNPCC or Lynch syndrome (estimate alle 
frequency 1:350 to 1:1700) and the FAP (estimated allele frequency 1:10000). 
(Jasperson, Tuohy, Neklason, & Burt, 2010)  
1.1.3.4! Obesity and insulin resistance 
 
It has been suggested that around 20% of all cancers are caused by excess weight 
(Wolin, Carson, & Colditz, 2010). Reports for the International Agency for Research 
into Cancer (IARC) and the World Cancer Research Fund (WRCF) indicated that 
common cancers in obese people are predominantly endometrial, esophageal 
adenocarcinoma, colorectal, postmenopausal breast, prostate, and renal (De Pergola 
& Silvestris, 2013). In 2013, a meta-analysis from Bardou et al estimated that he 
incidence of colon cancer, rectal cancer and CRC was significantly greater in men 
with obesity, with Relative Risk varying from 1.24 to 1.71 for colon cancer, from 
1.09 to 1.75 for rectal cancer, and from 1.37 to 1.95 for CRC.  The association 
between CRC in women was weaker and this difference might be explained partly by 
a protective effect of estrogen (reduced apoptosis and inhibition of cell proliferation) 
or by the variability in prevalence and age of onset of metabolic syndrome. (MS). 
Limited data also suggest that weight loss may be associated with reduced CRC risk. 
(Bardou, Barkun, & Martel, 2013)  
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Obesity is a remarkably heterogenous condition and in this regard body fat 
distribution was also found to play a role in CRC development. There appeared to 
be a dose-response relationship with central obesity in particular, which increases 
the risk of CRC (Oh et al., 2008). This association with active visceral fat, a 
surrogate marker for metabolic syndrome (MS) (syndrome characterized from 
insulin resistance with increase fasting glucose and proinflammatory changes and 
predisposition to type 2 diabetes and dyslipidaemia) may give insight into the 
mechanisms through which excess weight can increase cancer risk (Ahmed, Schmitz, 
Anderson, Rosamond, & Folsom, 2006). Not only have studies recognised close 
relationships between glucose levels and malignancy, experimental work has also 
demonstrated that insulin and insulin-like growth factor (IGF-1) can stimulate the 
proliferation of both normal colonic mucosal cells and carcinoma cell lines (Limburg 
et al., 2005).  
The burden of obesity on society continues to increase and warrants closer 
attention by clinicians for both cancer prevention and improved outcomes after 
diagnosis. Also what is not yet known if other BC profiles such as myopenia or 
myopenic obesity have an impact on CRC incidence.  
1.1.3.5! Other factors  
 
1.1.3.5.1! Non-steroidal anti-inflammatory drugs 
 
Screening can reduce the risk of CRC and recommendations for screening have been 
issued by several major medical organizations. It has also been proposed that a 
chemoprevention strategy may complement a CRC screening policy. Studies have 
suggested that there is an upregulation of cyclooxygenase (COX)-2 in CRC. In line 
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with this, the possible benefit of agents that may impede this upregulation has been 
proposed and in particular, as supported by observational studies suggesting a lower 
incidence of CRC in patients taking either selective COX-2 inhibitors or 
nonselective COX inhibitors (eg, aspirin). The evidence is diverse and is based upon 
animal models, epidemiologic data, intervention trials of NSAIDs in patients with 
FAP, and, more recently, randomized controlled trials of aspirin and selective COX-
2 inhibitors in humans. Rothwell et al followed up four randomised trials of aspirin 
versus control in primary and secondary prevention of vascular events and one trial 
of different doses of aspirin and reported that aspirin taken for several years at 
doses of at least 75 mg daily reduced CRC long-term incidence (Rothwell et al., 
2010). Despite this evidence the cardiovascular and gastrointestinal harms outweigh 
the benefits of aspirin and NSAID use for the prevention of colorectal cancer 
(Andersohn, Suissa, & Garbe, 2006).  
The exact mechanism of action of aspirin for chemoprevention in both hereditary 
and sporadic CRC is yet to be fully determined. It is now recognized that this class 
of drugs reduces the synthesis of prostaglandins through inhibition of COX enzymes, 
which are also implicated in carcinogenesis (Wu, Gu, Ji, Li, & Xu, 2003). An 
additional explanation is that NSAIDs can potentially moderate the local and 
systemic responses of the immune system (see paragraph 1.3.3.2 also), associated 
with the development and progression of CRC (Erlinger, Platz, Rifai, & Helzlsouer, 
2004) 
1.1.3.5.2! Statins 
 
Because of their pleiotropic effects, statins might have an effect on CRC risk and play 
a role in cancer chemoprevention. Statins are a class of drug, which inhibit HMG-
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CoA reductase, an enzyme important in the synthesis of cholesterol, and were 
originally used as lipid-moderating agents. HMG-CoA is over-expressed in CRC cell 
lines and its inhibition prevents the synthesis of mevalonic acid a important molecule 
for a number of processes including inflammation, cellular proliferation and 
angiogenesis (Hentosh, Yuh, Elson, & Peffley, 2001; Rao, Newmark, & Reddy, 2002). 
Different epidemiological studies have examined the effect of statins on CRC risk, 
with often inconsistent results ranging from very protective (47% risk reduction) to 
moderately harmful (7% risk increase). Recent metanalysis of 40 studies, involving 
more than eight million subjects concluded that a modest (on the order of 10% risk 
reduction) protective effect of statin use at therapeutic doses against CRC cannot be 
excluded (Lytras, Nikolopoulos, & Bonovas, 2014).  
1.1.3.5.3! Inflammatory response 
 
Bacterial and viral infections and various chemical agents naturally cause a self-
limiting acute inflammatory response that usually results in clearance of the 
pathogens. Sometimes inflammatory agents will elicit a prolonged low-grade immune 
response that does not lead to elimination of the pathogens, but to a state of 
continuous, unresolved, low-grade inflammation (Mantovani, Allavena, Sica, & 
Balkwill, 2008). This state of chronic inflammation may predispose to a diversity of 
diseases, including cardiovascular disease, diabetes mellitus, chronic asthma and 
rheumatoid arthritis. Rudolf Virchow first described the link between cancer and 
inflammation, suggesting that the ‘lymphoreticular infiltrate’ at sites of chronic 
inflammation reflected the origin of cancer (F. Balkwill & Mantovani, 2001). 
Systemic inflammatory response (SIR) is often present in patients with cancer 
(Tsilidis et al., 2008). The risk of CRC development is higher in individuals with low 
 38 
grade SIR measured mainly as elevated plasma C-reactive protein. Erlinger et al for 
example suggested that plasma CRP levels were consistently elevated among people 
who subsequently developed colon cancer (Erlinger et al., 2004).  Allin at al stated 
that the association between circulating levels of CRP and cancer risk may be due to 
(1) causality: elevated CRP levels cause cancer, (2) reverse causality: occult cancer 
increases CRP levels, (3) or confounding: a third factor, e.g. inflammation, obesity 
increasing both CRP levels and the risk of cancer (Allin & Nordestgaard, 2011). To 
examine further the causal role of SIR in the pathogenesis of cancer, genetic 
epidemiologic studies (Mendelian randomization studies) were also seen in the 
literature with conflicting results (Allin, Nordestgaard, Zacho, Tybjaerg-Hansen, & 
Bojesen, 2010; Siemes et al., 2006).   
1.1.3.5.4! History of inflammatory bowel disease (IBD) 
 
Association between inflammatory bowel disease (IBD) and CRC has been well 
established. It was estimated that there was 2.4-fold increase in CRC in both 
ulcerative colitis (UC) and Crohn’s disease. However, more recent reports have 
demonstrated declining incidence of CRC in IBD patients, most likely due to 
improved surveillance mechanisms and medical treatment. (Choi et al., 2015; Jess, 
Rungoe, & Peyrin-Biroulet, 2012; von Roon et al., 2007).  
1.1.3.6! Summary-Aetiology of colorectal cancer 
 
Several environmental and host factors have been identified as risk factors for the 
development of CRC. Environmental factors are associated mainly with a 
westernized lifestyle and include diets high in red and processed meat, low in fibre 
fruits and vegetables, increase consumption of alcohol and smoking. Host factors 
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include mainly genetic alterations that predispose to CRC but also the presence of 
certain body habitus profiles such as central obesity, age and comorbidity status (eg 
metabolic syndrome). Of interest is that SIR has been linked with some of these host 
/ environmental factors and more specifically emerging evidence suggest that SIR 
associates with the BC of the patient and also with cancer prognosis. The 
observation that SIR is linked with patients BC and the disease outcome may 
suggests that these factors may modulate the development and progression of CRC 
through a common pathway.  (The study of these associations will be discussed later 
on in detail).    
 
1.1.4! Management Principles of Colorectal cancer 
 
1.1.4.1! General Considerations 
 
Carcinoma of the right colon is more common in women and carcinoma of the 
rectum is more common in men. Around 25 % of the CRC cases are located in the 
right colon whereas 65% are located after the splenic flexure i.e 15% in the left colon 
and 50% in the rectosigmoid. An apparent proximal shift of the distribution of CRC 
(increased incidence in the right colon compared to the rectal cases) in recent 
decades is at partially explained by improved diagnostic modalities such as the 
colonoscopy. Multiple synchronous colonic tumours are found in 5% of the patients 
and the risk of metachronous CRC is up to 5-10%.  Over 90% of CRC cases are 
classified as adenocarcinomas, originating from the colorectal mucosa. More rare 
types of CRC include neuroendocrine, squamous cell, adenosquamous, spindle cell 
and undifferentiated carcinoma. 
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1.1.4.2! Presentation 
 
The site of the tumour within the bowel determines clinical presentation of CRC. 
Transient changes in bowel habits are common as a result of gastrointestinal 
infections or functional bowel diseases however persistence of bowel symptoms for 
more than 6 weeks especially in elderly individuals are of concern. Cancers located 
in the left side of the colon and rectum present with change in bowel habits and / or 
bleeding whereas right sided colon cancers can cause anaemia and small bowel 
obstruction.  The presence of metastatic disease is usually accompanied by anorexia 
weight loss and general malaise.  
 
1.1.4.3! Diagnosis 
 
The majority of the CRC cases are detected through outpatient investigations but as 
many as 25% are diagnosed as emergencies with bowel obstruction or perforation 
being common issues. Adenocarcinoma of the colorectum has a median doubling 
time of 130 days suggesting a long silent period of around 5 to 10 years before the 
tumour becomes clinically bothersome. The value of routine screening of 
asymptomatic population who lack high risk factors for the development of CRC has 
been established. The UK national bowel-screening programme was introduced as a 
phased programmed in 2006. A faecal occult blood-screening test was offered to 
people between 60 to 69 years old and the programme aims to reduce mortality 
from colorectal cancer by 16% in those invited for screening. Uptake of the 
programme ranged between 55-60% across England and analysis of the first million 
cases showed that the proportion of the screen detected cancers found in the right 
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colon was lower than expected and that early cancer was found in 70% of those with 
CRC (Logan et al., 2012). This suggests that the screening programme will identify 
early-stage neoplasia.  
Diagnostic work up and choice of investigations will depend on the type of 
presentation. Guidelines to CRC management published by National Institute for 
Health and Care Excellence suggests using multiple modes of diagnostic investigation 
depending on patient comorbidities. Gold standard investigation is colonoscopy to 
achieve direct visualization of the mucosa and tissue biopsy to obtain histological 
proof of cancer. However, due to associated patient comorbidities, limited 
endoscopy resources coupled with increased complication of colonoscopy other 
investigations such as flexible sigmoidoscopy, double-contrast barium enema and CT 
colonography are indicated. 
1.1.4.4! Preoperative Staging of CRC 
 
Accurate preoperative staging of the disease is essential in determining the optimum 
management plan and in providing prognostic information of CRC. Cancer of the 
colon and rectum spreads in three main ways. CRC can spread through direct 
extension where the lesion grows circumferentially with penetration of the outer 
layers of the bowel wall and it may also extend by contiguity into neighboring 
structures. Angiolymphatic invasion is another way of spread that may allow tumour 
cells to be carried via the venous system and establish distant metastases mainly to 
the liver and/or the lungs. Regional lymph node metastasis is the most common form 
of tumour spread. Longitudinal spread via extramural lymphatics is an important 
mechanism. The lymphatic drainage of the tumour must be considered and removed 
in curative operations and the presence of lymphatic involvement in CRC specimens 
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makes the patient eligible for additional systemic treatments such as adjuvant 
chemotherapy.  
Assessment for local invasion in colon cancer cases is obtained by computed 
tomography scan (CT) and this radiological test can provide information on invasion 
of adjacent structures such as ureter or duodenum, which can assist surgical 
planning. In the rectum this information is particularly important where proximity of 
tumour to the circumferential margin of resection can determine the need of 
neoadjuvant treatment. Magnetic Resonance Imaging and / or endoluminal ultrasound 
are preferably used in rectal lesion to clearly define the bowel wall layers and the 
surrounding mesorectal fat and fascia. CT scan of the abdomen and chest offers the 
most accurate and convenient mean to assess metastatic disease.  
 
1.1.4.5! Management of early CRC 
 
Early CRC is defined as invasive adenocarcinoma spreading into but not beyond the 
submucosa layers, that being a T1 tumour in the tumour node metastasis (TNM) 
classification. These lesions have smaller chance to metastasize to lymph nodes 
because of the paucity of lymphatics within the colorectal mucosa (Logan et al., 
2012). The management of these lesion aims to offer cure while minimizing the 
morbidity and mortality of the treatment. Endoscopic removal of such lesions is 
often adequate and this should be balanced against the risk of a surgical resection. 
Transanal excision or transanal endoscopic microsurgery (TEMS) is necessary for 
larger rectal tumours whereas new full thickness local excisions of colonic lesions 
are being developed (Tytherleigh, Warren, & Mortensen, 2008). 
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1.1.4.6! Management of advanced CRC 
 
The majority of the CRC lesions are managed surgically. Treatment consists of wide 
surgical resection of the lesion and its regional lymphatic drainage while preserving 
anatomical planes around the mesentery. The extent of resection is determined by 
the distribution of the regional lymph nodes along with the blood supply. The main 
arterial and venous vessels are identified and divided whereas the bowel is resected 
at appropriate points to achieve an adequate clear margin around the cancer and 
leave well vascularized healthy bowel ends to rejoined. The subsequent anastomosis 
is critical and problems with healing lead to an “anastomotic leak”. This 
postoperative complication may lead to a reoperation with high morbidity and 
mortality risks. Segmental colonic resections are usually described according to the 
involved segment: right hemicolectomy, left hemicolectomy, sigmoid colectomy. For 
the rectal cancers the choice of the operation depends mainly on the height of the 
lesion above the anal verge, the extent of the tumour and the patient’s body habitus 
and general condition. Preservation of the anal sphincter and avoidance of a stoma 
creation are desirable if possible. When adequate distal margins for low resection of 
rectal tumours cannot be achieved (anterior resection) a sphincter–sparing approach 
is obviated and an abdominoperineal resection is performed. Laparoscopic surgery 
has increasingly become an alternative to traditional open surgery. Laparoscopy is 
equal to open in oncological outcomes for CRC but also benefits from improved 
cosmesis, decreased LOS ad postoperative narcotic analgesia use and quicker return 
to bowel function (Kennedy et al., 2014).  
1.1.4.7! Management of metastatic disease 
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Greatest challenge for clinicians is the management of patients who present with 
advanced stage of CRC. Around 25% of patients with bowel cancer present with 
metastatic disease, most commonly affecting the liver and the treatment is aimed at 
optimizing palliation.  Careful initial assessment is required to determine whether the 
primary and metastatic tumours are considered resectable, and this process requires 
input from multidisciplinary teams (MDT) involving radiologists, surgeons, oncologist 
and palliative services.  Surgical resection can provide palliative effective treatment 
for bowel symptoms arising from bleeding or obstruction; if patients are unfit for 
surgery endoluminal stenting can be recommended. Localized metastatic lesions 
from primary CRC may be amenable to potentially curative treatment. 
1.1.4.8! Non-surgical treatment of CRC 
 
Chemotherapy and radiotherapy have key roles in the treatment of CRC. They can 
be considered in three forms: adjuvant, neoadjuvant and palliative. 
Adjuvant chemotherapy (AC) is recommended for all patients with stage III colon 
cancer after curative resection. High-risk patients with node-negative disease (stage 
II) colon cancer may have improved outcomes from the receipt of AC (Brenner et 
al., 2014). With regard to the rectal cancer patients with stage II and II uncertainty 
remains around the benefits of such chemotherapy for patients with stage II and III, 
especially if they have received neoadjuvant treatment. Despite the uncertainty 
patients with high-risk stage II and III rectal cancer are offered adjuvant 
chemotherapy to reduce the risk of systemic recurrence (Bosset et al., 2006). 
Potential benefits of adjuvant chemotherapy must be always balanced against the risk 
of side effects and treatment toxicity. Risk stratification models are needed to guide 
clinicians in prescription of adjuvant chemotherapy and the role of SIR and other 
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host factors such as the body profile needs to be considered. Question arises to 
what the best combination of chemotherapeutic agent is for Stage III CRC, and 
whether adjuvant chemotherapy has a role in Stage II CRC. Current UK guidelines 
recommend the use of either capecitabine as monotherapy or oxaliplatin in 
combination with 5-fluorouracil and folinic acid for Stage III CRC (Poston et al., 
2011). The choice of chemotherapeutic agent is tailored to patient factors after 
MDT discussions. 
Neoadjuvant therapy implies the initiation of chemo/radiotherapy before definitive 
management of CRC. The aim of the neoadjuvant treatment with chemo-
radiotherapy is to improve local control of resectable rectal cancer. Radiotherapy 
can reduce tumour bulk and therefore optimising the likelihood of margin free 
resection and reducing local recurrence.  This effect is further optimised with the 
addition of pre-operative chemotherapy. It is usually employed in cases of rectal 
cancer where preoperative staging suggests the involvement or threatening of the 
circumferential margin of the mesorectum. A complete pathological response with 
no cancer present in the resected specimen is seen in 10-15% of the patients (Wong, 
Tandan, De Silva, & Figueredo, 2007). Neoadjuvant chemotherapy is also used in the 
treatment of CRC cases with liver metastases aiming to reduce the size of the liver 
lesion to improve the likelihood of a successful resection.   
Palliative therapy is offered to patients with metastatic disease not suitable for 
surgical resection. Chemotherapy drugs mainly in the form of 5-FU are available, 
with the primary aim at this point to achieve control of progressive disease. Newer 
biological agents such as vascular endothelial growth factor inhibiter (bevacizumab), 
anti-epidermal growth factor receptor (cetuximab) and kinase inhibitor (regorafenib) 
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have demonstrated some benefit, in selected groups of patients (for example, anti-
EGFR agents are only used for tumours without KRAS mutation) (Arnold & 
Seufferlein, 2010). The most remarkable result so far is from cetuximab in 
combination with conventional chemotherapy, which demonstrated significant 
increase in overall survival rate in advanced stage CRC (Ye et al., 2013). 
 
1.1.4.9! Prognosis in Colorectal Cancer 
 
The prognosis of patients with CRC has progressively improved over the last 
decades. In the western world approximately 65% will still be alive 5-years after the 
CRC diagnosis but the percentage is less than 50% in less developed countries 
(Siegel et al., 2012). Following diagnosis and treatment, it is increasingly 
acknowledged that disease recurrence, progression and survival in CRC is 
determined by a variety of factors including tumour and host characteristics. Tumor 
factors include pathological stage and characteristics, molecular markers and genetic 
alterations whereas host factors include age, comorbidity, inflammatory response, 
and BC profile Prognostic tools are important in determining appropriate treatment 
as well as standardizing patients for research and audit. For these reasons, more 
accurate tools need to be developed that take into consideration both the tumour 
but also the host characteristics.  
The most well known prognostic factors are discussed below  
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1.1.5! Tumour Factors and colorectal cancer prognosis 
 
1.1.5.1! Pathological stage 
 
In 1932, Sir Cuthbert Dukes at St Mark’s Hospital first developed a staging system 
for rectal cancer, where he correlated outcome depending on the invasion of the 
tumour through bowel wall and involvement of the lymph nodes (Dukes, 1932). 
Tumours were categorized as those not penetrating the bowel wall without the 
presence of lymph node metastases [A], tumours though the bowel wall without 
lymph node metastases [B] and the presence of lymph node metastases [C]. In 1967, 
Dukes stage D was introduced to describe the presence of distant metastasis 
(Turnbull, Kyle, Watson, & Spratt, 1967). Despite undergoing several modifications, 
including the modified Astler-Coller classification (Astler & Coller, 1954), Dukes 
classification has been criticized for its lack of accuracy in predicting survival and 
need for more detailed and comprehensive staging system on a par with evolving 
cancer management, hence leading to the development of the TNM staging. 
The TNM system was first described in 1968 and initially included separated staging 
systems for colon and rectal cancers (Wood, 1970). The TNM system, which 
integrates the tumour size and invasion (T), lymph node involvement (N) and cancer 
metastasis (M) employed widely in 1977 by the International Union against Cancer 
(UICC) including a pre- and post-treatment stage. The main objectives of the TNM 
staging approach are to aid treatment planning, assess the effect of the treatment, 
indicate likely diagnosis and facilitate the standardization between the cancer centers. 
Although the TNM is revised regularly in order to incorporate new data and 
developments the Royal College of Pathologists currently recommends the 5th 
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edition of the TNM stage due to the controversy of the changes introduced 
(Loughrey, Quirke, & Shepherd, 2014) (Quirke et al., 2007).   
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Table 1-1 TNM classification of colorectal tumours (7th Edition) 
T-stage 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Invading submucosa 
T2 Invading muscularis propria 
T3 Invading through the muscularis propria into pericolorectal tissues 
T4a 
T4b 
Penetrating to the surface of the visceral peritoneum 
Directly invading or adherent to other organs or structures 
N-stage 
N0 No regional lymph node metastasis 
N1 
N1a 
N1b 
N1c 
Metastasis in 1-3 regional lymph nodes 
One lymph node  
2 to 3 lymph nodes  
Tumour deposits in subserosa, mesentery, or nonperitnealized pericolic or 
perirectal tissues without regional nodal metastasis 
N2 
N2a 
N2b 
Metastasis in 4 or more regional lymph nodes 
4 to 6 regional lymph nodes 
7 or more regional lymph nodes 
M-stage 
M0 No distant metastasis 
M1 
M1a 
M1b 
Distant metastasis 
Metastasis confined to one organ or site 
Metastasis in more than one organ or site or peritoneum 
 
  
 50 
Table 1-2 TNM stage and classification, Dukes’ stage and survival of colorectal 
tumours  (information obtained from CRUK, Cancer statistics website) 
UICC 
Stage 
T N M Dukes 
Classification 
5 year Survival % 
Men   Women 
0 Tis N0 M0 -   
I 
 
T1 N0 M0 A 
94.6 98.2 
T2 N0 M0 A 
II IIA 
IIB 
IIC 
T3 N0 M0 B 
83.5 85.9 T4a N0 M0 B 
T4b N0 M0 B 
III IIIA T1-T2 N1/N1c M0 C 
62.6 62.7 
T1 N2a M0 C 
IIIB T3-T4a N1/N1c M0 C 
T2-T3 N2a M0 C 
T1-T2 N2b M0 C 
IIIC T4a N2a M0 C 
T3-T4a N2b M0 C 
T4b N1-N2 M0 C 
IV IVA 
IVB 
Any T Any N M1a D 
6.9 8.1 
Any T Any N M1b D 
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1.1.5.2! Tumour grade 
 
Tumour differentiation is graded based on subjective pathological assessment on 
how closely the lesion resembles to normal colorectal tissue.  The scale used for 
grading colorectal cancers goes from 1 to 3. Grade 1 (G1) suggests the cancer looks 
much like normal colorectal tissue. Grade 3 (G3) means the cancer looks very 
abnormal. Grades 2 (G2) falls somewhere in between. The grade is often simplified 
as either well differentiated tumours (G1), moderate differentiated (G2) or poorly 
differentiated tumours (G3). Tumours with poorly diffentiation features are reported 
to have a worse prognosis although there have been reports placing the prognostic 
value of tumour grading into dispute (Bear, MacIntyre, Burns, Jarrett, & Wilson, 
1984; Halvorsen & Seim, 1988).  
1.1.5.3! Lymphovascular invasion 
 
Other descriptive factors incorporated into TNM staging include lymphatic vessel 
invasion (LI) and venous invasion (VI), which is now combined to lymphovascular 
invasion (LVI). Venous invasion is defined as tumour present within an epithelial lined 
space that is either surrounded by muscle tissue or contains red cells whereas 
lymphatic invasion is present once tumour cells are identified in and around the 
nearby lymphatics.  Evidence suggests that the presence of either LI and/or VI is 
associated with an increased risk of future development of distant metastases and 
cancer related death (Horn, Dahl, & Morild, 1991; Ouchi et al., 1996). Recent 
metanalysis identified the presence of LVI in the tumour specimen as a strong 
predictor of lymph node metastases in patients with early CRC (Beaton, Twine, 
Williams, & Radcliffe, 2013).  
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1.1.5.4! Margin Involvement  
 
A resection margin is the margin of non-cancerous tissue around a tumour that has 
been surgically removed. If cancerous cells or tissue are seen microscopically (RI) or 
macroscopically (R2) during the pathological assessment of the resected specimen is 
suggestive of poorer outcomes (Quirke, Durdey, Dixon, & Williams, 1986).  The 
absence of cancerous cells (R0) in the specimen is the desired result.  
1.1.5.5! Tumour Perforation 
 
Perforation defined as a macroscopically visible communication through the tumour 
between the bowel lumen and the external surface of the intact resection specimen 
is recognized as a high-risk feature in CRC. Perforated tumours are in higher risk of 
developing local recurrence and with poor overall survival (Petersen, Baxter, Love, & 
Shepherd, 2002).   
1.1.5.6! Molecular markers  
 
Prognostic molecular markers can be divided into the following categories: cell 
proliferation indices (Ki-67, Mib-1, proliferating cell nuclear antigen); 
oncogenes/tumor suppressor genes (p53, K-ras, Deleted in Colorectal Cancer 
(DCC), Bcl-2, c-erbB2); DNA repair (microsatellite instability); markers of 
angiogenesis (vascular count, vascular endothelial growth factor); markers of 
invasion/metastasis (plasminogen-related molecules, matrix metalloproteinases); and 
biochemical markers (CEA,thymidylate synthase) (Graziano & Cascinu, 2003). 
Recent development of biological agents is based on the knowledge of molecular 
pathways involved in cancer development. A prime example is the knowledge of 
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epidermal growth factor receptor (EGFR) pathway, where cell proliferation, 
adhesion and survival can be inhibited using anti-EGFR antibodies. However, there 
was high variability of response and outcome in patients with advanced CRC 
receiving anti-EGFR (Amado et al., 2008). Especially tumours expressing KRAS 
mutation demonstrated resistance, which can be explained due KRAS being a more 
downstream effector in the EGFR pathway. Similarly, BRAF, PI3K and PTEN mutations 
have been implicated in demonstrating resistance to anti-EGFR, but not yet proven 
(Heinemann, Douillard, Ducreux, & Peeters, 2013). KRAS mutation has been 
historically implicated as a marker of poor prognosis, associated with increase risk of 
CRC recurrence and death (Andreyev, Norman, Cunningham, Oates, & Clarke, 
1998). However, more recent studies suggest tumours arising from serrated 
pathway (CIMP positive) are associated with overall worst outcome regardless of 
KRAS mutation status (Kang et al., 2015; Phipps et al., 2015). In the modern era of 
personalized medicine, molecular markers will play an essential role in predicting 
outcome and optimizing treatment strategy in CRC management (Heinemann et al., 
2013; Sadanandam et al., 2013).  
1.1.5.7! Summary 
 
TNM stage still remains the most important prognostic tool that clinicians have to 
tailor the treatment, monitor its effect and inform patients diagnosed with CRC 
about their disease prognosis. Other tumour characteristics such as the LVI, tumour 
perforation, resection margin and grade of differentiation are core data items 
mentioned in the Royal College of Pathologists CRC dataset report. However these 
tumour features are dependent on accurate pathological assessment and reporting. 
Different molecular markers related to CRC development and progression, have 
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been identified to have prognostic value but very few of them are used routinely in 
the clinical practice due to financial and practical reasons. New prognostic factors 
that will provide accurate, fast and reliable information to the treating doctor of a 
patient with CRC are still needed.  
 
1.1.6! Host factors and colorectal cancer prognosis 
 
The growth and metastatic potential of CRC is the outcome of a dynamic balance 
between cancer and the host, summarized as the "seed and soil" hypothesis (Mathot 
& Stenninger, 2012). The staging and treatment tactics for CRC appeared to be 
orientated predominantly to the 'seed' component, nearly neglecting, in daily clinical 
practice, the impact of the 'soil' in the course of the disease. 
 We are currently seeing an increasing amount of evidence, from clinical to 
laboratory research, which highlight that cancer progression is the result of the 
dynamic balance between the disease itself and the host’s important features such as 
the immune response and its BC. 
1.1.6.1! Systemic inflammatory response 
 
Acute –phase inflammatory response to a pathogen or to tissue injury (ischaemia, 
tissue necrosis, trauma, hypoxia or cancer) typically leads to a resolution but 
sometimes the inflammatory agents produced will elicit a chronic low-grade immune 
response. During the acute-phase of the inflammatory response synthesis of several 
plasma proteins (positive acute phase proteins; CRP, serum Amyloid A, fibrinogen, 
haptoglobin and a1-antithrypsin) are increased or decreased (negative acute phase 
proteins; albumin and transferrin). Acute phase proteins are a class of proteins 
 55 
produced by hepatocytes under the control of cytokines originating form the site of 
pathology and whose concentration changes by at least 25% in the presence of 
pathology (Gabay & Kushner, 1999). The acute –phase response is complex and not 
entirely understood; involving molecules that stimulate or attenuate the process. In 
addition to the changes in plasma protein composition, the acute phase is also 
characterized by other local and systemic changes; such as an influx of neutrophils, 
complement and antibodies, physiological changes (fever, anorexia and lethargy), and 
metabolic changes (loss of lean muscle and cachexia). The prolonged production and 
presence of molecules, such as Il-6 and TNF-a, results in a chronic low-grade 
immune response and to a state of unresolved, low-grade inflammation (systematic 
and local).  
1.1.6.1.1! Measurement of SIR 
 
The commonest reported ways of measuring the SIR in patients with cancer are 
biochemical or hematological markers. These are mainly elevated CRP, increased 
white cells, neutrophil and platelet counts (Allin & Nordestgaard, 2011). Decreased 
levels of serum albumin, has also been recognized to reflect the presence of an 
altered SIR (Gabay & Kushner, 1999). In addition, combinations of the above 
markers have been used to develop prognostic tolls based on the presence and 
severity of the SIR.  Combination of plasma CRP and serum albumin levels has been 
used by McMillan et al to develop the Glasgow Prognostic Score(McMillan, Crozier, 
Canna, Angerson, & McArdle, 2007). During an acute inflammatory response the 
ratio of different leucocyte subsets is altered; there is a neutrophilia often 
accompanied by a relative lymphocytopenia. Therefore a simple measure of systemic 
inflammation can be generated by calculating the neutrophil-to-lymphocyte ratio 
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(NLR).  The NLR was first reported in 1967 as an indicator of ozone exposure; 
recently NLR has also been recognized as a surrogate marker of the SIR (Walsh, 
Cook, Goulder, Justin, & Keeling, 2005).  
1.1.6.1.2! Prognostic Utility of SIR in resectable CRC  
 
This state of low-grade inflammation may predispose or be a part of different 
diseases such as cancer. The role of the SIR as a risk factor for the CRC 
development was explored in paragraph 1.1.3.5.3. Altered SIR has also been linked 
with prognosis in patients with cancer.  Elevated levels of CRP measured with 
conventional or high-sensitivity analysis have been lined with poor outcomes for 
various types of solid cancers such as prostate (Beer et al., 2008), breast (Allin, 
Nordestgaard, Flyger, & Bojesen, 2011), ovarian (Hefler et al., 2008), hepatocellular 
(Hashimoto et al., 2005), cervical (Hashimoto et al., 2005), renal (Saito & Kihara, 
2011), pancreatic (Jamieson et al., 2005), bladder (Yoshida et al., 2008) and non small 
cell lung cancer (O'Dowd, McRae, McMillan, Kirk, & Milroy, 2010). The role of SIR 
has also been tested for CRC prognosis. SIR was tested as a prognostic marker for 
CRC recurrence and survival in two main settings; preoperatively in resectable CRC 
cases but also preoperatively in resectable colorectal liver metastases (CRLM).  
In1983 De Mello et al followed by Weinstein et al and McMillan et al, were amongst 
the first to report that preoperative increased levels of acute-phase proteins and 
mainly CRP, in CRC patients with resectable tumours, are important prognostic 
factor for cancer recurrence (de Mello, Struthers, Turner, Cooper, & Giles, 1983; 
McMillan et al., 1995; Weinstein et al., 1984). Preoperative high levels of CRP in 
patients undergoing surgical treatment for primary CRC are also linked with worse 
cancer survival outcomes (McMillan, Canna, & McArdle, 2003; Nielsen, Christensen, 
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Sorensen, Moesgaard, & Brunner, 2000; Nozoe, Matsumata, Kitamura, & Sugimachi, 
1998). In 1998 Heyds at al reported that low levels of preoperative serum albumin 
were associated with worse survival in patients with localized “curable” CRC (Heys, 
Walker, Deehan, & Eremin, 1998). Two other studies based on data for the National 
Veterans Affairs Surgical Quality Improvement programme showed that low serum 
albumin preoperatively was linked with increased early postoperative mortality in 
patients with primary colon and rectal cancer(Longo et al., 2000; Longo et al., 1998). 
Although there was variability for the CRP and albumin thresholds, the majority of 
the studies were reporting on cut-off values of  >10mg/L for CRP and <35g/L for 
albumin.  
In 2007 McMillan at al modified the Glasgow Prognostic Score (based on CRP and 
albumin) tested its prognostic utility in predicting cancer-specific survival after 
resection for CRC.  Patients with both an elevated CRP (>10 mg/l) and 
hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one 
or none of these biochemical abnormalities was present were allocated a score of 1 
or 0, respectively. A Glasgow Prognostic Score of 0 was associated with a 3-year 
cancer-specific survival of 95% compared to 61% of patients with Glasgow 
Prognostic Score of 2 (McMillan et al., 2007). In 2005 an association was 
demonstrated between NLR and outcome in CRC but this was not significant on 
multivariate analysis (Walsh et al., 2005). Few other studies followed assessing the 
prognostic significance of NLR in resectable cases of CRC but issues with the cutoff 
value and selection bias did not allow for a comprehensive evaluation of NLR as a 
prognostic marker (P. R. Ding et al., 2010; Hung et al., 2011; Mallappa, Sinha, Gupta, 
& Chadwick, 2013).   
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1.1.6.1.3! Prognostic Utility of SIR in colorectal liver metastases 
 
Changes in surgical techniques and advances in locoregional and biologic therapies 
have led to an increase in the 5-year overall survival (OS) of patients with resectable 
CRLM to 35–58 %. However, patients who undergo liver resection will exhibit 
recurrence either within the liver or elsewhere, and only 16 % of these are disease 
free 10 years after the liver section (Tomlinson et al., 2007). In an attempt to 
personalized perioperative systemic therapy and also to better identify patients that 
will benefit from hepatectomy, SIR markers have been used as prognostic marker of 
disease recurrence and survival. These include markers such as elevated CRP, low 
albumin levels, elevated neutrophil count, NLR and the PLR (Halazun et al., 2008; 
Neofytou et al., 2014; V. K. Wong et al., 2007). 
1.1.6.1.4! Underlying mechanisms of altered SIR in CRC  
 
The biologic underlying mechanisms of SIR in cancer are still unknown. We can 
hypothesize that three main factors may explain the basis of SIR in CRC; a.) tumour 
behaviour, b.) tumour microenvironment inflammation and c.) host behaviour. 
Tumour cells have been showed to produce pro-inflammatory mediators such as IL-
6, which stimulate the hepatic production of acute–phase proteins, promote 
catabolism, reduce synthesis of plasma albumin and increase peripheral subtypes of 
white cells such neutrophils and platelets and decrease the lymphocyte percentage in 
peripheral blood (Coussens & Werb, 2002). The link between SIR and CRC 
prognosis can also be explained by tumour behaviour as in different observational 
studies, altered SIR at the time of diagnosis was associated with larger tumour 
burden, high grade of tumour differentiation and presence of distant metastases.  
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These observations may suggest that SIR reflects the phenotype or aggressiveness of 
the tumour (Allin & Nordestgaard, 2011).  
It has also suggested that SIR is driven by inflammation in the tumour 
microenvironment and those markers of SIR may express the magnitude and the 
intensity of the local inflammatory response. In primary CRC cases elevated CRP is 
associated with low tumour CD4+ T-cells infiltration and increased tumour 
proliferation measured by the expression of the Ki-67 protein (Canna et al., 2008; 
Canna et al., 2005). It is also reasonable to speculate that the SIR may drive the 
inflammation in the tumour microenvironment and if that is the case then 
intervening against chronic SIR may potentially improve CRC outcomes.  
Finally the basis and the stimulus of SIR in CRC may be explained by differences in 
host factors and behaviour. Since previous epidemiological studies reported that 
altered SIR mainly measured as raised CRP is related to all-cause mortality, SIR may 
be acting as a general marker of health and longevity (Koenig, Khuseyinova, Baumert, 
& Meisinger, 2008; Zacho, Tybjaerg-Hansen, & Nordestgaard, 2010). One further 
hypothesis could be that nutritional and lifestyle profiles reflecting on the host’s body 
composition synthesis might have a direct link with the development and 
maintenance of this chronic low-grade systemic inflammation in cancer. 
1.1.6.2! Local inflammatory response 
 
Since late 1960s, there have been studies suggesting that intense peritumoural 
inflammatory reaction was associated with improved survival (Spratt & Spjut, 1967). 
This LIR documented in and around the tumour microenvironment is considered to 
represent the in-situ immune response of the host in reaction to tumour 
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development and progression. Details and overview of the fundaments of the 
tumour immunology are discussed in paragraph 1.3.4. 
Subsequently, Jass published extensive work correlating lymphocytic infiltration and 
survival in rectal cancer (Jass, 1986). He concluded that lymphocytic infiltration was 
an independent predictive factor in determining survival in rectal cancer patients. A 
significant peritumoural lymphocytic infiltration was linked with good outcome. This 
laid foundation to the Jass classification, which identifies lymphocytic infiltration, 
tumour growth beyond the bowel wall and increasing nodal involvement as the 
strongest variables that independently influence long-term survival in rectal cancer 
(Jass, Love, & Northover, 1987). Although the high inter-observer agreement 
amongst pathologists reporting on the new features proposed by Jass the subjective 
nature of these assessments led to problems with reproducibility and the Jass 
classification has not gain widespread acceptance (Koenig et al., 2008) .   
Despite the failure of the Jass classification to be widely adopted, numerous studies 
have since been published, all demonstrating the importance of immune cell 
infiltration in CRC prognosis (Roxburgh & McMillan, 2012). The latest meta-analysis 
by Mei et al. attempted pooled analyses of studies investigating the relationship 
between tumour infiltrating immune cells and CRC outcome. The authors 
highlighted that high-level of generalized tumour inflammatory infiltrate may be a 
good prognosis marker for CRC, but this statement was inconclusive due to 
significant heterogeneity and potential publication bias (Mei et al., 2014). 
Currently, there is no agreed system in scoring immune infiltrate in CRC. So far, the 
main contenders are the Klintrop-Makinen grading system (based on using 
haematoxylin and eosin stained sections)(Klintrup et al., 2005) and Galon immune 
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score (immunohistochemistry-based score grades of CD45RO and CD8) (Mlecnik et 
al., 2011). These two grading systems are both effective in predicting survival in CRC 
patients but yet not accepted by royal College of Pathologists or WHO as reliable 
prognostic markers (Richards et al., 2014).  
Galon’s immune score specifically investigates into T cells but there have been 
comparatively fewer studies looking into the role of tumour-infiltrating NK cells, B 
cells, macrophages and DCs in CRC outcome(Roxburgh & McMillan, 2012).  Future 
work is therefore required to identify mechanisms of how different subsets of 
infiltrating immune cells influence CRC outcome. It also apparent that not only the 
density or count of tumour infiltrating immune cells but also the phenotypical and 
functional characteristics of these cells might also play an important role in 
determining CRC progression. Therefore, in order to establish routine clinical utility 
there is a need by using novel techniques such as digital image analysis to further 
rationalise this prognostic information. Finally, taking into consideration other factors 
such the influence of the host’s body synthesis will also have potential to further 
understanding of the basis of LIR basis and also to inform novel therapeutic 
interventions.  
1.1.6.3! Body Composition 
 
An overview of the BC as a branch of human biology, its definition, way to measure 
it and the relationship with CRC is described in detail below. 
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1.1.7! Body Composition 
 
1.1.7.1! Background of Body Composition 
 
Recently there has been an increasing interest in the role of BC on the pathogenesis 
of cancer but also its impact on oncological patients outcomes. Wang et al defines 
BC research as the branch of human biology that deals with three interrelating areas: 
BC levels and their organization rules, measurement techniques and factors that 
influence BC(Z. M. Wang, Pierson, & Heymsfield, 1992).  Five levels of BC have been 
descripted; a.) atomic, b.) the molecular, c.) the cellular, d.) the tissue level and V.) 
the whole body level. Figure 1.2. shows graphically the five levels of BC. 
                          
Figure 1-2 The five levels of the human body composition 
Abbreviations; ECF = Extracellular fluid, ECS=Extracellular solids. Adapted from Am 
J Clin Nutr 1992:56; Page20 
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Obesity defined by BMI, visceral obesity, sarcopenia and sarcopenic obesity have 
been identified as parameters of the human BC with adverse effect in cancer 
outcomes.  
1.1.7.2! Obesity 
 
WHO defines obesity using the BMI. The BMI of an individual is calculated by its 
weight (Kilograms, kg) divided by the height (meters, m) squared. BMI from 25 -29.9 
Kg/m2 refers to overweight individuals, 30-34.9 Kg/m2 to class I obesity, 35-39.9 
kg/m2 to class II and > 40 kg/m2 to morbid obese individuals ("Obesity: preventing 
and managing the global epidemic. Report of a WHO consultation," 2000) . Despite 
the recognised increased risk of CRC development in obese individuals  (described 
in paragraph 1.1.3.1.4) the associations between BMI and long-term outcomes and 
prognosis are weak in cancer patients. BMI obesity confers a survival advantage in 
patients treated for cancer, a phenomenon known as the “obesity paradox”(McAuley 
& Blair, 2011).  
Banack and Kaufman tried to explain the paradox in the context of the effect of 
obesity on mortality amongst patients with cardiovascular disease (Banack & 
Kaufman, 2014). Two broad classes of explanation were hypothesised: 1.) the 
associations are true due to physiological mechanisms and 2.) the associations reflect 
methodological issues. Renehan suggested that these two classes of explanation can 
also be applied to explain the “obesity paradox” in cancer (Renehan, 2014).  
 If associations are true then Renehan speculated that there are at least three sub-
categories of explanation. Tumours that develop on an obesity-based pathway may 
be:  a.) less  aggressive and /or b.) more responsive to treatment. Third, host related 
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factors might favour obese compared to normal weight patients. Although these 
hypotheses are plausible, further research is needed to determine the true links 
between physiological parameters and the “obesity paradox”.  
There are also different methodological explanations for the “obesity paradox”. 
Using the BMI to define and calculate obesity has been identified as a possible design 
flaw as BMI does not correspond to the same level of adiposity in patients with 
different height, nor does specifies for the BC or the location of the adipose tissue 
and hence alternative ways of BC measurement might have a key role. Other 
methodological issues are the inadequate control for important confounding 
variables such as smoking and alcohol and the reverse causality effect. The 
hypothesis that pre-existing chronic diseases result in weight loss and higher 
mortality among the BMI lower groups, making the obesity appear to confer survival 
advantage could explain the reverse causality effect. Also an alternative assumption is 
that obese patients may tolerate weight loss better than non-obese individuals due 
to higher metabolic reserves and body fat, resulting in improved prognosis and 
survival (Oreopoulos et al., 2008). An additional methodological explanation is that 
the “obesity paradox” is due to a form of selection bias known as collider 
stratification bias (Banack & Kaufman, 2013). Conditioning on a variable such as 
cancer that is affected by exposure (eg obesity) and outcome (eg mortality) can 
introduce false association between exposure and outcome and reverse the 
direction of association.  Table 1.3 summarizes the possible classes of explanation for 
the “obesity paradox” and cancer survival 
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Table 1-3 Possible explanation for the “obesity paradox” in cancer. 
Class of Explanation Subclasses of Explanation 
1. Associations are true and based 
on physiological mechanisms  
a.) Tumour-related  
Obesity –driven tumours are less aggressive  
 b.) Treatment-related 
Obesity- driven tumours are more responsive 
to treatment  
 3.) Host-related 
Excess adiposity is an energy reserve to fight 
physiological stress 
2. Associations are due to 
methodological issues  
a.) BMI is a suboptimal measurement tool of 
body adiposity 
 b.) Confounding 
 c.) Reverse causality 
 d.) Collider bias 
Adapted from Cancer Causes Control 2014 Oct;25(10)1419 
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1.1.7.3! Visceral Obesity 
 
Although the association between obesity and cancer is well recognised what drives 
this link is still unclear. Emerging research has targeted the study of different 
compartments of fat storage such as the subcutaneous and also the visceral fat that is 
considered to be more pro-inflammatory and pro-tumorigenic (Kershaw & Flier, 
2004).  Visceral obesity is defined as the excessive accumulation of visceral (central) 
fat in the abdominal cavity. VAT contains adipocytes, connective tissue, nerves, 
stromal cells and immune cells that work as a unit with a key endocrine, metabolic 
and immunological role. The adipocytes secrete factors such as leptin, cytokines, 
adiponectin, and components of the complement system and metabolise steroids and 
glucocorticoids (Kershaw & Flier, 2004). Because accumulation of fat tissue intra-
abdominally varies with age, gender, race, coexisting illness and more importantly the 
method of measurement, there is no well-accepted normal range of visceral 
adiposity.  
1.1.7.4! Sarcopenia 
 
Sarcopenia from the Greek words “sarco” that means flesh and “penia” that means 
lack, refers to condition of the lack of muscle mass as well as function. Skeletal 
muscle is the largest tissue in the human body and accounts for around 50% of the 
body weight of a healthy individual. Muscle tissue plays a vital role in body 
movements and locomotion and also enables the maintenance of posture, respiration 
and vocal communication. Skeletal muscle is also involved in a variety of metabolic 
pathways such as energy and regulation, insulin and amino acid metabolism and has 
recently been identified as an endocrine organ. Muscle-derived cytokines, named 
myokines, as well as other metabolic peptides can be produced and released by 
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muscle to exert an endocrine action. These cytokines enable crosstalk between 
muscle and other tissues, mainly adipose tissue, liver and bone and play a key role in 
regulation of systemic inflammation, immune function, energy metabolism, insulin 
sensitivity, cell growth, myogenesis and osteogenesis (Biolo, Cederholm, & 
Muscaritoli, 2014) .  
Sarcopenia can be age-related and that is recognised as “primary” sarcopenia or 
“secondary” associated with other chronic conditions and cancer. Sarcopenia is a 
multifactorial disorder and the mechanisms that causes it, are difficult to distinguish 
between individuals. Reduced skeletal muscle mass is associated with aging and is 
influenced by the level of physical activity, functional impairment and loss of 
autonomy (Janssen, Heymsfield, & Ross, 2002). Low protein –energy intake (Ji, Meng, 
& Dong, 2012), neurodegeneration, decrease in anabolic stimulation by factors such 
as sex hormones and glucocorticoids intake may also contribute to sarcopenia (Biolo 
et al., 2007). Recent evidence suggests that SIR due to stress, injury or infection is 
linked to prolonged bed rest and inactivity and therefore sarcopenia (Seelaender, 
Batista, Lira, Silverio, & Rossi-Fanelli, 2012). SIR is also a feature of cancer disease 
but the association between SIR and BC profiles in cancer and especially in CRC are 
yet to be identified. Figure 1.3 describes the main condition that can lead to muscle 
loss and function impairment of skeletal muscle. 
Although these changes in muscle mass and function have been recognised, 
sarcopenia remains inconsistently defined due to the complex aetiology. Most 
frequently sarcopenia is defined on values of measured appendicular skeletal muscle 
mass that are less that two standard deviations below the mean of a young healthy 
adult (K. Fearon, Strasser, et al., 2011). In 2010 the European Society of Parenteral 
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and Enteral Nutrition (ESPEN) on the premises of a Special Interest Group on 
cachexia and anorexia in chronic wasting diseases proposed that sarcopenia should 
be diagnosed based on the presence of two criteria: a.) low muscle mass and 2.) 
reduced muscle function (Muscaritoli et al., 2010). In attempts to develop a 
framework for the definition and classification of cachexia a panel of experts through 
a formal consensus process suggested that there was no clear consensus on the 
methodology of routine assessment of muscle mass. The order of preference for 
muscle mass assessment was cross-sectional imaging (CT or MRI), dual energy x-ray 
imaging (DEXA) followed by anthropometry and bioimpedance analysis (K. Fearon, 
Strasser, et al., 2011).   
 
 
Figure 1-3 Conditions that lead to sarcopenia 
Adapted form: Clin Nutr. 2014 Oct;33(5):737-48  
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The term ‘sarcopenia’ is now widely used but the rash of recent publications about 
the definitions of cancer ‘cachexia’ and sarcopenia and also the increasing population 
of the elderly in the western world made the word synonymous with the 
progressive muscle wasting observed specifically in the elderly. In order to avoid 
confusion Fearon et al in 2011 proposed the term “myopenia” to indicate the 
presence of clinically relevant muscle wasting due to any illness and at any age.  
Another important issue that the same group suggested is that future studies need 
to refine these muscle wasting values in a disease-specific manner and link them to 
degrees of functional impairment that are clinically relevant and/or to degrees of risk 
of morbid or fatal event (K. Fearon, Evans, & Anker, 2011). The term “myopenia” 
instead of sarcopenia will be used for the rest of the thesis. 
1.1.7.5! Myopenic Obesity 
 
Muscle depletion and dysfunction associated with increased accumulation of adipose 
tissue is defined as myopenic (sarcopenic) obesity (Prado et al., 2008). Biolo et al 
suggested that two different trajectories could lead to myopenic obesity. First, 
positive energy intake combined with prolonged physical inactivity may lead to 
obesity with muscle depletion or second, in obese patients with chronic illness such 
as cancer the activation of SIR may rapidly lead to muscle atrophy and dysfunction. 
Again, there are subtle variations in the exact definition of myopenic obesity 
depending on the method of assessment; however the presence of documented 
decreased skeletal muscle mass in individuals with BMI>30Kg/m2 is widely accepted 
as the main definition.  
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1.1.7.6! Myosteatosis 
 
Fat is also associated with skeletal muscle in the form of intramyocellular lipid 
droplets within the cytoplasm as well as intramuscular adipocytes (Wronska & 
Kmiec, 2012). The excess deposition of fat within cells and tissues such as skeletal 
muscle is defined as ectopic fat accumulation and is considered to be a pathological 
condition (Aubrey et al., 2014). Abnormal accumulation of fat in skeletal muscle 
tissue is called myosteatosis and is linked with diabetes, obesity and reduced muscle 
activity (Miljkovic & Zmuda, 2010). In contrast to fatty liver disease, the role 
myosteatosis is poorly understood in patients with cancer and especially solid 
malignancies such as CRC. 
 
1.1.7.7! Cachexia  
 
Cachexia translates as “bad” (cac) “condition” (hexis) in Greek is well recognized in 
patients with chronic illness such as cancer, renal failure, cirrhosis and chronic 
obstructive pulmonary disease (Muscaritoli et al., 2010). Cancer cachexia was 
defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle 
mass (with or without loss of fat mass) that cannot be fully reversed by conventional 
nutritional support and leads to progressive functional impairment (K. Fearon, 
Strasser, et al., 2011). In the oncological setting it is challenging to recognize 
myopenia for cachexia as most cachectic patients have an element of myopenia by 
definition but not all myopenic patients are cachectic.  
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1.1.7.8! Measurement techniques 
 
A number of methods for BC measurement have been proposed including 
assessments at the atomic, molecular, cellular, tissue-system and whole-body levels. 
Techniques used include anthropometric, bioelectrical impedance analysis (BIA) and 
image based approaches such as dual energy X-ray (DEXA), MRI and CT.  
Skin fold thickness, mid arm and calf perimeter measurements are some of the 
anthropometric approaches used.  These methods however are prone to operator 
introduced error and also have increased inter-observer variability; hence they are 
not recommended for the routine diagnosis of myopenia (Cruz-Jentoft et al., 2010). 
BIA is inexpensive with no radiation exposure technique that uses differences in the 
impedance of a low-level electric current applied by placing electrodes in certain 
points in the body. BIA is used to calculate the lean body mass (LBM). LBM is 
anatomically defined as the sum of all the non-adipose tissue of the body whereas 
muscle mass is a term usually refers to the sum of the skeletal muscle tissue of the 
body. Impedance measurement can be affected by various factors such as hydration 
status and thus BIA lacks precision and also cannot provide any details on the quality 
of the skeletal muscle (Thompson et al., 1991).   
DEXA method uses a fan beam at two average X-ray energies and exploits the 
difference in the attenuation form the different tissues. Attenuation increases with 
tissue thickness and is greater for bone compared with soft tissues. DEXA technique 
enables the measurement of LBM, fat mass and the bone mineral mass (Albanese, 
Diessel, & Genant, 2003). Although this technique bears a low radiation exposure 
dose and is a widely used clinical tool, limitations exist such as the low precision 
compared to CT and MRI, distinction between the different fat compartments 
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cannot be made and the quality of the muscle tissue cannot be analyzed(Albanese et 
al., 2003).   
A simpler technique and with no radiation exposure for assessing BC is the MRI 
approach. MRI has better soft tissue recognition particularly for adipose tissue 
compared to CT but is more expensive, requires longer time for image acquisition 
and the quality of the skeletal muscle cannot be analyzed (Thibault & Pichard, 2012).   
CT is a contrast resolution cross-sectional method that can provide estimates of 
LBM, adipose tissue as well as details of fat infiltration within the skeletal muscle. 
Using dedicated software, the delineation of the different fat and muscle 
compartments is feasible. Specific skeletal landmarks especially in the lumbar area 
that contain visceral, subcutaneous and intermuscular adipose tissue, psoas, 
paraspinal, transversus abdominus, external oblique, internal oblique and rectus 
abdominus muscle, have been widely used and these regions of interest are then 
further refined using predefined range of Hounsfield Units (HU).  
The performance of CT BC analysis is superior to DEXA and other anthropometric 
techniques. Mourtzakis et al in 2008 published a key study proving that the cross-
sectional areas of tissues in single CT images in the 3rd lumbar vertebra level, are 
strong correlates of whole-body adipose tissue, muscle, and lean tissue mass 
(Mourtzakis et al., 2008). Individuals may be then compared directly on this basis; 
however, these quantities may be translated to approximate whole-body tissue 
masses using regression equations. Prado et al reported first sex-specific cut-offs that 
defined a significant association between low muscle mass measured by CT BC of 
the L3 level with mortality by optimum stratification analysis in patients with solid 
tumours of the respiratory and gastrointestinal track. The sex-specific cut-offs for L3 
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skeletal muscle index (LSMI) (L3 skeletal muscle area normalized by height squared) 
associated with mortality were 52·4 cm2/m2 for men and 38·5 cm2/m2 for women; 
patients below these values were classified as having sarcopenia (Prado et al., 2008). 
Work from the same group (Prof V. Baracos; Alberta, Canada) followed in 2013 and 
gender and BMI specific thresholds of LSMI and muscle attenuation (MA) were 
determined using optimal stratification in 1473 patients with a diagnosis of GI or 
respiratory tract malignancy. MA represents the mean HU for the entire muscle area 
at L3 and has been used to defined myosteatosis (Martin et al., 2013). Figure 1.4 
shows an original CT image and measurement of the degree of visceral adiposity and 
muscle. 
Skeletal muscle contains intramyocellular lipid droplets within the cytoplasm of 
myocytes as well as intermuscular adipocytes. These lipid droplets exhibit 
physiological and pathological variation which has been revealed with the advent of 
diagnostic imaging approaches: magnetic resonance (MR) imaging, MR spectroscopy 
and computed tomography (CT). CT uses computer-processed X-rays and is now 
being applied in muscle physiology research. Pre-defined radiation attenuation ranges 
are used to demarcate intermuscular adipose tissue [from −190 to −30 Hounsfield 
units (HU)] and muscle (−29 HU to +150 HU). Within the latter range, the mean 
muscle radiation attenuation [muscle (radio) density] is reported. Criteria for the 
upper and lower HU cut-offs used to characterize muscle attenuation limit 
comparisons and define the condition named myosteatosis. One of the more recent 
developments in research on skeletal muscle radiation attenuation in clinical 
populations is the association of reduced muscle attenuation with the progression 
and outcomes of cancer. Martin et al. (2013) reported that reduced muscle 
attenuation was independently prognostic of poor survival in a large cohort of 
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patients with solid tumours of the lung and gastrointestinal tract. MA varied with 
BMI, not with sex. The overall prevalence of MA below threshold values demarcating 
significantly reduced survival was 49%. The BMI-specific cut-offs for lumbar MA 
associated with mortality in this study were MA < 41 for BMI < 24.9 kg/m2 and < 33 
for BMI > 25 kg/m2.  These, are the values that will be used for the analysis of the 
original data for the purpose of this thesis.  
The basis of this predictive value of MA for survival is unknown. There is direct 
evidence that muscles of cancer patients develop increased numbers of 
intramyocellular lipid droplets (Stephens et al. 2011). These authors observed 
muscle biopsy material using electron microscopy and found that the lipid droplets 
were significantly more abundant in muscles of patients experiencing progressive 
cancer-associated weight loss, as compared to weight-stable individuals. Reduced 
radiation attenuation of muscle is a relatively newly characterized and distinctive 
abnormality in people with cancer, thus the relationship of reduced attenuation of 
muscle to clinical outcomes and morbidity in cancer patients remain to be explored.  
Along with magnetic resonance imaging, CT is also a gold standard for abdominal fat 
quantification and is routinely available for gastrointestinal cancer research. 
Commonly used BMI cut-off values to diagnose obesity have high specificity, but low 
sensitivity to identify adiposity, as they fail to identify those with excess body fat. 
Furthermore, visceral fat area (VFA) is superior to both waist circumference 
measurements and BMI for discriminating individuals. Hence, when researching the 
implications of excess adiposity, reliable methods to discriminate between visceral 
and subcutaneous adipose tissue depots are essential. Computed tomography (CT) 
imaging and magnetic resonance imaging are the gold standard for the quantification 
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of total, visceral, and subcutaneous adipose tissue. Numerous studies have employed 
these gold standard techniques to quantify visceral fat area and have confirmed that 
an increased volume of visceral adipose tissue is deleterious to metabolic function, 
promotes inflammation and promotes tumorigenesis. The absence of appropriate 
VFA thresholds is hampering the field of cancer research.  CT scanning is generally 
limited to individuals under medical investigation; nevertheless, an appropriate 
threshold should be generated for use in obesity research when CT scanning is 
available. In the absence of healthy individuals, gastrointestinal cancer patients 
represent an appropriate cohort for the study of VFA thresholds.  
Doyle et al, focused on oesophageal and colorectal adenocarcinoma cohorts and 
used the collective factors of the Metabolic Syndrome (MetSyn) as a pathological 
indicator(s) for visceral obesity. Visceral adipose tissue has multiple endocrine, 
metabolic and immunological functions [4] and is central to the pathogenesis of the 
metabolic syndrome a pro-inflammatory, pro-coagulant state associated with insulin 
resistance. The MetSyn was diagnosed if there is central obesity (WC ≥94 cm in 
males and ≥80 cm in females) plus any 2 of the following 4 risk factors: fasting plasma 
glucose ≥5.6 mmol/L or previously diagnosed type 2 diabetes; triglycerides ≥1.7 
mmol/L or specific treatment for this lipid abnormality; high-density lipoprotein 
cholesterol (HDL-C) <1.03 mmol/L for males and <1.29 mmol/L for females or 
specific treatment for this lipid abnormality; systolic blood pressure ≥130 mmHg 
and/or diastolic blood pressure ≥85 mmHg or treatment for hypertension. Visceral 
fat area (VFA) strongly correlated with the presence of MetSyn and the cut-off 
values for VFA associated with the presence of MetSyn was 163.8 cm2 in males and 
80.1 cm2 for females. This new anthropometric measure is of paramount importance 
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for determining the accurate pathological obesity status of cancer patients and these 
values will be utilized for the proposes of this thesis. 
CRC patients undertake routine CT scans for diagnosis and to monitor disease 
progression. Although these patients are routinely evaluated by diagnostic imaging, 
the information content of these images is barely exploited, therefore CT BC can be 
an accessible and convenient method of determining certain clinical relevant BC 
profiles and changes. 
Table 1.4 summarizes the main methods used in BC analysis with their advantages 
and disadvantages.  
 
1.1.7.9! Body Composition and its role in colorectal cancer prognosis 
 
This will be covered in detail as a systematic review of the literature in Chapter 3.  
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Figure 1-4 Measurement of the degree of visceral adiposity and muscle 
An original computed tomogram obtained at the L3 level showing the region 
coloured red represents the skeletal muscle area and the region coloured yellow 
represents the visceral adipose area and the region coloured blue represents the 
subcutaneous fat area. 
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Table 1-4 Summary of the main methods used in BC analysis and their advantages 
and disadvantages 
Methods Advantages Disadvantages 
Computer 
Tomography  
•! Reproducible 
•! Accurate 
•! Lean Body Mass, 
subcutaneous and 
visceral fat can be 
analyzed 
•! Skeletal Muscle 
quality can be 
analyzed 
 
•! Radiation Exposure 
•! Cost 
Magnetic Resonance 
imaging  
•! No radiation 
exposure 
•! Better soft tissue 
recognition 
•! Expensive 
•! Long acquisition 
time  
 
Dual X-ray absorption  •! Inexpensive 
•! Low radiation 
exposure 
•! Two dimensional 
data  
•! Low precision 
•! Unable to 
differentiate 
between different 
fat compartments 
•! Unable to analyse 
skeletal muscle 
detail 
Bioelectrical 
impedance analysis 
•! No radiation 
exposure  
•! Inexpensive 
•! Portable 
•! Immediate results 
•! Low accuracy 
•! Unable to analyse 
skeletal muscle 
detail 
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1.2! Immune system 
 
1.2.1! Overview of the Immune system  
 
The immune system is a sophisticated network of cells that communicate and 
collaborate in order to recognize danger signals such foreign pathogens and initiate 
an effective response against them, leading to their elimination. Antigens are usually 
foreign substances that are specifically recognized by receptors on the cells of the 
immune system.  
Adaptive immunity is the antigen-specific host defense that is mounted following 
exposure to an antigen and involves lymphocytes and their products.  Adaptive 
immunity is linked with innate immunity, which comprises the cells and mechanisms 
that provide the first line of the host’s defense system (Iwasaki & Medzhitov, 2015). 
Innate immune responses are rapid and independent of antigen. 
Each immune response is specific after the encounter with different antigen, 
therefore the immune system need to be diverse in its capacity to recognize and 
respond to danger signals. It is also of vital importance that the immune system has 
the ability to mount a quick response upon succeeding exposure to the same 
antigen.  This ability is called memory. Therefore the immune system has to be 
specific, diverse and able to develop memory in order to produce an efficient 
response (Tannock, 2005). Another important feature of the immune system is the 
self-tolerance ie the ability not to respond against self-antigen.  The mechanisms that 
secure protection against self-reactivity were initially considered to be the weakness 
of the immune system against tumours but this has recently changed.  
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1.2.2! Overview of the immune response 
 
T and B-lymphocytes, which are the heart of the adaptive immune system, are mainly 
responsible for the specificity and diversity that characterizes the immune system. 
These lymphocytes have specific antigen receptors through which, they recognize 
small part of proteins called epitopes. Different types of antigens trigger B and T cell 
activation. The T-cell receptor (TCR) is triggered by interaction with peptides 
presented by self major histocompatibility complex (MHC) molecules on an antigen 
presenting cell (APC) whereas the intact protein bound to a membrane 
immunoglobulin is the antigen –specific stimulus from the B cells. Professional APCs 
(macrophages, dendritic cells (DCs) and activated B cells) have the ability to capture 
and present antibodies and they also cable to express co-stimulatory molecules. 
Activated B cells will proliferate and differentiate into plasma cells that can produce 
antibodies responsible for humoral immunity. T lymphocytes are responsible for the 
cell-mediated immunity. Activated T cells differentiate into effector and memory 
cells. Cytotoxic T cell (CTL) is one of the effector cells that can cause lysis of the 
cells and T helper lymphocytes (Th) are cells that organize and help the cooperation 
of the humoral and cell-mediated immune response.  
The MHC is group of genes that encodes various proteins including the MHC 
molecules. There are three different classes of MHC; class I MHC are expressed on 
all cells; class II MCH is limited to APCs and class III MHC proteins are mainly 
components of the complement system and some cytokines (TNF- α, TNF-β).  The 
human MHC region is known as the human leukocyte antigen (HLA) complex. The 
human MHC class I proteins are HLA-A, HLA-B and HLA–C and the human MHC 
class II proteins are, HLA-DQ, HLA-DR and HLA-DP. If the MHC class I – antigen 
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complex is recognized as foreign, the cell will be become a target for CTL-mediated 
lysis and if the MHC class II/antigen complex expressed by APCs is recognized as 
foreign by antigen-specific Th, an immune response will be initiated (Pamer & 
Cresswell, 1998), (Watts, 1997).  
T cells are categorized into two main subsets. CTLs and their precursors are in the 
first subset; that express the CD8 marker, recognize antigen presented by MHC 
class I molecules and their primarily function is to eliminated virally infected cells and 
potentially tumor cells through the delivery of enzymes that can cause DNA 
fragmentation and ultimately cell death, (Kagi, Ledermann, Burki, Zinkernagel, & 
Hengartner, 1996). For the anti-tumour immunity, a CTL response is desired as 
most tumour cells express MHC class I molecules.  Th cells are the other main 
subset of T lymphocytes. Th cells express the CD4 marker and recognize antigen 
presented by MHC class II molecules and their role is to regulate other immune cells 
by producing a range of soluble mediators called cytokines. The cytokines can act as 
growth factors for the proliferation and differentiation of CD8+, CD4+ T cells and B 
cells. The Th 1 cells produce interleukin 2 (IL-2), interferon-γ (INF-γ) and 
granulocyte macrophage colony-stimulating factor (GM-CSF) and with these 
cytokines are involved in the cell-mediated branch of the immune response. Th 2 
cells secrete IL-4, IL-10, IL-13 and GM-CSF and they are involved in the humoral 
branch of the immune response.  There is also a third category of Th cells that 
produce TGF-β or IL-10 and their role is to regulate the immune response. 
(O'Garra & Arai, 2000) 
Antigens in the form of either infected cells or tumour related can be potentially 
found anywhere in a human body. However, T lymphocytes are mainly in the blood 
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circulation and the secondary lymphoid tissues such as the lymph nodes but they 
must be also able to locate the danger signals that are found in the periphery. In 
addition to these the virally infected or the tumour cells often they cannot activate 
naive T cells, as there is a lack of co-stimulatory molecules. APC and in particular 
DCs help the immune system to overcome these limitations described above. 
1.2.3! Dendritic Cells 
 
1.2.3.1! Morphology and properties of DC 
 
In 1868, Paul Langerhans a German pathologist was the first to describe the 
Lagerhan’s cells (LC) in the skin, which he mistook for nerve endings. We now know 
that these cells were actually epithelial DC responsible for the initiation of immune 
response to epidermal pathogens. In the 1970s studies in vitro postulated that 
accessory non-lymphoid immune cells were required for efficient lymphocyte 
activation a notion that was later confirmed with the discovery of MHC restriction 
of T cell stimulation. About the same time in 1973 Ralph Steinman found a rare 
population of cells in the mouse spleen that were potent stimulators of the immune 
system (Steinman & Cohn, 1973). These cells were initially thought to be 
macrophages. However the cytoplasm of these accessory cells was arranged in 
pseudopods of varying width, length, form and number, and these cells constantly 
extended and retracted these processes. They also lacked an abundant membrane 
enzyme typical of macrophages, and unlike macrophages, had few digestive bodies or 
lysosomes and were poorly phagocytic both in vivo and in vitro. These cells were 
characterized by stellate morphology and extended veils and they were called 
dendritic cells from the Greek word “Dendron”. At around the same time, Brigid 
Balfour was filming similar cells from the afferent lymph of pigs and rabbits; she 
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originally called these cells “frilly macrophages” but she too decided that they 
constituted a separate cell type and christened them “veiled cells” (Drexhage, 
Mullink, de Groot, Clarke, & Balfour, 1979). 
Not only their morphology is ideal to facilitate interaction with T cells but also the 
discovery that DCs expressed high levels of MHC and were much more potent 
stimulator of a mixed leukocyte reaction than other professional APC led to the 
concept that DC are the most potent APC of the immune system (Steinman & 
Witmer, 1978). DCs are distinct from other professional APC (B-cells and 
macrophages) because they possess the unique ability to initiate the primary immune 
response, generating immunological memory. An important finding that contributed 
in unraveling the DC biology was the discovery that the veiled cells in rabbits’ lymph 
nodes could stimulate T cell responses suggesting that these are lymph-borne 
precursors of dendritic cells in the lymph nodes (Knight et al., 1982). 
DC act as immune sentinels, patrolling the peripheral tissues; upon encounter with 
antigen, migrate to secondary lymphoid organs to initiate the adaptive immune 
response. DC can determine whether an active or tolerogenic immune response 
occurs to a particular antigen, and whether an inflammatory or tolerogenic immune 
response predominates (Banchereau & Steinman, 1998; Bell, Young, & Banchereau, 
1999).  
1.2.3.2! DC origins and their intrinsic Network  
 
DCs originate from CD 34+ hematopoietic stem cells (HSC) in the bone marrow. 
Within the bone marrow, undifferentiated CD34+ precursor cells give rise to two 
progenitor cell lines, consisting of the common myeloid progenitor cell (CLP) 
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CD11c+ and the common lymphoid progenitor cell (CLP) CD11c- (Ardavin et al., 
2001). These progenitors cells are believed to ultimately differentiate into myeloid 
DCs and plasmacytoid DCs. These two types of cells will subsequently seed the 
blood and tissue where they will give rise into their respective DC subtype. Newly 
generated DC precursors migrate from the bone marrow into the blood stream, 
whence they disperse to various peripheral sites, including most surface epithelia 
such as the skin, and mucosal tissues, including the gastrointestinal tract. Within 
these sites, DCs differentiate into their respective immature phenotype. Different 
subsets of DCs can be distinguished based on their cellular origin, half-life in 
peripheral tissues and the mechanisms by which they are renewed.  Figure 1.5 shows 
the differentiation pathways of human DC subsets  
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Figure 1-5 Differentiation pathways of human DC subsets. 
These differentiation pathways are largely controlled by cytokines; presence of particular cytokines 
can alter the differentiation pathway e.g. myeloid DC can differentiate into LC in the presence of 
TGFβ. Some DC lineages progress to a mature but quiescent state under the influence of cytokines 
alone, requiring antigen challenge via exogenous stimulation for full DC activation. However, other 
DC lineages remain in precursor form until stimulation by microbial products occurs.   
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1.2.3.2.1! Human Blood DC 
 
Our work focuses on human blood samples, and therefore human DC. Human 
blood DCs are heterogeneous in their expression of various cell surface markers, 
but many of these populations reflect differences in the maturation or activation 
states of DCs rather than separate sublineages (Hart, 1997).  
Human CD11c+ CD14+ blood monocytes give rise to immature myeloid DC 
(mDC) under the influence of granulocyte-monocyte colony-stimulating factor (GM-
CSF) and IL-4. The low levels of co-stimulatory molecules (CD40, CD80 and CD86) 
expressed on mDC in the blood suggest that these cells are immature DC (Sallusto 
& Lanzavecchia, 1994). Final maturation to DC expressing high levels of surface 
MHC class II is achieved by stimulating with proinflammatory cytokines such as TNF-
α or microbial products such as lipopolysaccharides (Albert, Jegathesan, & Darnell, 
2001). 
Human plasmacytoid DC (pDC) are distinguished phenotypically from mDC by the 
expression of IL-3 receptor (CD123), Toll-Like receptors 9 (TLR 9), BDCA-2 and by 
not expressing the myeloid markers CD11c and CD 33. Originally called interferon 
producing cells due to production of type I interferons (IFNs), they are found in the 
blood and many lymphoid tissues (Shortman & Liu, 2002). pDCs are considered the 
front line in anti-viral immunity owing their ability to rapidly produce of INF type I in 
response to viruses (Siegal et al., 1999).  
DC constitute less than 2% of the circulating leukocytes in human blood. Estimates 
vary depending on the methods used to isolate DC and the criteria used to define 
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them. Values range from 0.1-2% (Knight et al., 1986; Van Voorhis, Hair, Steinman, & 
Kaplan, 1982) 
1.2.3.2.2! Interstitial DC 
 
Interstitial DC are located in the interstitial spaces drained by afferent lymphatics in 
most organs. DC can be found at mucosal surfaces e.g. the gastro-intestinal tract and 
respiratory tract, as well as other organs including the skin, the spleen, the thymus 
and the liver. Although certain phenotypic differences have been observed amongst 
these different DC subsets, their lineage origins, maturation stages, and functional 
differences have not been clearly established. 
One of the significant properties of the gut mucosal immune system is to recognize 
and differentiate between commensal bacteria, food, and infectious agents in order 
to generate and balance specific immune responses. This supports the notion that 
DCs in gut mucosal tissue possess unique functions that allow them to regulate 
mucosal immune responses. The role of intestinal DCs in the induction of mucosal 
immune responses has been of great interest; however, intestinal DCs comprise a 
large network that has yet to be fully investigated. Appreciating the diversity of 
mucosal DCs, the origin of intestinal DCs has been under careful investigation. To 
date, most of the knowledge regarding intestinal DCs has been drawn from murine 
studies. 
There are a few important differences between the systemic DCs and the gut 
mucosal DCs. In response to pathogen-associated molecular patterns (PAMPs) or T 
cells, mucosal DCs secrete more anti-inflammatory cytokines, while systemic DCs 
secrete greater proinflammatory signals. Antigen presentation to T helper cells by 
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mucosal DCs induces Th2, Th3, or T regs, while systemic DCs induce Th1. Mucosal 
DCs play a role in the induction of gut homing markers on lymphocytes, while 
systemic DCs instruct naive CD8 T cells to home to the skin. (Iwasaki, 2007) 
1.2.3.2.3! Langerhans cells 
 
Human LCs are found in the epidermis of the skin and constitute the first 
immunological barrier against invading pathogens.  Although LCs are able to 
stimulate T cells and detect antigens, their role in generating an in vivo immune 
response has been questioned. Until recently it was assumed that cutaneous antigens 
were recognized and processed by epidermal LCs which then become activated to 
mature and migrate into draining lymph nodes for efficient antigen presentation to T 
cells. However, recent studies have questioned the role of LCs in antigen 
presentation, as antigen-specific T cell activation remains intact in LC deficient 
murine models (Kaplan, Jenison, Saeland, Shlomchik, & Shlomchik, 2005). Table 1. 5 
summarizes the characteristics of the main DC subpopulations.  
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Table 1-5 Main characteristics of the human DC subpopulations 
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1.2.3.3! In vivo and in vitro models of systemic DCs 
 
DC characterization in humans is usually carried out by exclusion of other cells 
types. DCs express MHC class II (HLA-DR), but this is also expressed on other APC 
such as B-cells and macrophages. However, DC do not express a set of lineage 
markers such as CD3 (T-cells), CD14 (monocytes), CD16 (macrophages), CD19 (B-
cells), CD34 (stem cells) and CD56 (NK cells). Therefore DC can be classified as 
HLA-DR positive but lineage marker negative. This approach is challenging due to 
the difficulty in readily isolating real live DCs from human blood but also due to the 
low numbers of circulating DC and the limited availability of human samples as 
opposed to animal models. All the experiments requiring isolation of blood DCs 
described later on in this thesis have been performed with the HLA-DR positive but 
lineage marker negative approach.  Molecules involved in maturation, co-stimulation, 
antigen uptake, microbial recognition, migration and also cytokine production are all 
used to phenotypically distinguish DC subsets. 
The in vitro generation of monocyte-derived dendritic cells (MoDCs) from CD14+ 
monocytes was first described by Sallusto and Lanzavecchia in 1994 (Sallusto & 
Lanzavecchia, 1994). With this in vitro model in the presence of GM-CSF and IL-4 
they were able to produce reasonable numbers of DCs that maintained the antigen 
capturing and procession capacity characteristics of the immature DCs in vivo. 
Although existence of MoDCs in vivo at the steady state is not certain, the existence 
of inflammatory MoDCs in vivo has previously been documented (Randolph, 
Beaulieu, Lebecque, Steinman, & Muller, 1998). In addition, data has suggested that 
TLR activation triggers differentiation of monocytes into dendritic-like cells (Krutzik 
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et al., 2005). Hence, the fact that they are an in vitro model should be remembered 
when experimental data derived from the use of MoDCs is interpreted.  
1.2.3.4! DC life span 
 
The life span of DCs can be split into two phases, the immature and the mature 
stage.  
1.2.3.4.1! Immature Phase 
 
DCs in their immature phase reside in the peripheral tissues and in the absence of 
inflammatory signals remain tissue-specific immature DC with low expression of co-
stimulatory molecules and cytokine production.  Immature DC also show weak 
migratory activities and T-cell priming properties; furthermore they are able to 
induce T-cell tolerance (Hawiger et al., 2001; Roncarolo, Levings, & Traversari, 
2001). These cells have a high phagocytic capacity and monitor the local environment 
for tissue injury and capture any antigen encountered (Hart, 1997). Immature DC 
are very efficient in antigen capture, and can use several pathways such as a.) non 
selective macropinocytosis which allows internalization of large volumes of fluid 
(Sallusto, Cella, Danieli, & Lanzavecchia, 1995) , b.) receptor mediated endocytosis 
via mannose receptor or via FcγR I and II which update IgG-antigen molecules 
(Fanger, Wardwell, Shen, Tedder, & Guyre, 1996; Stahl & Ezekowitz, 1998) c.) 
phagocytosis of particles such as apoptotic and necrotic cell fragments (Albert et al., 
1998), viruses, bacteria (Inaba, Inaba, Naito, & Steinman, 1993) as well as intracellular 
parasites (Moll, 1993).   
1.2.3.4.2! Mature phase 
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Activation of DCs in context of an inflammatory response is largely initiated by 
signals from pattern recognition receptors (PRRs) that respond to pathogen-
associated molecular patterns (PAMPs) on the surface of various pathogens. 
Maturing DC lose endocytic activity, increase surface expression and stability of 
MHC–peptide complexes, upregulate the surface expression of adhesion and co-
stimulatory molecules, while secreting inflammatory cytokines that are essential for 
T-cell activation. LPS-mediated maturation causes DCs to lose their ability to take up 
and process antigen (Granucci et al., 1999). During the maturation stage DCs have 
been shown to up-regulate the expression levels of new MHC molecules to allow 
efficient peptide presentation to T cells (Cella, Engering, Pinet, Pieters, & 
Lanzavecchia, 1997). DC maturation also involves the up-regulation of CD40, CD83 
and co-stimulatory molecules CD80 and CD86, which enables DCs to activate naïve 
T cells. Signaling via PRRs on DC induces expression of response genes including 
those encoding pro-inflammatory cytokines and chemokines and those that prolong 
the DC survival (Banchereau et al., 2000). 
Overlapping with DC phenotypic changes, there is an increase in their migratory 
capacity to regional lymph nodes where mature DC activate effector cells essential 
for the immune response. Inflammatory signals not only will trigger maturation of 
DCs but also a concomitant upregulation of CCR7, the chemokine receptor 
centrally required for DC trafficking to lymph nodes (Forster et al., 1999). Many 
DCs that seed peripheral organs enter lymph nodes through afferent lymph and this 
constitute part of the functional advantage that DCs have, to sample antigens in the 
periphery (Randolph, Angeli, & Swartz, 2005). These activated and migrating DCs 
move to distinct areas of the lymph node. Only a few DCs enter the blood either 
through reentry into venules found within peripheral tissues or through escape into 
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efferent lymph (Dandie, Watkins, Ragg, Holloway, & Muller, 1994). However, their 
true trafficking patterns remain to be determined (Randolph, Ochando, & Partida-
Sanchez, 2008).  
1.2.3.5! Overview of Lymphocyte Activation by DCs 
 
Effective activation of lymphocytes requires a molecular dialogue between receptors 
and ligands expressed by lymphocytes and DCs. ICAM-1 is an adhesion molecule 
that DC express and binds to its ligand LFA-1 on lymphocyte s, promoting cell 
adhesion (Marlin & Springer, 1987).  DCs also upregulate CD80, CD83 and CD86, 
all of which bind to CD 28 an important co-stimulatory molecule expressed on T 
cells. Interruption of this signaling pathway with CD28 antagonists not only results in 
the suppression of the immune response, but in some cases induces antigen-specific 
tolerance (Lenschow, Walunas, & Bluestone, 1996). CD 40 is a member of the TNF 
molecule family and is also expressed on DC. It binds to its ligand (CD40L) that is 
expressed mainly by activated Th cells (Grewal & Flavell, 1998).  Upon interaction 
and processing with exogenous proteins, DCs present the antigen by MHC class II / 
peptide complexes which enables the triggering of naïve CD4+ T cells. If a foreign 
endogenous protein infects the DC itself then the processing and the presentation 
through a MHC class I / peptide complex triggers the naïve CD+ T cells. However 
the phenomenon of cross-presentation enables the DCs to undertake MHC class I 
restricted presentation of exogenous antigen (Carbone, Kurts, Bennett, Miller, & 
Heath, 1998). Cross-presentation of antigens is a unique feature of DCs, which is 
critically important for antitumor immunity (see paragraph 1.3.4.3.5) 
Triggered Th cells upregulate the expression of CD40L and through its ligation with 
the CD40 molecule on DC leads to DC maturation and the upregulation of further 
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co-stimulatory molecules and cytokine expression (Steinman, Hawiger, & 
Nussenzweig, 2003). Increased expression of CD80 provides a ligand for CD28 on 
the Th cells leading to complete Th cell activation.  Functionally mature DCs may 
also facilitate naïve CD8+ T-cell activation as they can provide signals such as TCR-
specific and co-stimulatory signals. Activated Th cells play a vital role in the efficient 
activation of CD8+ T-cells, firstly through the CD40L upregulation that helps further 
on the maturation of DCs and secondly through the production of the cytokine IL-2 
and its receptors (Bennett et al., 1998; Ridge, Di Rosa, & Matzinger, 1998). IL-2 
promotes proliferation of CD8+ T-cells and Th cells by autocrine and paracrine 
growth. 
The DC facilitates B-cell activation by activating Th cells and by secreting cytokines 
such as IL-12 which B cells require for antibody production (Banchereau & Steinman, 
1998).  
Other APC such as macrophages, activated B cells can stimulate naïve T cells; 
however they are less potent than the DCs. Studies have shown that DC shave a 10 
to 100 fold greater number of MHC/peptide complexes on their cell surface and that 
they can produce greater quantities of co-stimulator, adhesion and IL-12 molecules 
(Guery & Adorini, 1995).  
The maturation dependent functional activity of DCs has been a commonly accepted 
paradigm. However emerging evidence suggests that the DCs can exist in a spectrum 
of functional states (plasticity) and that both phenotypically “immature” and mature” 
DCs may be conditioned by their microenvironment to maintain either immune 
tolerance (tolorogenic) or immunostimulation (immunostimulatory). Hence DCs are 
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the most potent APCs with high functional plasticity that play a key role in immune 
response regulation.    
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Figure 1-6 Dendritic Cells activation leads to phenotypic and morphologic changes 
Various factors such as pathogens and cytokines lead to the activation of immature 
DC. This process leads to DC maturation and alterations in the cells surface 
phenotype. (Adapted from Banchereau and Steinman 1998) 
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1.2.4! Tumor Immunology 
 
1.2.4.1! Immunosurveillance 
 
The concept of  “immunosurveillance” was originally proposed in the 1950s and 
describes the capacity of the immune system to generate an effective immune 
response to tumor associated antigens (TAA) that eradicates the developing cancer 
(Burnet, 1957). These TAA may be tumour specific such as unique products of 
mutated or activated oncogenes, or they may be antigens that are encoded by 
normal genes that are inappropriately expressed and are detected as a result of 
malignant transformation. The majority of the TAA expressed by tumours are self-
molecules.  However the role of “immunosurveillance” has extensively been 
debated. Experimental evidence from tumour formation in athymic nude mice and 
therefore with limited T-cell mediated immunity, did not showing an increased 
frequency of induced tumours after carcinogen injection compared to the wild-type 
counterparts and led to the abandonment of the “immunosurveillance” hypothesis 
(Rygaard & Povlsen, 1974; Stutman, 1979). This view demoted “immunosurveillance” 
and was clearly echoed when Hannah & Weinberg listed the six critical hallmarks of 
cancer development (Hanahan & Weinberg, 2000). There was not a significant 
mention with regards the immune response against cancer.  
Two key findings renewed the interest for the immune surveillance against cancer. 
Firstly it was the observation that the endogenously produced interferon γ (INF-γ) 
acts as a tumour surveillance system and protects against the development of 
chemically induced and spontaneously arising tumours (Kaplan et al., 1998). The 
second finding was the important role of other components of the immune system 
such as the NK cells which are involved in tumour rejection process (Smyth et al., 
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2000). The anti-tumour “immunosurveillance” concept was supported from 
definitive work from Shankaran et al in mice that were deficient in recombination-
activating gene-2 (RAG-2) and / or signal transducer and activators of transcription 
STAT-1 (Shankaran et al., 2001). RAG-2 is responsible for the expression of diverse 
antigen receptors on lymphocytes and therefore vital in adaptive immunity. STAT-1 
is the transcription factor involved in INF-γ signal transition and therefore important 
in innate immunity. RG-2 -/- and or STAT-1 -/- mice developed malignant tumours 
more rapidly and with greater frequency than the matched immunecompetent 
controls.  This observation supports the existence of a cancer immunosurveillance 
process that is dependent on both the INF-γ and lymphocytes. Since then many 
studies have shown the involvement of the different arms of the immune system 
against the development of cancer and positioned the evading of the immune 
destruction as an emerging hallmark of cancer development in the second review by 
Hannah and Weinberg in 2011(Hanahan & Weinberg, 2011).   
In humans the role of the immunological resistance to the development of cancer 
was noticed with the increase incidence of malignancies in patients with 
immunodeficiency. Cohorts of patients infected with HIV and transplanted patients 
in particular showed an increased occurrence of cancer (Frisch, Biggar, Engels, 
Goedert, & Group, 2001; Pham et al., 1995). Especially for CRC meta-analysis have 
shown an increased risk of 1.2 to 1.8 in patients with solid organ transplant in situ 
(Collett, Mumford, Banner, Neuberger, & Watson, 2010; Engels et al., 2011) with a 
more controversial increase for the HIV-infected patients (Grulich, van Leeuwen, 
Falster, & Vajdic, 2007).  
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1.2.4.2! Immunoediting and immune escape 
 
Several studies showed the immunoselective effect of repassage of transplantable 
tumours through immunecompetent hosts and the generation of tumour variants 
with reduced immunogenicity, suggesting that the tumours are imprinted by the 
immunologic environment in which they form (Urban, Holland, Kripke, & Schreiber, 
1982; Uyttenhove, Van Snick, & Boon, 1980). This imprinting process often lead to 
the survival of tumour variants of reduced immunogenicity or that have developed 
other mechanisms of immune escape. The changes that lead to the immune escape 
are believed to occur during the immunologic sculpting of a tumour when the 
tumour is perhaps not clinically detectable and the inherent genetic instability of the 
tumours facilitates the process (Lengauer, Kinzler, & Vogelstein, 1998). This term 
“cancer immunoediting” was then introduced to complete the concept of 
“immunosurveillance” (Dunn, Bruce, Ikeda, Old, & Schreiber, 2002). These term 
attempts to describe the dual host-protecting and tumour –sculpting actions of the 
immune system. According to the theory the “immunoediting” encompasses three 
phases: a.) Elimination of the tumour cells (“immunosurveillance”), b.) Equilibrium 
where the immune system selects or promotes the generation of tumour variants 
with less immunogenic characteristics and more likely to survive an immune attack 
and c.) the Escape phase that is characterize by tumour progression and clinical 
detection. Components of both the innate and the adaptive immune system play a n 
important role for all the phases of the “Immunoediting” process. 
In the first phase of the elimination, solid tumours reach a certain size and an 
invasive state that they need blood supply and this requirement causes the 
production of angiogenic and stromatogenic factors (Hanahan & Folkman, 1996). The 
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invasive growth leads to a rearrangement of the surrounding microenvironment that 
cause recruitment of the innate immune system into the site (Smyth, Godfrey, & 
Trapani, 2001). The cells responsible for the innate response include the 
granulocytes (neutrophils, eosinophils and basophils), mast cells, NK cells, γδ T cells 
a subset of T cells called NKT cells, DC and macrophages (Bendelac & Medzhitov, 
2002).  During the innate response, the bidirectional crosstalk among DCs and NK 
cells plays a fundamental role. DC promote NK cells activation, whereas NK cells 
influence DC maturation (Zitvogel, 2002).  Tumour cells that have downregulated 
their surface MHC class I molecules become targets for cytolytic function of the NK 
cells. This initial accumulation of NKT, NK and γδ T cells around the transformed 
tumour cells leads also to the production of INF-γ (Yokoyama, 2000). In the second 
phase of the elimination we observe the multiple function that INF-γ plays; a.) 
induction of angiostatic chemokines that not only block the tumour angiogenesis but 
also promote the recruitment of immune effector cells which leads to tumour cell 
death; b.) the activation of cytocidal activity  of NK and macrophages cells (Coughlin 
et al., 1998; Qin & Blankenstein, 2000). In the third phase of the elimination, tumour 
cell debris is ingested by DC which home to draining lymph nodes. In the lymph 
nodes the DC induce tumour specific CD4+ Th cells expressing INF-γ that they can 
also facilitate the development and recruitment of CD8+ T cells (Ferlazzo et al., 
2002; Piccioli, Sbrana, Melandri, & Valiante, 2002). During the final step of the 
elimination the tumour specific CD4+ and CD8+ T cells move to the tumour site 
with the help of a chemokine gradient where they destroy the TAA bearing cells 
(Shankaran et al., 2001).  
Given the ability of the immune system to fight cancer through the 
“immunosurveillance” phase, why then does cancer still occur? A tumour site 
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potentially contains many genetically unstable and rapidly dividing cells that the 
elimination phase did not manage to extinguish and these tumour cells that they 
survived enter the equilibrium stage. During this second phase of the 
“immunoediting” new variants arise carrying new mutations that provide the tumour 
cells with increase resistance to immune attack. The equilibrium stage is a period of 
Darwinian selection and it is believed to occur over a period of years.  
Once the surviving tumour variants acquire a definitive mechanism of avoiding the 
immune detection and elimination then the malignant disease becomes clinically 
detectable. The exposure of TAA to the immune system may induce tolerance via 
mechanisms of deletion, anergy or regulatory cell-mediated suppression (Pardoll, 
2003). This stage is called the “escape” and tumours at this stage are what clinicians 
and scientists have been trying for years to diagnose and treat.  
1.2.4.3! DC dysfunction in cancer 
 
DCs play a pivotal role in the tumour microenvironment and as described in 
paragraph 1.2.3 they are key determinants of whether the adaptive arm of the 
immune system is or is not be turned on during the “immunosurveillance” phase.  
Tumour infiltrating DCs (TIDCs) have been found in the tumour microenvironment 
in many cancers such as ovarian, breast, colorectal, lung, renal, head and neck and 
gastric (Karthaus, Torensma, & Tel, 2012).  Despite their crucial role in generating 
an immune response, DCs are a heterogeneous and rare type of immune cell. DC 
subtypes depend on their localization and differ in phenotype and function. Their 
diverse phenotypes allow the various DC subsets to specifically respond to the 
danger signals they encounter in their microenvironment (Ueno et al., 2010). Hence, 
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it is not only the presence of a DC but the DC’s explicit subset type and maturation 
status that will predict the nature of the immune response. Studies mainly using 
immunohistochemistry (IHC) have focused on DCs because of their crucial function 
in responding to tumour antigens and the presence of TIDCs correlates to the 
clinical prognosis for a variety of solid tumours including CRC.  
A variety of factors have been identified or suggested as potential mechanisms of 
immune escape with regards the DCs function against carcinogenesis.  
1.2.4.3.1! Abnormal frequency and infiltration of DC 
 
Quantitative and functional impairments of circulating DCs but also of TIDCS have 
been observed in various types of cancer. Blood DC numbers were reported as 
reduced in patients with gastric, hepatocellular, cervical, melanoma, renal, breast and 
head and neck squamous carcinoma compared with healthy controls (Della Bella et 
al., 2003; Hasskamp, Zapas, & Elias, 2008; Ormandy et al., 2006; Pinzon-Charry, 
Maxwell, & Lopez, 2005; Sakakura, Chikamatsu, Takahashi, Whiteside, & Furuya, 
2006). Similarly, TIDCs were presented in limited numbers in the tumour 
microenvironment for a variety of tumours such as breast, CRC and thyroid cancer 
(Ambe, Mori, & Enjoji, 1989; Lespagnard et al., 1999; Yamakawa et al., 1995). 
Although these findings were associated with a significantly worse prognosis the 
background mechanisms responsible for this phenomenon are still difficult to be 
explained. 
1.2.4.3.2! Abnormal differentiation and maturation of DC 
 
Bells et al in 1999 reported an immature/mature TIDCs compartmentalization 
pattern when they analyzed specimens of with breast adenocarcinoma. Immature 
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DCs adhere to the tumor cells, whereas mature DCs adhere selectively to 
peritumoral areas (Bell, Chomarat, et al., 1999). This distribution has led to the 
hypothesis that soluble factors derived from the tumour microenvironment may be 
responsible for the compartmentalization pattern of the TIDCs. Similar findings were 
seen in patients with melanoma, renal and prostate cancer (Toriyama, Wen, Paul, & 
Cochran, 1993; Troy, Summers, Davidson, Atkinson, & Hart, 1998; Zou et al., 2001); 
indicating that tumours could actively recruit immature DC to the tumour site and 
therefore control their differentiation into fully functional APC.  
One of the first cytokines reported to have an inhibitory effect on DC function in 
cancer was IL-10. It irreversibly blocks the differentiation of monocytes to DC and 
impairs the potent APC function of DC (Fricke & Gabrilovich, 2006; Ormandy et al., 
2006). Beckebaum et al showed that increased serum IL-10 correlated with 
decreased frequency and immature phenotype of circulating DC in patients with 
hepatocellular carcinoma (Beckebaum et al., 2004). TIDCs also were reported to 
overexpress several important regulatory genes that regulate their immune-
suppressive and/or paralyzed phenotype. The transcription factor STAT3, is 
hyperactivated in DCs following exposure to tumor-derived factors such as IL-10 
(Tran Janco, Lamichhane, Karyampudi, & Knutson, 2015). STAT3 hyperactivation 
induces S100A9 protein, which prevents complete maturation of DCs, thereby 
jamming their responsiveness to local danger signals.  An IL-6 and M-CSF secretion 
from tumour cell has also been shown to block the differentiation of CD34+ 
progenitors of DCs (Bharadwaj, Li, Zhang, Chen, & Yao, 2007; Menetrier-Caux et al., 
1998). Similar inhibition of DC differentiation has been attributed to tumour-derived 
vascular endothelial growth factor (VEGF). In addition to its function to induce 
neoangiogenesis and proliferation of endothelial cells, studies showed that increased 
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levels of VEGF correlated with reduced number of TIDCs and in peripheral blood 
and also with increased number of immature APC in the circulation of cancer 
patients (Gabrilovich et al., 1996; Hargadon, 2013). Transforming growth factor β 
(TGF-β), produced by the tumour cells immobilizes DC and inhibit their migration 
from the tumour site to the draining lymph nodes(Imai et al., 2012).  In addition to 
the cytokines , tumours also secrete other factors such as inflammatory mediators 
(gangliosides, PGE2) and metabolic products such as polyamines that affect DC 
differentiation (Della Bella et al., 2003; Peguet-Navarro et al., 2003; Yang et al., 
2003). Taken together the altered balance between mature and immature DC 
caused from tumour derived factors could underlie immune escape.   
1.2.4.3.3! Increased apoptosis of DC 
 
Esche et al in 1999 reported that tumour derived factors could induce apoptosis of 
DCs; making the programmed DC death as a potential escape route of the tumour 
cells from the immune recognition (Esche et al., 1999). Tumour cells release various 
pro-apoptotic factors such as IL-10, nitric oxide (NO), gangliosides and ceramides 
that can ultimately induce DC to undergo apoptosis (Pirtskhalaishvili, Shurin, Esche, 
et al., 2000; Pirtskhalaishvili, Shurin, Gambotto, et al., 2000). 
1.2.4.3.4! Functional Deficiency of DC  
 
In addition to the inhibitory effects of these tumour-derived factors on DC 
differentiation, certain subsets of DC fail to upregulate necessary co-stimulatory 
molecules and initiate vital cytokine signals to T cells and these functional DC 
impairments may cause tolerance or anergy (Ma, Shurin, Peiyuan, & Shurin, 2013). 
Anergy is induced through unsuccessful activation of antigen specific CD4+ and 
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CD8+ T cells and anergy through their unsuccessful proliferation (Legitimo, 
Consolini, Failli, Orsini, & Spisni, 2014). TIDCs also may suppress adaptive-immune 
responses indirectly with the induction of T regulatory that prevent immune 
responses by producing IL-10 and TGF-β (Ramos, de Moraes, Zelante, & Barbuto, 
2013).   
1.2.4.3.5! Effect of lipid accumulation   
 
In 2010, Herber et al during investigation of the effect of tumor-derived factors on 
DC differentiation, observed accumulation of lipids in DCs generated in the 
presence of tumor cell conditioned medium (Herber et al., 2010). This unexpected 
observation, alongside emerging evidence that dietary lipids and their metabolism 
may effect DC function (Knight, 2008; Sanderson, MacPherson, Jenkins, & Calder, 
1997); led them to investigate the potential role of lipid accumulation in DC function 
in cancer. This study demonstrated that a substantial proportion of DCs in tumour 
bearing hosts had increased amount of lipids, specifically triglycerides and that 
scavenger receptors (especially Msr1 CD 204) represented a major route in 
acquiring fatty acids from the DC.  The results also gave another explanation on how 
the host immune system can be compromised during cancer; an increase in lipid 
content of DCs diminishes their capacity to present antigens from tumour cells and 
to activate effector T cells. The authors finally demonstrated that normalization of 
lipid levels in DCs in mice using an inhibitor of acetyl-CoA carboxylase restored the 
ability of DCs to stimulate T cells. Work from the same group showed that oxidized 
lipids affect only cross-presentation and not presentation of endogenous Ags by DCs 
in cancer. This effect was caused by intracellular accumulation of different types of 
oxidized neutral lipids: triglycerides, cholesterol esters, and fatty acids (Ramakrishnan 
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et al., 2014). Efficient CTL priming requires an uptake of tumor Ags by DCs, their 
migration to draining lymph nodes, and a cross-presentation of the Ags to CD8+ T 
cells in the context of MHC-I (Alvarez, Vollmann, & von Andrian, 2008). O’Shea et al 
studying the susceptibility to viral infection observed in severe obesity also showed 
that clinical obesity negatively impacts the ability of systemic DC’s to mature and 
elicit appropriate T-Cell responses to a general stimulus (O'Shea et al., 2013).  
The suggested direct link between immune dysfunction in cancer and fat 
(intracellular lipid accumulation and clinical obesity) generated the basis for my thesis 
as it is described in Chapter 2.  
1.2.4.4! DC and colorectal cancer 
 
Similar to other type of cancer, CRC antigens can cause DC recruitment, maturation 
and activation in order to generate an effective T cell immune response (Cui et al., 
2007).  Several studies investigated the role and the clinical significance of the TIDCs 
in CRC and this aspect will be discussed in detail in Chapter 8.  
As pointed out previously (see 1.2.4.3), tumours such as CRC use various 
mechanisms to escape the “immunosurveillance” phase and more specifically to 
suppress the DC activation. Decreased mature DC density was reported in both 
human CRC and precancerous lesions such as colorectal adenomas (Yuan et al., 
2008). In an attempt to further explain the distribution pattern of the TIDCs Yan et 
al using quantitative real-time PCR demonstrated a gradually increasing level of 
COX-2 mRNA in the local tissues along the adenoma-carcinoma sequence, and 
double immunofluorescence staining showed a colocalization of PGE2 receptors with 
mDCs in the stroma of CRC. Upregulation of COX-2 is currently recognized as an 
important target for chemoprevention of CRC and the inhibition of host anti tumour 
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immune activity by suppressing DC activation and maturation may be one of the 
potential mechanisms (Chan et al., 2012). Schwaab et al also concluded that number 
of mature TIDCs was significantly lower in primary CRC specimens compared with 
normal colon mucosa ones and this decrease was correlated with the expression of 
VEGF in the tumour microenvironment (Schwaab, Weiss, Schned, & Barth, 2001).  
Changes in the DCs and other cells of the immune system not only occur in the 
microenvironment but also in the systemic circulation although with limited evidence 
from the literature. Huang et al showed a significant increase in the serum level of 
TGF-β correlated with a significant reduction up to 60% in the level of circulating 
DCs in CRC patients compared to healthy control levels and also that the 
prevalence of co-stimulatory molecules expression in circulating DCs from CRC 
patients was reduced compared to patients with inflammatory bowel conditions (A. 
Huang et al., 2003). Della Porta et al studied a cohort of 54 CRC patients and at 
diagnosis CRC patients presented with significantly reduced levels of blood DC 
compared to healthy individuals; this observation was also correlated with the 
disease stage and inversely correlated with serum VEGF levels. The surgical removal 
of the tumor and chemotherapy appeared to reduce this DC loss after 6 to 12 
months post treatment. In contrast, patients with CRC metastatic disease had 
peripheral DC numbers comparable to those at diagnosis when measured after 
treatment.(Della Porta et al., 2005) Orsini et al demonstrated similar results when 
they enumerated ex vivo myeloid and plasmacytoid DCs, through multicolor flow 
cytometry, in 26 CRC and 33 healthy controls. At diagnosis the absolute number of 
pDCs in CRC patients was significantly reduced in comparison to controls and this 
result was correlated with the stage of the disease. This reduction was recovered 
after surgical removal of the tumour (Orsini et al., 2014). Other studies showed 
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numerical differences and differences in the functional phenotype of circulating DC 
from CRC patients but the vast majority of them are based on experiments from 
monocyte-derived DCs. Nevertheless, the paucity of DC–specific reagents and the 
different methods for DC identification make a direct comparison of the results 
difficult. Data about the phenotype and function of circulating DCs in CRC patients 
are still limited (Bellik et al., 2006; Orsini et al., 2013). Table 1.6 summarizes the 
important studies looking into systemic DC changes in CRC. 
In Chapter 7 we investigate the relationship between DC phenotype in CRC disease 
and its relationship with disease and host’s BC characteristics using blood DCs 
isolated ex-vivo from health controls and CRC patients.  
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Table 1-6 Summary of important studies identified though the literature looking into 
systemic DC changes in CRC 
Source Number 
of patients 
Method of DC 
identification 
Important findings 
Huang et al 
2008 
106 CRC 
27 IBD 
61 healthy 
controls 
PBDC isolation ex-vivo 
Lineage (–) 
[CD3, CD14, CD16, 
CD19, CD20, CD56] 
HLA DR (+) and  
CD86 (+) 
•! Increase in the serum level of TGF-β 
correlated with a significant reduction in the 
level of circulating DCs in CRC 
•! The prevalence of co-stimulatory molecule 
expression in circulating DCs was reduced in 
patients with CRC compared to IBD patients. 
Della Porta 
et al 2005 
54 CRC 
6 healthy 
controls 
PBDC isolation ex-vivo 
Lineage (–) 
[CD3, CD14, CD10, 
CD16, CD19, CD34, 
CD56] 
ILT3 (+)  
 
•! CRC had reduced number of DCs compared 
to healthy controls 
•! The reduction was positively correlated with 
CRC stage and negatively with VEGF serum 
level. 
•! DC in CRC displayed an ‘immature’ 
phenotype with very low levels of accessory 
signals for T cell activation such as 
CD40, CD86 and of surface MCH II 
molecules and with a reduced T cell 
stimulation capability. 
Orsini et al 
2014 
26 CRC 
33 healthy 
controls  
PBDC isolation ex-vivo 
Lineage (–) 
[CD14, CD16, ILT3 
(+)] 
ILT3 (+)  
Subsets  
CD33 (+) for the 
myeloid DCs and 
CD123 (+) for the 
plasmacytoid DC 
subset  
•! Reduction of plasmacytoid DCs in total and 
advanced stage-CRC patients compared to 
healthy controls 
•! Reduction was totally recovered after 
complete tumor resection 
 Bellik et al 
2006 
27 CRC  
10 healthy 
controls 
monocyte-derived DCs 
 
Subsets 
BDCA-1 and BDCA-3 
for myeloid DCs 
BDCA-3 for 
plasmacytoid DCs 
•! Both myeloid and plasmacytoid circulating 
DCs were significantly lower in CRC patients 
compared to healthy controls 
•! Both DC subsets were increase in metastatic 
compared to non metastatic disease 
Orsini et al 
2014 
23 CRC  
14 healthy 
controls 
monocyte-derived DCs 
 
 
•! DCs had lower co-stimulatory molecule 
expression and were less able to present 
antigens to allogeneic T cells in CRC patients 
compared to healthy controls 
Abbreviations; CRC = Colorectal Cancer, PBDC= Peripheral Blood Dendritic Cell 
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Chapter 2 
2! Summary and aims  
 
2.1! Summary 
 
CRC is the fourth most common cause of cancer death and the third most common 
cancer worldwide. There have been recent advances in molecular and cellular 
biology that have improved our understanding of the genetic pathways and 
background involved in CRC development but the elements that regulate the disease 
progression are still uncertain. Pathological stage remains the basis of CRC prognosis 
and decisions making tool regarding the provision of additional treatments such as 
adjuvant chemotherapy. CRC are classified according to the TNM classification 
system.  Treatment planning is based on combinations of the tumor local invasion 
depth (T-stage), the presence of positive lymph node (N-stage) and distant 
metastasis (M-stage). Although the TNM staging system provides useful prognostic 
information, an individual patient outcome from therapy cannot be accurately 
predicted. Therefore, there is a need for additional prognostic markers to 
complement the TNM system.  
Data support the fact that colorectal carcinogenesis, recurrence and progression are 
determined by complicated interactions between tumour- and host-related factors. 
A general term, named “immunoediting”, has been proposed to describe the process 
whereby the host immune system may act to either eliminate or facilitate tumour 
progression (tumorigenic effect). With this model in mind, there is consistent 
evidence that activation and maintenance of a SIR is associated with the development 
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and the progression of CRC while an effective local immune response in the tumour 
microenvironment also contributes to a favorable outcome. NLR has recently been 
proposed as a surrogate marker for SIR and as predictor for cancer outcomes. 
Despite the fact that is readily available and easy to calculate marker, its prognostic 
utility and optimization for patients undergoing treatment for primary operable CRC 
has yet to be determined. The inter-relationships between SIR and other clinical and 
pathological features of CRC such as age, gender, comorbid status, stage, grade of 
differentiation, lymphovascular invasion is still unclear. 
Emerging evidence support the link between SIR with certain BC profiles of the host 
but limited information exists on how the inflammatory response is associated to 
these alterations. BC defined the proportions of fat, muscle and bone of an 
individual. Muscle depletion is characterized by reduction in muscle size (myopenia) 
and an increased infiltration by inter- and intramuscular fat, described as 
myosteatosis. Visceral obesity is defined as the excessive accumulation of central fat 
intrabdominally. A number of BC measurements have been proposed methods 
including assessments at the atomic, molecular, cellular, tissue-system and whole-
body levels exist. CT BC imaging is particularly relevant in patients with solid cancers 
as it is routinely employed for disease staging and therefore can be assessed with 
little increase in healthcare costs. The underlying basis of the inflammatory response 
in patients with CRC is unclear and previous reports have linked SIR with increasing 
burden of comorbidity but it is uncertain whether these associations are dependent 
on other aspects of the host such as BC. Emerging evidence advocate that 
inflammation and cancer cachexia are closely related and it may be that an activation 
of the SIR is indicative of, or indeed responsible for, the changes in BC seen in 
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cancer patients. However, there is a lack of studies aiming to identify associations 
between systemic and local immune response with BC profiles of patients with CRC.  
In addition, specific BC phenotypes have also been proposed, as poor prognostic 
indicators in patients with cancer but evidence are still weak. Obesity defined by BMI 
seems to confer a survival advantage in patients treated with cancer and this 
phenomenon has been called “the obesity paradox”. In attempt to explain this 
paradox, it has been suggested that BMI does not correspond to the same level of fat 
tissue in patients with different statures nor specifies the BC synthesis of an 
individual. With the development of novel ways to measure not only the adipose 
tissue but also the quantity and the quality of the muscle tissue of a human body, 
new indexes have been developed. Therefore the role of myopenia, myosteatosis 
and visceral obesity as prognostic factors for short and long-term outcomes in 
patients treated for CRC needs to be explored. Understanding what BC parameters 
contribute to CRC outcomes may lead to novel and more effective interventions 
that support optimal BC and metabolism, ultimately improving clinical and metabolic 
outcomes in cancer patients.  
Dendritic cells (DCs) are the most potent antigen presenting cells, capable of 
sampling antigens and initiating cytotoxic T-lymphocyte response against cancer cells. 
Colorectal tumor antigens induce DCs recruitment, maturation, and cytokine 
release in order to generate effective Th1-type immune response. Despite their 
crucial role in generating an immune response, DCs are a heterogeneous and rare 
type of immune cell. DC subtypes depend on their localization and differ in 
phenotype and function. The infiltration of DCs into primary tumours has also been 
found to be associated with survival and the incidence of recurrent disease in 
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patients with different malignancies, including CRC.  To date very little data are 
available in the literature on how parameters of the patient’s BC like myopenia, 
myosteatosis and visceral adiposity influence the DCs phenotype and function. 
In patients with CRC the presence of high numbers of tumour infiltrating 
lymphocytes is generally perceived as beneficial but here again there remains a 
number of outstanding questions. Similar to the systemic response, the factors 
responsible for initiating and/or maintaining a local inflammatory response are 
unknown. Many previous studies have investigated lymphocyte subtypes in isolation 
or have failed to describe their localization within the tumour microenvironment. 
Fewer still have analysed the relationships between individual immune cells and 
patient-related characteristics. Finally, although a large number of studies have 
examined the prognostic impact of immune cells in colorectal tumours, there is 
considerable disparity in the methodologies and definitions used. Local inflammatory 
response depends on the ability of immune cells to actively migrate in and out of 
tissue, and chemokines are established regulators of immune cell migration and 
survival. CCR7 is an essential chemokine that is expressed on naıve T cells, memory 
T cells, B cells, and mature dendritic cells, and is considered to play an important 
role in lymphocyte cell trafficking and homing to lymph nodes. In cancer, CCR7 
expression on immune cells regulates homing of lymphocytes into secondary 
lymphoid organs and may also be involved in the lymphatic spread of solid tumors. 
Evidence suggests that assessment of the CCR7 expression on CRCs specimens 
might improve prediction not only of the survival outcome but also of lymph node 
spread. No study has yet determined the expression of CCR7 in primary colorectal 
cancer and investigated its impact on disease progression and survival and also the 
relationship with the body composition profile of the host.  
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2.2! Hypothesis 
 
Based on the ambiguity identified above the following hypothesis was generated: 
 
“A Colorectal Cancer Patient’s Body Composition Influences Outcomes And Is Associated 
With Differences In Systemic And Local Immune Response” 
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2.3! Aims 
 
To investigate the areas of uncertainty detailed above, in patients undergoing 
potentially curative resection of colorectal cancer, studies were carried out: 
•! To examine the role of body composition evaluation by computerized 
tomography in determining colorectal cancer outcomes. 
•! To investigate the impact of BC on CRC short and long term outcomes. 
•! To identify, optimize and examine the relationships between patient 
physiology, the systemic inflammatory response and treatment outcomes. 
•! To investigate the link between Systemic IR and BC in CRC. 
•! To question if there is a trajectory of change in BC over time and identify 
factors that may contribute to the changes 
•! To characterize the phenotype of circulating Dendritic Cells in patients with 
CRC disease and healthy controls. 
•! To examine the relationships between the BC anthropometric parameters on 
DC phenotype in patients with CRC. 
•! To grade the Local IR and evaluate its relationship with BC parameters in 
patients with CRC. 
•! To investigate the relationship of LIR with BC and its prognostic utility for 
CRC outcomes. 
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Chapter 3 
 
3! The Role of Body Composition Evaluation by Computerized 
Tomography in Determining Colorectal Cancer outcomes; A 
systematic review of the literature 
 
A highly differentiated understanding of human BC has evolved in tandem with 
image-based modalities such as computed tomography. The premise of CT scans for 
body composition research has been described in detail Chapter 1. In this chapter a 
systematic review of the literature was undertaken to identify evidence that link 
parameters derived from CT BC and CRC outcomes. The selected evidence was 
critically appraised and the limitations of the included studies were identified. The 
conclusions of this study founded the basis for the following Chapters 3+4.  
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3.1! Introduction 
 
Colorectal cancer (CRC) is the second leading cause of cancer mortality in the UK 
(CRUK, 2011). Research has focused largely on tumour molecular biology, whereas 
little is known about the importance of host-related homeostatic factors and more 
specifically, host body composition (BC). BC defines the proportions of fat, muscle 
and bone of an individual. Obesity is a well-established risk factor for development of 
CRC, and is associated with cancer-related mortality (Bardou et al., 2013) . What 
drives the association between obesity and cancer remains unclear. Emerging 
research has targeted the study of different fat compartments, with visceral fat 
considered as more pro-inflammatory and pro-tumorigenic than subcutaneous fat 
(Kershaw & Flier, 2004). Sarcopenia, originally described as the depletion of skeletal 
muscle with age, has also been identified as a predictor of poor outcome in gastro-
intestinal cancers (Muscaritoli et al., 2010).   
CTBC imaging is particularly relevant in patients with CRC because it is routinely 
employed for disease staging and therefore can be assessed with little increase in 
healthcare costs. It utilises cross-sectional imaging and enables measurements at the 
tissue-system level. Using pre-established Hounsfield Units (HU), various tissue 
compartments are demarcated and measured. Measurements are reported using of 
tissue cross-sectional area (cm2) from a single image from a level regarded as most 
representative of whole-body tissue volumes. Measured at the Lumbar 3 level, total, 
visceral or subcutaneous adipose (fat) area (TFA, VFA, SFA), total psoas area (TPA), 
visceral adipose volume (VFV) or skeletal muscle index (SMI) form part of the 
taxonomies used. SMI (cm2/m2) is defined as the cross-sectional areas (cm2) of the 
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sum of all the skeletal muscles at the lumbar 3 level normalized for height in meters 
squared (m2).   
Mourtzakis et al have demonstrated that cross-sectional areas of fat and fat-free 
tissues at lumbar level measured on CT scanning correlate strongly with whole body 
tissues (Mourtzakis et al., 2008). To date, research using CTBC quantification 
techniques has suggested that patients with high visceral adipose tissue or skeletal 
muscle mass depletion have a poorer functional capacity, greater chemotherapy 
toxicity, more rapid time to cancer progression and higher mortality in situations 
where weight loss and body mass index (BMI) lack predictive power (Martin et al., 
2013; Morley, Baumgartner, Roubenoff, Mayer, & Nair, 2001; Prado et al., 2008). 
This systematic review of the literature aims to evaluate the role CTBC analysis in 
relation to the short-term, oncological, and long-term outcomes for colorectal 
cancer patients.  
 
 
3.2! Methods 
 
3.2.1! Search strategy  
 
This study was performed in accordance with PRISMA recommendations (Moher, 
Liberati, Tetzlaff, Altman, & Group, 2009). Medline, EMBASE, Google Scholar, and 
Cochrane databases were interrogated using the following search terms: (“body 
composition” OR “sarcopenia” OR “myopenia” OR “visceral adiposity” OR “visceral 
obesity” OR “visceral fat” OR “adipose tissue” OR “fat” OR “skeletal muscle” OR 
“lean body mass” OR “ lean soft tissue”) AND (“colorectal” OR “colon” OR 
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“rectal” OR “rectal”) AND “Computerized Tomography”. The search protocol was 
registered on PROSPERO (identification number CRD42014013784). The reference 
lists of all identified publications were searched for additional studies. Two reviewers 
independently assessed all identified abstracts and titles of studies meeting the 
predetermined selection criteria to confirm eligibility. An independent third reviewer 
resolved discrepancies in data extraction.  
3.2.2! Selection criteria  
 
Only articles published in the English language between January 1990 and March 
2014 were considered. All studies evaluating body composition parameters 
(sarcopenia or myopenia or visceral obesity) on outcomes from patients following 
colorectal cancer treatment using a well-described CT-based analysis in an adult 
population (aged 18 years or more) were selected. They were excluded if they did 
not include a colorectal cancer patient group, used modalities other than CTBC, or 
did not report the outcomes of interest. Conference abstracts were excluded.   
3.2.3! Outcomes of Interest 
 
The following demographic data were extracted: study type, patient numbers, 
disease stage, treatments, timing of CT analysis, level of CT image used for analysis, 
software and calculated BC parameters. Outcomes of interest included operative 
outcomes (thirty day mortality, operation time (OT), length of stay (LOS), wound 
infection, post-operative complications, resumption of oral intake and anastomotic 
leak), oncological outcomes (lymph node harvest, chemotherapy outcomes) and 
survival (recurrence-free or disease-free and overall survival). Study quality was 
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assessed according to the Scottish Intercollegiate Guidelines Network (SIGN) 
(Harbour & Miller, 2001).  
 
3.3! Results 
 
3.3.1! Search outcome 
 
Twenty studies matched the selection criteria. Four exclusions included three 
reviews and one study investigating the impact of BC parameters on the host’s 
inflammatory response. Sixteen studies were eligible for review (Ballian et al., 2012; 
Barret et al., 2014; Clark et al., 2013; Guiu et al., 2010; Ishii, Hasegawa, Nishibori, 
Watanabe, & Kitajima, 2005; Lieffers, Bathe, Fassbender, Winget, & Baracos, 2012; 
Moon et al., 2008; Peng et al., 2011; Prado et al., 2007; Reisinger et al., 2015; Rickles 
et al., 2013; Seki et al., 2007; Tsujinaka et al., 2008; van Vledder et al., 2012; 
Watanabe et al., 2014; Yamamoto et al., 2012). All were cohort studies (evidence 
grade C). In three studies (Barret et al., 2014; Reisinger et al., 2015; Watanabe et al., 
2014), data were collected prospectively with the remaining thirteen studies being 
retrospective. One retrospective study used registry data (Lieffers et al., 2012) and 
another analysed a multicentre database (Barret et al., 2014). The remainders were 
single centre studies.  
3.3.2! CTBC analysis 
 
Thirteen studies chose L3 vertebral level; two studies used L4-5 vertebral level 
(Clark et al., 2013; Watanabe et al., 2014). One study used three-dimensional 
reconstruction to calculate VFV (Rickles et al., 2013). Nine-image analysis software 
were reported. One study did not specify the software (Ishii et al., 2005).  
 121 
Two categories were assessed; visceral adiposity and skeletal muscle. Visceral 
obesity was defined by measuring VFA, VFA/SFA, VFV and muscle mass using TPA or 
SMI with different cut-off values 
3.3.3! Prevalence of sarcopenia and visceral obesity 
 
The incidence of visceral obesity varied from 17.5% to 61.4% and sarcopenia 
prevalence varied from 15.9% to 71%. Table 3.1 shows study demographics, CTBC 
software, and analysis levels. 
3.3.4! The effect of CTBC on short-term post-operative outcomes 
 
Eleven studies investigated CTBC’s impact on short-term outcomes after curative 
CRC resections or resections for colorectal liver metastasis (CRLM). (Table 3. 2)  
3.3.4.1! Thirty-day mortality 
 
Reisinger et al prospectively investigated the relationship between functional decline 
reflected by sarcopenia and postoperative morbidity and mortality after colorectal 
cancer surgery (n=310 patients). Data were reported as SMI. The cut-off values used 
for sarcopenia were 52.4cm2/m2 for men and 38.5cm2/m2 for women, based on a 
previous study from Prado et al (Prado et al., 2008). Thirteen out of fourteen deaths 
within 30 days were in the sarcopenic group. Sarcopenia independently predicted 
mortality (OR=43.30; 95%CI=3.09-313.9; P=0.007), adjusted for age, sex and 
previous abdominal surgery.  
3.3.4.2! Postoperative length of stay  
 
Seven studies examined BC parameters and postoperative LOS. Two studies 
demonstrated a significant association with sarcopenia (Lieffers et al., 2012; Peng et 
 122 
al., 2011); one study showed significant associations with visceral obesity (Tsujinaka 
et al., 2008).  
Tsujinaka et al retrospectively assessed 133 consecutive patients undergoing elective 
laparoscopic colectomy for stage I to IV sigmoid cancer.  Based on previous studies, 
patients with VFA≥130 cm2 were classified as visceral obese (Hunter, Snyder, Kekes-
Szabo, Nicholson, & Berland, 1994). Only visceral obesity and not patients 
categorised as obese according to BMI, had a longer LOS (10.5 days Vs 9 days; 
P=0.007).  
Lieffers et al assessed muscle depletion and postoperative outcomes in 234 patients 
with stage II-IV CRC. Sarcopenic patients were identified using sex-specific cut-off 
values for the SMI.15 Patients without sarcopenia had LOS of 10.6±6.2 days 
compared with 13.2 ±8.8 days in patients with sarcopenia (P= 0.012) (Lieffers et al., 
2012). 
 Peng and collegues investigated sarcopenia in 259 patients undergoing liver 
resection for CRLM by measuring TPA on perioperative CT images at L3 level. 
Through sensitivity analysis, 500mm2/m2 was defined as the most relevant cut-off 
value for sarcopenia. Sarcopenic patients had longer LOS (6.6 vs. 5.4 days; P = 0.03) 
and a higher likelihood of extended intensive care stay (>2 days; P = 0.004) (Peng et 
al., 2011). 
Four studies investigating visceral obesity and LOS found no associations. Visceral 
obesity in two studies (Ishii et al., 2005; Watanabe et al., 2014) was defined as 
VFA>100 cm2 according to Japanese Society for the Study of Obesity (Examination 
Committee of Criteria for 'Obesity Disease' in & Japan Society for the Study of, 
2002).  Ballian et al studied 113 rectal cancer patients treated with neoadjuvant 
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chemoradiation (NCR) and total mesorectal excision (Steinman & Witmer) assessing 
VFA and SFA as continuous variables (Ballian et al., 2012). Rickles et al studied VFV 
in 219 patients undergoing curative surgical resection (Rickles et al., 2013). No BC 
parameters were related to postoperative LOS.  
3.3.4.3! Operative time 
 
Seven studies considered visceral obesity and OT, significant differences were 
reported in four. Watanabe et al identified OT in VFA obese patients was longer 
than VFA non-obese (197 vs 178 min; P=0.001) (Watanabe et al., 2014). Tsujinaka et 
al also concluded that patients with VFA or BMI obesity had longer OT than non 
VFA or BMI obese patients undergoing laparoscopic colectomy for sigmoid colon 
cancer (220 Vs 190 min; P=0.006 [VFA]; 237 Vs 207.5 min; P=0.01 [BMI variable]) 
(Tsujinaka et al., 2008). Seki et al studied VFA in 58 patients undergoing laparoscopic 
resection of early rectosigmoid tumours demonstrating longer OT with visceral 
obesity (OT=209 Vs 179 mins; p=0.031) (Seki et al., 2007). A significant difference 
between VFA obese and non VFA obese patients (OT= 377 Vs 305 mins; p=0.026) 
was also identified by Ishii and colleagues (Ishii et al., 2005). Studies from Yamamoto, 
Rickles and Ballian found no association between OT and visceral obesity (Ballian et 
al., 2012; Rickles et al., 2013; Yamamoto et al., 2012). 
3.3.4.4! Post-operative wound infection 
 
Tsujinaka et al showed wound infection incidence in patients undergoing 
laparoscopic surgery for sigmoid cancer, was significantly higher in VFA-obese 
compared with VFA-non-obese patients (14/68 vs 3/65; P=0.006) (Tsujinaka et al., 
2008). Watanabe et al showed that the incidence of surgical site infections was 
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significantly higher in the VFA obese group when compared to the non-obese group 
(19/194 Vs 28/144; P=0.016) (Watanabe et al., 2014). Incisional wound infection 
incidence was threefold higher in visceral obese patients as stated by Rickles et al 
(13/111 vs 4/108; P=0.041) (Rickles et al., 2013). Two studies found no relationships 
with wound infection rates and visceral obesity (Clark et al., 2013; Ishii et al., 2005). 
3.3.4.5! Overall post-operative complications 
 
Lieffers et al found sarcopenia was associated with an increased rate of post-
operative infection identified from ICD-10 diagnostic codes (23.1% vs 12.6%, 
P=0.036) (Lieffers et al., 2012). In a multivariate analysis, sarcopenia independently 
predicted postoperative infections (OR 4.6; 95%,CI=1.5–13.9).  Tsujinaka et al 
demonstrated more than twofold increase in the overall post-operative 
complications VFA-obese patients (Tsujinaka et al., 2008). Ishii and colleagues found 
that complications overall were significantly more frequent in the visceral, but not 
BMI-categorised obese group, with visceral obesity being an independent risk factor 
after laparoscopic rectal cancer surgery (OR=10, 95%CI=1·2-84·5;P =0·035)(Ishii et 
al., 2005). Watanabe et al showed that VFA obesity was an independent predictor of 
thirty-day morbidity (OR=2.14, 95%CI=1.23-3.72; P=0.007) (Watanabe et al., 2014). 
Peng et al studied patients undergoing surgery for CRLM. Multivariate analysis found 
sarcopenia to be independently associated with major complications. (Clavien - 
Dindo >= 3 43) (OR 3.12, [95% CI  1.14–8.49]; P=0.02) (Peng et al., 2011). Three 
studies found no association, between visceral obesity and all complications (Clark et 
al., 2013; Rickles et al., 2013; Seki et al., 2007). Reisinger et al found no relationship 
between sarcopenia and postoperative septic complications (Reisinger et al., 2015). 
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3.3.4.6! Resumption of normal oral intake  
 
Three studies investigated visceral obesity in relation to the number of postoperative 
days before resumption of normal oral intake (Ballian et al., 2012; Ishii et al., 2005; 
Seki et al., 2007; Tsujinaka et al., 2008). Seki and colleagues reported a low VFA/SFA 
ratio was significantly associated with earlier resumption of oral intake (2 .4 vs 3 .1 
days respectively; p=0.005)(Seki et al., 2007). 
3.3.4.7! Anastomotic leakage 
 
Four studies investigated BC and anastomotic leakage. Watanabe et al reported that 
increased visceral obesity was associated with a greater risk of an anastomotic 
leakage in 338 consecutive elective laparoscopic resections for colon cancer (9/100 
Vs 2/192; p=0.011). In multivariate analysis, VFA-defined obesity was an independent 
predictive factor for anastomotic leakage (OR 6.27 [95%CI=1.32-29.69], p=0.021) 
(Watanabe et al., 2014). Studies by Ishii and colleagues and Seki and colleagues with 
smaller populations found no differences in the incidence of anastomotic leak in 
relation to visceral obesity (Ishii et al., 2005; Seki et al., 2007). Reisinger et al did not 
find sarcopenia to be associated with anastomotic leakage (Reisinger et al., 2015).  
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Table 3-1 Characteristics of the studies assessing Computer Tomography Body Composition Analysis in Colorectal cancer outcomes 
Author, Year, 
Country 
Type of study Registry ⁄ 
Centre 
Number of 
patients 
Timing of CT 
scam 
Level of 
analysis 
Image software 
used 
Level of 
Evidence* 
Reisinger et al, 2014, 
U.S.A  
Prospective cohort 
study 
Single Centre 310 Preoperative L3 Osirix® 2+ 
Watanabe et al, 2014, 
Japan  
Prospective cohort 
study 
Single Centre 338 Preoperative L4 FatScan® 2+ 
Clark et al, 2013,  
U.S.A  
Retrospective 
cohort study 
Single Centre 99 Pre-treatment L4-L5 Siemens Medical 
Solutions® 
2- 
Ballian et al, 2012, U.S.A  Retrospective 
cohort study 
Single Centre 113 Preoperative Umbilicus Ziosoft® 2- 
Rickles et al, 2012, 
U.S.A  
Retrospective 
cohort study 
Single Centre 219 Preoperative S1 to 12cm 
cranially 
Institution’s PACS 2+ 
Lieffers et al, 2012, 
Canada  
Retrospective 
cohort study 
Cancer registry 234 Preoperative L3 Slice-O-Matic® 2+ 
Yamamoto et al, 2012, 
Japan  
Retrospective 
cohort study 
Single Centre 273 Preoperative Umbilicus FatScan® 2- 
Moon et al, 2008, South 
Korea  
Retrospective 
cohort study 
Single Centre 161 Preoperative Umbilicus and iliac 
crest level 
Institution’s PACS 2+ 
Tsujinaka et al, 2008, 
Japan  
Retrospective 
cohort study 
Single Centre 133 Preoperative Umbilicus Ziosoft® 2- 
Seki et al, 2007 Japan  Retrospective 
cohort study 
Single Centre 58 Preoperative Umbilicus “Fat-Scan” 2- 
Van Vledder et al, 2011, 
Netherlands  
Retrospective 
cohort study 
Single Centre 196 Perioperative L3 MeVisLab® 2+ 
Peng et al, 2011, U.S.A  Retrospective 
cohort study 
Single Centre 259 Perioperative L3 UltraVisual® 2+ 
Barret et al, 2012, 
France  
Prospective cohort 
study 
Multicentre 
study 
51 Pre-treatment L3 Slice-O-Matic® 2+ 
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Prado et al, 2007, 
Canada  
Prospective cohort 
study 
Single Centre 62 Pre-treatment L3 Slice-O-Matic® 2+ 
Guiu et al, 2009,  
France  
Retrospective 
cohort study 
Single Centre 120 Pre-treatment Umbilicus ImageJ® 2+ 
Ishii et al, 2005 
Japan  
Retrospective 
cohort study 
Single Centre 46 Pre-treatment L3-L4 NA 2- 
Abbreviations: L=lumbar; NA=Not available  
* Study quality was assessed according to the Scottish Intercollegiate Network (SIGN) 
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Table 3-2 . The effect of CTBC on short-term post-operative outcomes 
Study Stage  CTBC parameter 
used 
30-Day 
Mortality 
Length of 
Stay 
Operative 
Time 
Wound 
Infection 
Complications Resumption of 
oral intake 
Anastomotic 
leakage 
Reisinger  I-IV  
CRC 
Sarcopenia; L3 SMI; 
<52.4cm2/m2 for 
men <38.5cm2/m2 
for women 
↑ in Sarcopenic 
patients  
_ _ - No association 
for sepsis 
_ No association 
Watanabe   I-IV  
CC 
Visceral Obesity; L3 
VFA; >100 cm2 
_ No 
association 
↑ in 
Viscerally 
obese 
patients 
↑ in Viscerally 
obese patients 
↑ in Viscerally 
obese patients 
_ ↑ in Viscerally 
obese patients 
Clark  I-IV RC Visceral Obesity; L4-
L5 VFA/SFA; <0.4 
_ _ _ No association No association   
Ballian  I-IV RC  Visceral Obesity; L3 
VFA (continuous) 
_ No 
association 
No 
association 
_ _ ↑ Viscerally obese 
patients 
_ 
Lieffers  II-IV CRC Sarcopenia; L3 SMI; 
<52.4cm2/m2 for 
men <38.5cm2/m2 
for women 
_ ↑ in 
Sarcopenic 
patients 
_ _ ↑ in Sarcopenic 
patients 
_ _ 
Rickles  I-III CRC Visceral Obesity; 
S1to 12cm cranial 
VFV; >50th percentile 
_ No 
association 
No 
association 
↑ in Viscerally 
obese patients 
No association _ _ 
Yamamoto  Dukes’ A-C 
CRC  
Visceral Obesity; L3 
VFA; >130cm2 for 
men >90 cm2 for 
women 
_ _ No 
association 
_ _ _ _ 
Tsujinaka  I-IV SC Visceral Obesity; L3 
VFA; >130cm2 
_ ↑ in Viscerally 
obese 
patients 
↑ in 
Viscerally 
obese 
patients 
↑ in Viscerally 
obese patients 
↑ in Viscerally 
obese patients 
No association _ 
Peng  IV CRC  Sarcopenia; L3 TPA; 
<500mm2/m2 
_ ↑ in 
Sarcopenic 
patients 
_ _ ↑ in Sarcopenic 
patients 
_ _ 
Ishii  I-IV RC Visceral Obesity; L3 
VFA; >100 cm2 
_ No 
association 
↑ in 
Viscerally 
obese 
patients 
No association ↑ in Viscerally 
obese patients 
_ No association 
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Seki  Early RC Visceral Obesity; L3 
VFA/BSA; >85cm2/m2 
_ _ ↑ in 
Viscerally 
obese 
patients 
 No association ↑ Viscerally obese 
patients 
No association 
Abbreviations: CRC = colorectal cancer; CC = colon cancer; RC = rectal cancer; SC = sigmoid cancer; CTBC= computer tomography body composition; L = lumbar; S = 
Sacral; SMI = skeletal muscle index; VFA = visceral fat area; SFA = subcutaneous fat area; VFV = visceral fat volume; TPA = total psoas area; BSA = body surface area
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3.3.5! Impact of CTBC on oncological outcomes  (Table 3.3) 
 
3.3.5.1! Lymph node harvest 
 
Moon et al first examined the relationship between the CTBC parameters and the 
number of the lymph nodes harvested. There was no difference between the 
retrieved lymph nodes between high and low VFA/SFA ratio groups (Moon et al., 
2008). However, in rectal cancer surgery, Ballian et al found that both increasing 
VFA and VFA/SFA ratio were associated with a reduced lymph node retrieval 
(P=0.03 and P =0.009, respectively) (Ballian et al., 2012). 
3.3.5.2! Response to Chemotherapy and Radiotherapy  
 
Prado et al prospectively assessed how skeletal muscle influenced drug toxicity. Pre-
treatment CT images from 62 patients with high-risk stage II and stage III colon 
cancer were assessed. All were planned to receive protocol-based adjuvant 
chemotherapy (Prado et al., 2007). Cross-sectional areas of muscle tissues were 
extrapolated to whole-body LBM using a previous published formula (Shen et al., 
2004). LBM was a significant predictor of 5-FU toxicity. 
In a retrospective study from Guiu et al, CT measurements of SFA and VFA were 
made in 120 patients with metastatic CRC receiving bevacizumab-based treatment 
(n=80) or chemotherapy alone [FOLFOX (77.5%, n=31) and FOLFIRI (22.5%, n=9)] 
as first-line treatment (Guiu et al., 2010). Associations between BMI, SFA and VFA to 
tumour response according to the Response Evaluation Criteria in Solid Tumours 
(Therasse et al., 2000), time-to-progression (TTP) and overall survival (OS) were 
evaluated. On multivariate analysis, a high VFA in the bevacizumab group had a 
poorer response (HR=7.18, [95%CI= 1.69-30.6]; P=0.008), OS (HR=2.88, 
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95%CI=1.13-7.32; P<0.05) and shorter time to progression (TTP) [HR=2.80 
95%CI=1.35-5.79; P=0.005]. In the chemotherapy group, median follow-up lasted for 
30 months; BMI, SFA and VFA were not associated with response, TTP or OS. 
 Barret et al also studied sarcopenia and treatment toxicity in 51 patients with 
metastatic CRC in a prospective multicentre study. Sarcopenia was defined as SMI  
<55cm2/m2 for men and <39cm2/m2 for women. In multivariate analysis the only 
factor associated with grade 3-4 toxicity was sarcopenia (OR=13.55; 95%CI=1.08-
169.31; p=0.043) (Barret et al., 2014).  
Clark et al, found that high VFA/SFA ratio rectal cancer patients were less likely to 
be successfully down-staged by NCR (P=0.04) (Clark et al., 2013). 
3.3.6! Impact of CTBC on CRC survival  (Table 3.4) 
 
Moon et al demonstrated that increased visceral adiposity expressed as high 
VFA/SFA ratio was independently prognostic for disease free survival (DFS) (HR 
1.98, [95%CI 1.02–3.87]; P=0.044) (Moon et al., 2008). With a median follow-up of 
20 months, Ballian et al found elevated BMI, and VFA/SFA ratio were associated with 
reduced OS (P=0.02 and P=0.003, respectively) (Ballian et al., 2012). Rickles et a 
showed in stage II cancer, visceral obesity had nearly threefold reduction in disease-
free survival (HR 2.72; [95 %CI=1.21- 6.10]) and that in stage III cancer, visceral 
obesity patients had a longer time to recurrence  (HR 0.39; [95%CI 0.16 – 0.99]) 
(Rickles et al., 2013). Yamamoto et al reviewed 273 patients with resectable 
colorectal cancer (Yamamoto et al., 2012). Sex-specific values categorized patients 
into VFA-obese or VFA-non-obese patients (Seki et al., 2007). At 72 months median 
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follow-up, there was no significant difference in recurrence free survival (Krutzik et 
al.) or overall survival (OS) between VFA-obese and VFA-non-obese groups. 
Clark et al used VFA/SFA ratios to categorize 99 rectal cancer patients treated with 
NCR and surgery as visceral obese and non-obese.  Patients with VFA/SFA>0.4 had 
shorter DFS (p=0.02) and OS (p=0.047) (Clark et al., 2013). Van Vledder et al 
analysed CT images of 196 patients diagnosed with CRLM undergoing liver surgery 
and/or neoadjuvant chemotherapy.30 Five-year DFS (15 % with sarcopenia vs 28·5 % 
without sarcopenia; P = 0·002) and OS rates were lower for patients with 
sarcopenia (20 % vs 49·9 %; P < 0·001) at a median follow-up of 29 (range 1–97) 
months. Sarcopenia independently predicted poorer RFS [HR=1·88, 95%CI=1·25 to 
2·82; P = 0·002)] and OS [HR=2·53, 95%CI=1·60 to 4·01; P < 0·001] (van Vledder 
et al., 2012).  
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Abbreviations: CRC = colorectal cancer; RC = rectal cancer; CTBC= computer tomography body composition; L = lumbar; LBM = lean body mass, VFA = visceral fat area; 
SMI = skeletal muscle index; SFA = subcutaneous fat area; NCR = neo-adjuvant chemoradiation  
 
  
Study Stage CTBC parameter used Treatment Important Findings 
Lymph node 
Harvest 
Treatment 
Toxicity 
Tumour response Time to Progression 
Moon  I-III 
CRC 
Visceral Obesity; L3-L4/L4-L5 
VFA/SFA; >50th percentile 
Surgical resection No association _ _ _ 
Ballian   I-IV 
RC 
Visceral Obesity; L3 VFA 
(continuous) 
NCR / surgical resection  ↓ in Viscerally 
obese patients 
_ _ _ 
Prado  II/III 
CC 
Sarcopenia; L3 LBM 
(continuous) 
Adjuvant 5-FU/ 
Leucovorin 
_ ↑ 5-FU toxicity in 
sarcopenic patients 
_ _ 
Guiu  III 
CRC 
Visceral Obesity; L3 VFA; 
>117.58 cm2 
Bevacizumab or 
Conventional 
Chemotherapy 
_ _ ↓ in Viscerally obese 
patients receiving 
bevacizumab 
↓ in Viscerally obese 
patients receiving 
bevacizumab 
Barrett  IV 
CRC 
Sarcopenia; L3 SMI; <55 cm2/m2 
for men <39 cm2/m2 for women 
Chemotherapy _ ↑ toxicity in 
sarcopenic patients 
  
Clark  I-IV 
RC 
Visceral Obesity; L4-L5 
VFA/SFA; <0.4 
NCR / surgical resection _ _ ↑  in Viscerally obese 
patients receiving NCR  
_ 
Table 3-3 Impact of CTBC in Oncological Outcomes 
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Table 3-4 Impact of CTBC in Long Term Outcomes 
Study Stage CTBC parameter used Treatment Important Findings 
    DFS RFS OS 
Guiu  III CRC Visceral Obesity; L3 VFA; 
>117.58 cm2 
Bevacizumab or 
Conventional 
Chemotherapy 
_ _ ↓ in Viscerally obese 
patients 
Rickles  I-III CRC Visceral Obesity; S1to 
12cm cranial VFV; >50th 
percentile 
Surgical Resection ↓ in Viscerally obese 
patients for stage II but 
↑ for stage III 
↓ in Viscerally obese 
patients for stage II but 
↑ for stage III 
No association 
Yamamoto  Duke’s A-C CRC  Visceral Obesity; L3 VFA; 
>130cm2 for men >90 
cm2 for women 
Surgical Resection _ No association No association 
Moon  I-III CRC  Visceral Obesity; L3-
L4/L4-L5 VFA/SFA; >50th 
percentile 
Surgical Resection ↓ in Viscerally obese 
patients 
_ _ 
Clark  RC Visceral Obesity; L4-L5 
VFA/SFA; <0.4 
NCR / surgical 
resection 
↓ in Viscerally obese 
patients 
_ ↓ in Viscerally obese 
patients 
Ballian  I-IV RC Visceral Obesity; L3 VFA 
(continuous) 
NCR / surgical 
resection 
No association _ ↓ in Viscerally obese 
patients 
Van Vledder  IV CRC Sarcopenia; L3 SMI; <43.7 
cm2/m2 for men <40.1 
cm2/m2 for women 
Chemotherapy +Liver 
surgery 
↓ in Sarcopenic patients _ ↓in Sarcopenic patients 
Abbreviations: CRC = colorectal cancer; RC = rectal cancer; CTBC= computer tomography body composition; L = lumbar; S = Sacral; SMI = skeletal muscle index; VFA = 
visceral fat area; SFA = subcutaneous fat area; VFV = visceral fat volume; NCR = neo-adjuvant chemoradiation
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3.4! Discussion 
 
To date, this is the first systematic review to summarise the role of CT based 
assessment of body composition on outcomes following colorectal cancer treatment. 
Visceral obesity based on CT analysis appears to exert adverse effects on LOS, OT, 
wound infection, complication rates, anastomotic leak and resumption of oral intake 
for patients undergoing surgery for CRC. Sarcopenia negatively impacts 30-day 
mortality, LOS, complication rates and the need for postoperative rehabilitation. 
CTBC parameters are predictors for CRC survival outcomes with a significant 
associations between excess visceral adipose tissue preoperatively and poorer DFS, 
RFS and OS. Sarcopenic patients can also have a poorer DFS, and OS. Fat and lean 
tissue compartments represent sites for drugs distribution and therefore are likely 
to be determinants of the efficacy and toxicity of chemotherapy (Aslani, Smith, Allen, 
Pavlakis, & Levi, 2000). If VFA was high in patients with metastatic CRC receiving 
first line bevacizumab then poorer treatment responses, OS and TTP were likely. 
The presence of muscle depletion or reduced LBM both estimated from CTBC 
analysis (LBM was estimated from muscle cross-sectional area using a regression 
equation) is a prognostic factor for developing severe toxicity in patients receiving 
chemotherapy for CRC.  
Visceral obesity may have prognostic significance. The underlying mechanism is 
believed to be due to endocrine and paracrine effects exerted by visceral adipose 
tissue (Bardou et al., 2013). Adipocytes produce insulin-like growth factor, various 
angiogenic factors (VEGF) and adipokines (Cao, 2007). Inflammatory cells infiltrating 
adipose tissue contribute to VEGF production and VEGF-driven angiogenesis by 
colon epithelial cells (Frezza, Wachtel, & Chiriva-Internati, 2006). The cytokine 
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production profile differs between subcutaneous and visceral fat and may explain 
why subcutaneous fat was not a significant predictor in the reviewed studies.  
The evidence strongly suggests skeletal muscle mass is associated with outcomes in 
CRC patients. The high prevalence of sarcopenia at presentation suggests that 
muscle atrophy occurs prior to cancer diagnosis and surgery. Neither the point of 
onset of muscle loss nor exact aetiology is known.  Muscle depletion may be 
associated with the SIR in CRC patients and this relationship may explain the 
mechanism by which sarcopenic patients have worse outcomes (In Chapter 6 we 
explore this hypothesis.) Patients with altered skeletal muscle are also prone to 
treatment-related toxic effects. An explanation is that toxicity reflects overdosing 
owing to their smaller muscle (K. Fearon, Arends, & Baracos, 2013). Evidence 
support the hypothesis that muscle depletion measured from CTBC analysis reflects 
the catabolic status of the host but its clinical utility for nutritional assessment 
remains unclear. 
CT is the gold standard pre-treatment CRC staging modality and is used assess each 
patient throughout their individual disease trajectory. The limitations of this method 
are related to exposure to ionising radiation, the repeatability, reproducibility, and 
the accessibility of measurements to the researcher and clinician (MacDonald, Greig, 
& Baracos, 2011). While other anthropometric quantification methods such as BMI, 
waist circumference, waist-to-hip and waist-to-height ratios have been linked with 
poorer outcomes among CRC patients, comparison studies between these 
techniques are still absent (Fedirko et al., 2014). It is also feasible on CTBC using HU 
variation in skeletal muscle tissue to determine intramyocellular lipid accumulation, a 
term called myosteatosis and related to pain, functional decline, obesity and insulin 
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resistance (Miljkovic & Zmuda, 2010). These emerging possibilities may stimulate 
development of new interventions or treatment protocols whereby monitoring and 
modifying BC has therapeutic potential. 
  The heterogeneity in protocols used by the included studies to assess clinical 
phenotypes such as sarcopenia or visceral obesity must be taken into account when 
interpreting the results of this review. For example some studies calculated the SMI 
or the LBM based on the sum of all the skeletal muscles at the lumbar 3 level 
whereas others measured only the area of the psoas muscle. The distribution of 
skeletal muscle is lower at a higher degree of adiposity especially in men who store 
more adipose tissue at the trunk compared to women who proportionally store 
more adipose tissue at the limbs (Bosy-Westphal & Muller, 2015). Hence using the 
SMI with sex specific cut off values to report sarcopenia has an advantage over 
studies reporting TPA.  SMI and LBM have also limitations with increasing age and 
advancing body adipose mass. Careful statistical modeling based on age, gender, 
height and adipose mass must be used when body composition is studied.    
There are several limitations to our study. The number of studies is small and with 
restricted patient numbers. Studies have varying designs and quality; hence evaluation 
of aggregated data was unsuitable. No RCTs are available and most studies were 
retrospective cohort studies from single institutions. Hence no causal relationship 
between BC parameters and CRC outcomes can be truly ascertained. Common cut-
off values and methodology were not identified. Study heterogeneity made 
explanation of the data difficult. What is clear is that further and more rigorous 
studies are required to validate a widely accepted protocol for assessing BC from 
CT scans in CRC patients.  
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3.5! Conclusion 
 
In conclusion, current evidence suggests that BC parameters derived from CT 
images may be associated with CRC outcomes. Further studies are required with 
larger patient numbers and comparable homogeneous patient group and CT analysis 
protocols to permit better data aggregation to optimise analysis of the influence of 
visceral obesity and skeletal muscle on outcomes in the treatment of CRC. Whether 
surveillance imaging after CRC can identify early BC changes that herald eventual 
future metastatic disease remains to be determined.  
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Chapter 4 
 
4! Body Composition Profile Impacts Short and Long Term Outcomes 
in Patients Following Colorectal Cancer Surgery 
 
Valid and convenient approaches for determining BC synthesis are required to 
evaluate BC in CRC patients, and the secondary analysis of CT images is an 
accessible mean of making this evaluation. However the heterogeneity of the 
methodology used and the studies with small number of patients identified in 
Chapter 3, did not allow for secure conclusion to be drawn.  Furthermore the role 
of the quality of muscle; a term described as myosteatosis has not been explore, 
neither a direct comparison between the different BC phenotypes for their 
prognostic utility in CRC outcomes was found. Here, in a very large cohort of CRC 
patients undergoing surgery, the prevalence of different CT defined BC profiles 
including visceral obesity, myopenia, myosteatosis, their impact on short outcomes 
and their prognostic utility on long term outcomes [overall survival (OS) and disease 
free survival (DFS)] are evaluated. 
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4.1! Introduction 
 
Following potentially curative surgery for CRC, the prognostic stratification and 
provision of adjuvant therapy is usually guided by tumour pathology.(Figueredo, 
Coombes, & Mukherjee, 2008) It is increasingly recognized, however, that 
pathological stage is not the sole determinant of outcome. Host-related factors, in 
particular the body composition (BC) profile, also appear to be important. There is 
now considerable evidence that BC parameters such as the presence of obesity or 
muscle depletion can predict outcomes in patients with primary operable colorectal 
cancer (see Chapter 3).(Malietzis, Aziz, et al., 2015) This appears to be independent 
of TNM stage and other high-risk pathological features.  
Despite the high prognostic and predictive value of tumour biology in patients with 
cancer; malnutrition and changes in body habitus, especially muscle mass; remain 
unappreciated by most clinicians. A lack of validated modalities to identify such high-
risk patients and a current absence of recognized guidelines contribute to the 
apparent neglect.(Spiro, Baldwin, Patterson, Thomas, & Andreyev, 2006) Skeletal 
muscle is one of the most modifiable human tissues. Changes in skeletal muscle 
occur for numerous reasons, combining physiological and metabolic conditions.(K. 
Fearon, Strasser, et al., 2011) To indicate the presence of clinically relevant muscle 
wasting irrespective of illness and age, Fearon proposed the term myopenia (mys in 
Greek is muscle) in 2011.(K. Fearon, Evans, et al., 2011) Myopenia is clinically 
relevant muscle wasting that is associated either with impaired functional capacity 
and/or with increased morbidity or mortality risk. CTBC imaging is particularly 
relevant in patients with CRC, as firstly, it is routinely employed for disease staging 
and follow-up purposes and secondly, can be assessed with little increase in 
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healthcare costs. Skeletal muscle and visceral adipose tissue areas at the lumbar 
vertebral landmark (L3) have been shown to correspond to whole-body tissue 
quantities in non-malignant populations as well as in cancer patients. It is also feasible 
by using Hounsfield Unit (HU) disparity in skeletal muscle tissue to determine 
intramyocellular lipid accumulation; a term called myosteatosis that is related to pain, 
functional decline, obesity and insulin resistance. (Mourtzakis et al., 2008),(Martin et 
al., 2015) Besides the recent developments and the emerging evidence, further effort 
is needed to evaluate the prognostic impact of BC parameters and identify profiles 
that are high risk in patients with colorectal cancer. 
The aims of this study were to evaluate the prevalence of CT defined visceral 
adiposity, myopenia, myosteatosis and to assess their prognostic utility on short 
(hospital length of stay (LOS), 30 day mortality and morbity, anastomotic leak) and 
long term outcomes (overall survival (OS) and disease free survival (DFS) after 
elective surgery for colorectal cancer. 
 
4.2! Patients and Methods   
4.2.1! Study Population 
 
A cohort of 1177 consecutive patients with primary CRC who underwent colorectal 
resection at St Mark’s Hospital between January 2006 and December 2011 were 
identified from a prospective database. Patients with recurrent disease confirmed 
preoperatively or at surgery, emergency cases and those with a non-available pre-
operative CT were excluded. All recorded clinical and pathological data were 
revalidated from medical and pathology records. Data collected prospectively during 
the perioperative period (within 30 days of surgery) included age, sex, the American 
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Society of Anesthesiologists (ASA) physical status classification system, body mass 
index (BMI), diabetes mellitus (DM) disease, surgical approach, tumour site (rectal if 
<15cm from anal verge on sigmoidoscopy), histological grading, TNM stage (UICC 
5th version), the presence of vascular invasion on histopathology, tumour location, 
operation type, and 30-day postoperative complications (Clavien-Dindo classification 
>=3 considered a major complication) (Dindo, Demartines, & Clavien, 2004), 
anastomotic leak rates, mortality and length of primary hospital stay (from date of 
operation to the date of discharge). Anastomotic leaks were further categorized into 
conservatively managed (including the use of antibiotics) and/or radiologically drained 
(Grade B) or managed by operative intervention (Grade C).(Rahbari et al., 2010) 
Laboratory blood test data collected within 3 weeks before surgery included 
preoperative neutrophil, and lymphocyte count. The systemic inflammatory response 
of the host was quantified by the preoperative neutrophil to lymphocyte ratio (NLR). 
All treatment decisions were discussed and agreed at weekly multidisciplinary team 
meetings. All patients were monitored by a standardized surveillance protocol that 
follows up patients for 5 years. Postoperative follow-up data included clinical 
assessment records, laboratory and radiology results, as well as endoscopic 
surveillance findings. All-cause mortality data were obtained from the UK Thames 
Cancer Registry and linked to our institutional CRC data set. 
4.2.2! Body Composition Analysis 
 
Images were retrieved from digital storage in the Picture Archiving and 
Communication System [PACS]. CT image analysis Slice-O-Matic V4.3 software 
(Tomovision, Montreal, Canada) was performed as described previously(Mourtzakis 
et al., 2008). Briefly, total skeletal muscle and visceral adipose tissue (Della Porta et 
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al.) surface area (cm2) were evaluated on a single image at the third lumbar vertebrae 
(L3) using Hounsfield unit (HU) thresholds of -29 to 150 for skeletal muscle, -50 to 
150 for visceral adipose tissue and -190 to -30 for subcutaneous adipose tissues. The 
sum of skeletal cross-sectional muscle areas was normalised for stature (m2) and 
reported as LSMI (cm2m-2). Mean Muscle Attenuation [MA] (HU) was reported for 
the whole muscle area at the third lumbar vertebra level. Reduced L3 skeletal muscle 
index (myopenia) and low MA (myosteatosis) were defined using predefined sex-
specific skeletal muscle index cut-points. Increased visceral adipose tissue area 
(visceral obesity) was also described by using gender-specific and pathologically 
relevant cut-off values(Doyle et al., 2013; Prado et al., 2008). Myopenic obesity was 
defined as the combination of myopenia with a BMI of > 30 Kg/m2.  
4.2.3! Study endpoints and statistical analysis  
 
The primary study end points were OS and DFS, calculated from the date of surgery 
to the date of death. OS was defined as the time in months from the date of surgery 
to an individual's death from any cause. DFS was defined as the time in months from 
the date of surgery to the date of identification of disease recurrence, either 
radiological or histological. The secondary endpoints were LOS, 30-day mortality 
and morbidity and incidence of anastomotic leak (Grade B+C). Overall and disease-
free survival rates were calculated and compared with the nonparametric Kaplan–
Meier method and the log rank test.  
Continuous data are presented as median and interquartile range (IQR) as 
appropriate. Categorical data are presented as proportions. Differences between 
groups were investigated using the appropriate non-parametric tests. To investigate 
the correlation between myopenia, myosteatosis and visceral obesity and survival, 
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univariable and multivariable Cox regression analyses were performed, and hazard 
ratios (HR) with 95 per cent confidence intervals (CI) calculated. The following 
variables were included in the univariable analysis: age, sex, presence of DM, BMI, 
ASA grade, location of primary tumour, UICC staging, tumour grade, lymphovascular 
invasion, administration of adjuvant chemotherapy and the three main BC profiles 
mentioned above. All variables were checked for interaction and multicolinearity, 
and were included in the multivariable model when significant. The level of 
significance permitting multivariate analysis inclusion and the statistical significance 
for all other tests used was set at P < 0.05. All analyses were performed using the 
statistical software, Statistical Package for the Social Sciences, version 20.0 (SPSS, Inc, 
Chicago, IL). The database is registered with the UK National Research Ethics 
Committee (reference number: 12/LO/1556), and local ethical committee approval 
was granted for this study (reference number: 12/088) 
 
4.3! Results 
 
Eight hundred and five patients with a median age of 69 years  [IQR 61-77] qualified 
for the study. Five hundred and twelve patients (64%) had a laparoscopic operation 
approach with intention to treat and for two hundred and fifty seven (32%) were 
rectal cancers. Table 4.3 summarizes the Demographics of this study’s population. 
4.3.1! Body Composition analysis 
 
The median intra-abdominal VAT area was 132.6 cm2 (IQR 72.1-197.6). For LSMI the 
median was found to be 42.9 (IQR 37.4-49.5) cm2m2.  The MA varied between 4.86 
to 58.20 HU with a median value of 53.34 HU. Men had a higher LSMI, VAT and MA 
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compared with women (P < 0.001). The main BC profiles calculated from the CT 
analysis and the gender specific cut-off values are summarized in Table 4.1. Patients 
with myopenia or myosteatosis were older (p<0.01), had significantly more advanced 
disease stage (p=0.04), higher ASA (p=0.047) and higher NLR (p=0.01) compared to 
the non-muscle depleted patients. Patients with visceral obesity had higher ASA than 
the non-visceral obese patients (p<0.01).  There were no differences between the 
BMI obese [BMI >= 30 Kg/ m2] and non-BMI obese population.  
4.3.2! Short-term outcomes 
 
4.3.2.1! Primary Length of Stay 
 
The overall median value for the primary LOS was 6 (IQR 5-12) days. The presence 
of myopenia, myopenic obesity, visceral obesity and BMI defined obesity did not have 
any statistically significant impact on the primary LOS. However, patients with 
evidence of myosteatosis stayed longer in the hospital compared with patients 
without myosteatosis [7 IQR (5-11) vs 6 IQR (4-9) days respectively; p=0.03)]  
4.3.2.2! 30 day Morbidity 
 
One hundred and twelve patients (13.8%) had a major complication (CD>/= 3) 
within 30 days postoperatively. Patients with myopenic obesity had more major 
complications compared to patients without myopenic obesity (22.2 % Vs 12.1%; 
p=0.03). No other BC profile was found to be associated with the incidence of 30-
day major morbidity.   
4.3.2.3! 30 day Mortality 
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There were ten deaths (1.2%) during the 30-day postoperative period of which 
seven had myopenic obesity demonstrating a significant increase compared to 
patients without myopenic obesity (p=0.04). Myopenia, myosteatosis, visceral and 
BMI defined obesity did not exert a significant effect upon 30-day mortality.  
4.3.2.4! Anastomotic Leak 
 
Of 768 patients undergoing a restorative procedure, anastomotic leaks (Grade B+C) 
were detected within 30 days of surgery in 50 patients (6.5%), of whom, 17 (2.2 %) 
required active therapeutic interventions including antibiotics or percutaneous 
drainage (Grade B) and 33 (4.3%) required re-laparotomy or relaparoscopy (Grade 
C). No relationship with any of the BC profiles assessed and the anastomotic leak 
rate were identified.  
Table 4.2 demonstrates the relationship between BC profiles and short-term 
outcomes following elective CRC resection.  
4.3.3! Long-term outcomes  
 
To investigate, whether a specific BC profile was associated with clinical outcome, 
univariable and multivariable survival analyses for OS and DFS were performed.   
4.3.3.1! Overall Survival [OS] 
 
From the prospective cohort assessed, 22.7 % (156 / 805) had died after a median 
follow-up of 47.1 months IQR (24.9 - 65.6). Univariable analysis identified older age, 
an open surgical approach (open vs laparoscopic), higher ASA score (1 + 2 Vs 3 + 4), 
higher UICC stage (Stage I vs Stage II, III and IV), higher tumor grade (G1 and G2 vs 
G3), the presence of lymph-vascular invasion (V0 vs V1 and V2), the non-
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administration of adjuvant chemotherapy, and the presence of myopenia; as poorer 
prognostic indicators of overall survival; whereas gender (male vs female), BMI and 
Diabetic status did not. None of the other BC profiles were significantly associated 
with overall survival.  
To determine whether any of the univariable prognostic factors above had 
independent prognostic significance to overall survival, multivariable analysis using a 
Cox proportional hazards model was performed. All factors, except tumour grade 
were independent prognostic factors for overall survival. The presence of myopenia 
was associated with a higher mortality rate and poorer overall survival (Hazards 
ratio (HR)= 1.70 [95% CI 1.25-2.31]; p<0.01). Figure 4.1 shows the Kaplan – Meier 
curve for overall survival for patients with and without myopenia. Myopenic patients 
had a higher mortality rate. (log-rank test; p<0.01). 
 
 
4.3.3.2! Disease Free Survival [DFS] 
 
Of the 721 patients with stage I to III disease included in this study, 101 (14%) 
developed disease recurrence, of whom 68 (67% of recurrences) have subsequently 
died. The median time to recurrence was 13 months [IQR= 5.7-24.0]. On univariable 
analysis for DFS, only advanced age, high UICC stage, poor grade of differentiation, 
presence of lymph-vascular invasion, non-administration of adjuvant chemotherapy, a 
high NLR (>3) and presence of myopenia were identified as significant predictors of 
disease recurrence. The presence of myopenia was the only body composition factor 
that was an independent prognostic factor for DFS (HR= 1.53; 95% CI= 1.06-2.39; 
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p=0.04) after applying Cox regression analysis. Figure 4.1 shows the Kaplan – Meier 
curve for DFS for patients with and without myopenia (log-rank test; p=0.01).  
Table 4.4 summarizes the univariable and multivariable Cox regression analysis for 
OS and DFS.  
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Table 4-1 Demographics of the study population 
Demographics N= 805 Median, [IQR] Count Column N % 
Age 69, [61-77]   
BMI 26.66, [24.00-29.98]   
Gender Male  472 58.6% 
Female  333 41.4% 
ASA status ASA 1+2  709 88.1% 
ASA 3+4  96 11.9% 
Surgical 
Approach 
Open  293 36.4% 
Laparoscopic  512 63.6% 
Diabetes No  766 95.2% 
Yes  39 4.8% 
Tumour site Colon  548 68.1% 
Rectum  257 31.9% 
UICC stage I  190 23.6% 
II  265 33.0% 
III  267 33.2% 
IV  82 10.2% 
LVI None  525 65.2% 
Present  280 34.8% 
Grade 
(differentiation) 
Well + Moderate  706 87.7% 
Poor  99 12.3% 
Adjuvant 
Chemotherapy 
No   623 77.4% 
Yes  182 22.6% 
Abbreviations: ASA = American Society of Anaesthesiologists; BMI = Body Mass Index; UICC = Union for 
International Cancer Control; LVI = Lymphovascular Invasion; IQR= Inter Quartile Range  
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Table 4-2 Main body composition profiles calculated from the CT analysis and the 
gender specific cut-off values 
 Count Column N % 
BMI Obesity BMI<30 601 74.7% 
BMI>30 204 25.3% 
Myopenia Absent 320 40.3% 
Present 485 59.7% 
Myopenic Obesity No 725 89.7% 
Yes 80 10.3% 
Myosteatosis Absent 158 22.4% 
Present 547 77.6% 
Visceral Obesity Absent 385 47.0% 
Present 420 52.0% 
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Table 4-3 The relationship between BC profiles and short-term outcomes following 
elective CRC resection 
Short term Outcomes Median 
[IQR] 
Count / 
Column 
(%) 
Median Count / 
Column 
(%) 
p-
value 
 
Total 
     
Primary LOS (days) 6 [5-12]     
30d Major 
complication  
no  693 (86.1%)    
yes  112 (13.9%)    
30d Mortality no  795 (98.8%)    
yes  10 (1.2%)    
Anastomotic 
leak* 
no  718 (93.5%)    
Grade 
B+C  
 50 (6.5%)    
 
Myopenia 
  
Absent 
 
Present 
 
Primary LOS 
(days) 
 6 [5-12]  7 [5-12]  0.65 
30d Major 
complication  
no  275 (85.9%)  418 (86.2%)  
 yes  45 (14.1%)  67 (13.8%) 0.90 
30d Mortality no  318 (99.4%)  477 (98.4%)  
 yes  2 (0.6%)  8 (1.6%) 0.33§ 
Anastomotic 
leak* 
no  283 (91.6%)  435 (94.8%)  
 Grade 
B+C 
 26 (8.4%)  24 (5.2%) 0.08 
 
Myosteatosis 
  
Absent 
 
Present 
 
Primary LOS 
(days) 
 6 [4-9]  7 [5-11]  0.03 
30d Major 
complication  
no  132 (83.5%)  479 (87.9%)  
 yes  26 (16.5%)  68 (12.2%) 0.15 
30d Mortality no  156 (98.7%)  539 (98.5%)  
 yes  2 (1.3%)  8 (1.5%) 0.66§ 
Anastomotic 
leak* 
no  234 (91.4%)  494 (94.6%)  
 Grade 
B+C 
 22 (8.6%)  28 (5.4%) 0.08 
 
Myopenic 
Obesity 
  
Absent 
 
Present 
 
Primary LOS 
(days) 
 6 [5-12]  6 [5-12]  0.12 
30d Major 
complication  
no  637 (87.9%)  62 (77.8%)  
 yes  88 (12.1%)  18 (22.2%) 0.03 
30d Mortality no  722 (99.4%)  73 (91.3%)  
 yes  3 (0.4%)  7 (8.7%) 0.04§ 
Anastomotic 
leak* 
no  673 (93.8%)  40 (96.3%)  
 Grade 
B+C 
 46 (6.2%)  4 (3.7%) 0.48 
 
Visceral Obesity 
  
Absent 
 
Present 
 
Primary LOS 
(days) 
 7 [5-12]  6 [5-10]  0.54 
30d Major 
complication  
no  329 (85.2%)  378 (87.9%)  
 yes  57 (14.8%)  51(12.1%) 0.28 
30d Mortality no  381 (98.6%)  414 (99.0%)  
 yes  5 (1.4%)  5 (1.3%) 0.75 
Anastomotic no  360 (93.3%)  358 (93.7%)  
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leak* 
 Grade 
B+C 
 26 (6.7%)  24 (6.3%) 0.79 
 
BMI Obesity 
  
Absent 
 
Present 
 
Primary LOS 
(days) 
 6 [4-9]  6 [4-9]  0.32 
30d Major 
complication  
no  534 (87.9%)  165 (83.7%)  
 yes  74 (12.1%)  32 (16.3%) 0.22 
30d Mortality no  601 (98.8%)  194 (98.5%)  
 yes  7 (1.2%)  3(4.7%) 0.57§ 
Anastomotic 
leak* 
no  556 (94.2%)  162 (91.1%)  
 Grade 
B+C 
 34 (5.8%)   16 (8.9%) 0.13 
Abbreviations: LOS= Length of stay; 30d = 30 days; BMI = Body Mass Index; IQR= Inter Quartile 
Range  § Fisher’s exact test  * Total numbers analysed for anastomotic leak n=768 after exclusion 
of non-restorative resections (n=37)   
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Figure 4-1 . Kaplan-Meier curves for Overall Survival (OS) and Disease Free Survival 
(DFS) of patients with colorectal carcinoma undergoing elective resections based on 
the presence or absence of myopenia   
(Log-Rank test for OS; p<0.01, DFS; p=0.01) 
Months 0 12 24 36 48 60
Numbers4
at4risk44
(Absent)
323 291 257 216 167 116
Numbers4
at4risk4
(Present)
482 403 343 283 218 147
Months 0 12 24 36 48 60
Numbers4
at4risk44
(Absent)
291 220 157 107 72 38
Numbers4
at4risk4
(Present)
430 298 216 136 75 29
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Table 4-4 Univariable and multivariable analysis for overall survival and disease free survival.  Median F-up 47.1 months IQR (24.9 - 65.6)   
 Overall Survival (n=805) Disease Free Survival (Stage I-III; n= 721) 
Parameter  Univariable Analysis Multivariable Analysis   
 HR 95% CI P-Value HR 95% CI P-value HR 95% CI P-Value HR 95% CI P-value 
Age (continuous variable; years) 1.02 (1.01-1.04) B=+0.01 <0.01 1.02 (1.01-1.04) 0.04 1.01(1.01-1.02) <0.01 1.00 (0.99-1.02) 0.64 
BMI (continuous variable; Kg/m2) 1.02 (0.97-1.05) B=+0.01 0.87   1.04 (0.98-1.10) 0.12   
Gender Male 1    1    
 Female 0.98 (0.80-1.40) 0.94   1.09 (0.73-1.65) 0.67   
ASA 1+2 1  1  1    
 3+4 1.83 (1.28-2.62) <0.01 1.68 (1.14-2.47) 0.01 0.78 (0.38-1.62) 0.52   
Diabetes No  1    1    
 Yes 1.41 (0.47-2.43) 0.34   0.76 (0.24-2.39) 0.63   
Surgical Approach Open 1  1  1    
 Laparoscopic 0.58 (0.44-0.77) <0.01 0.65 (0.48-0.87) 0.03 0.68 (0.45-1.02) 0.06   
Tumour Site Colon 1    1    
 Rectum 1.09 (0.82-1.45) 0.55   1.09 (0.72-1.66) 0.66   
UICC stage I 1  1  1  1  
 II 1.23 (0.76-1.98) 0.60 0.91 (0.51-1.52) 0.73 2.39 (0.88-6.49) 0.08 1.79 (0.64-4.97) 0.19 
 III 2.18 (1.51-3.63) <0.01 3.10 (1.81-5.21) <0.01 11.04 (4.46-27.31) <0.01 6.94 (2.69-17.85) <0.01 
 IV 6.62 (3.75-9.99) <0.01 4.68 (2.79-7.85) <0.01 - -   
Grade 
(differentiation) 
Well + Moderate 1  1  1  1  
Poor 2.07 (1.28-2.91) <0.01 1.33 (0.93-1.91) 0.12 2.43 (1.49-3.99) <0.01 1.49 (1.01-2.51) 0.04 
LVI Absent 1  1  1  1  
Present 2.23 (1.94-3.39) <0.01 1.42 (1.05-1.94) 0.02 2.63 (1.76-3.94) <0.01 1.60 (1.04-2.46) 0.03 
Adjuvant 
Chemotherapy* 
No 1  1  1    
Yes 0.64 (0.45-0.92) 0.01 0.34 (0.22-0.53) <0.01 0.48 (0.28-0.83) <0.01   
Systemic 
Inflammatory 
Response 
LNLR 1    1  1  
HNLR 1.15 (0.89-1.53) 0.09   1.57 (1.03-2.38) 0.03 1.44 (1.03-2.20) 0.04 
Myopenia Absent 1  1  1  1  
 Present 1.77 (1.32-2.38) <0.01 1.70 (1.25-2.31) <0.01 1.79 (1.15-2.77) 0.01 1.53 (1.06-2.39) 0.04 
Myosteatosis Absent 1    1    
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 Present 1.42 (1.09-2.50) 0.07   1.14 (0.67-1.93) 0.62   
Myopenic Obesity Absent 1    1    
 Present 1.88 (0.92 – 3.26) 0.07   1.73 (0.81-3.68) 0.16   
Visceral Obesity Absent 1    1    
 Present 0.80 (0.57-1.07) 0.14   0.68 (0.44-1.05) 0.08   
Abbreviations: ASA = American Society of Anaesthesiologists; BMI = Body Mass Index; UICC = Union for International Cancer Control; LVI = Lymphovascular Invasion; LNLR= Low 
Neutrophil to Lymphocyte Ratio; HNLR= High Neutrophil to Lymphocyte Ratio; HR = Hazard Ratio; CI = Confidence Intervals.  
*Due to high multicollinearity between the “Adjuvant Chemotherapy and the UICC stage” (VIF= 8.6) when tested for recurrence events the variable “adjuvant chemotherapy” was not 
included in the MVA analysis for DFS. Low degree of multicollinearity was seen between the Systemic Inflammatory Response and the Myopenia variable (VIF=3.9).     
Bold value indicates statistical significance at p < 0.05 
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4.4! Discussion 
 
This study highlights the potential ability of CT defined muscle depletion to act as a 
prognostic indicator for survival in patients undergoing elective surgery for CRC. It 
represents a large cohort of consecutive patients undergoing elective operations for 
CRC with a standardized follow-up surveillance program and complete data. Patients 
with myopenia were older, had significantly more advanced disease, a higher ASA 
and preoperative NLR suggestive that myopenia accurately reflects patients of high 
risk. We identified the presence of myosteatosis as a parameter associated with a 
prolonged primary LOS and that myopenic obesity is related to increased 30-day 
morbidity and mortality. No other BC profiles assessed, including visceral or BMI 
defined obesity, were related to the outcomes assessed.  
The findings of this study build upon the limited evidence from the literature that 
variation in a patient’s BC profile is associated with poorer outcomes in patients 
with CRC. Low MA (myosteatosis) has been linked with obesity, diabetes and forms 
of muscle atrophy but neither has it been studied in relation to either short 
postoperative outcome nor survival in CRC.(Miljkovic & Zmuda, 2010) We found 
that the presence of myosteatosis is related to prolonged LOS and may reflect a 
slow functional recovery inherent in these patients. Obese patients with myopenia 
undergoing surgery had more major complications within 30 days and more deaths 
than those who were not categorized with myopenic obesity. Muscle depletion in 
the presence of BMI-defined obesity has been associated with increased mortality in 
patients with end-stage renal disease and all-cause mortality is increased with high 
proportions of body-fat mass with at low proportions of fat-free mass.(Honda et al., 
2007) To date , this is the first study to have tested various CTBC profiles and found 
that myopenia is an independent prognostic factor for poorer survival after CRC 
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surgery whereas visceral obesity trended towards a more protective role. The 
reason of these survival differences remains to be determined. Studies have 
suggested the apparent survival advantage conferred by obesity relates to the 
relatively large energy store in a disease process such as cancer where the energy 
balance is likely to be negative.(Amundson, Djurkovic, & Matwiyoff, 2010) Myopenia 
has also been associated with major chemotherapy toxicities resulting in dose 
reduction, treatment delay, or omission.(Prado et al., 2007) The susceptibility of 
myopenic patients to infections during hospitalization and in nursing homes has also 
been described, and this reflects the general inability of these individuals to respond 
suitably to stress.(Cosqueric et al., 2006),(Richards et al., 2012) It is likely that both 
early termination of adjuvant treatment and vulnerability to infection contribute to 
shortened survival.  
The high prevalence of myopenia and myosteatosis at presentation suggests that 
muscle depletion occurs prior to cancer diagnosis and hence surgery. Neither the 
point at time of onset of muscle loss nor the exact aetiology, are known.  Myopenia 
has been found to be associated with the SIR in CRC patients and this relationship 
may explain the mechanism by which myopenic patients are prone to poorer 
outcomes (chapter 6). (Malietzis, Johns, et al., 2015) Muscle mass may be enhanced 
by several factors including sex hormones, insulin like growth factor-1 and 
glucocorticoid therapy. (Biolo et al., 2014) 
Traditionally, controlling the progress of a cancer using interventions directed 
specifically at the cancer has been regarded as the most appropriate method to 
contain muscle depletion. However the emerging possibility of assessing and 
modifying muscle tissue before and after CRC treatment will stimulate the 
development of new treatment protocols. Appetite regulation and physical activity 
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level are major determinants of energy balance and BC changes. In most patients, 
systemic inflammation produces anorexia and fat loss in combination with myopenia. 
In others, appetite can be sustained, despite systemic inflammation, permitting the 
association of myopenia with increased BMI; a condition termed myopenic obesity. 
This broad BC profile variability with the same underlying disease requires careful 
tailoring of nutritional interventions and consequently patient optimization. Cyclo-
oxygenase inhibitors, including ibuprofen and indomethacin, can moderate the host 
systemic inflammatory response and have been tested in severely malnourished 
patients with promising results.(Roxburgh & McMillan, 2014) Protein intake should 
be increased in order to counteract the anabolic resistance associated with 
inflammation and inactivity. Both endurance and resistance-type exercises can 
maintain skeletal muscle mass and function. Studies using prehabilitation programmes 
report moderate gains in muscle reserve after a minimum period of three weeks.(K. 
C. Fearon, Jenkins, Carli, & Lassen, 2013) Prehabilitation integrates several exercise, 
nutrition, education, and/or psychosocial approaches to increase physiological and 
metabolic reserves of the surgical candidate. A recent study, using preoperative 
cross-sectional imaging also described the independent relationship between muscle 
depletion and costs associated with major surgery.(Sheetz et al., 2013) It is therefore 
clear that BC analysis not only offers a novel opportunity to identify high risk 
patients preoperatively but also identify those that might potentially incur high 
resource use and costs to payers and providers. 
Certain limitations in this study merit explanation. First, this was an uncontrolled 
study despite comprising a relatively large and homogenous data set. Second, CTBC 
analysis is a static window into a patient’s BC changes, but as the standard 
pretreatment staging modality, parameters from this type of analysis have proven 
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reliable in previous studies. Third, electronic records of CT scans were not available 
before 2007 as the Picture Archiving and Communication System was introduced at 
a later stage and this may have contributed to the exclusion of a proportion of 
patients operated on early in this cohort. Intra- or inter-observer variability of the 
CTBC analysis was not assessed for this study, however the objectiveness and 
reliability of our approach has been consistently proven in the literature. (Cruz et al., 
2013; Irving et al., 2007)  
 
4.5! Conclusion 
 
For patients with CRC, myopenia appears to exert an independent prognostic effect 
upon survival. Muscle depletion is a common feature of all chronic pathologies but 
may represent a modifiable risk factor in cancer patients undergoing treatment. The 
advent of the concept and application of “prehabilitation” is clinically relevant and 
early identification of muscle depletion may permit timely therapeutic intervention 
prior to and after surgery to optimize the host’s reserve to both cancer and its 
treatment. 
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Chapter 5 
5! What is the relationship between systemic inflammatory response 
and colorectal cancer surgery outcomes?  
 
There are several biochemical or haematological markers of measuring the SIR in 
patients with cancer. During an acute phase of an inflammatory response the ratio of 
different leucocyte subsets change and often neutrophilia accompanied by a relative 
lymphocytopenia is observed. A simple measure of SIR is therefore the calculation of 
the Neutrophil-to-lymphocyte ration (NLR). Some evidence suggests that an 
elevated preoperative NLR is associated with poorer outcomes in CRC patients. 
However due to studies with small number of patients not allowing optimization of 
its cut-off value to maximise its clinical utility, a comprehensive evaluation of this 
biomarker and its prognostic utility on CRC has not been performed. In chapter 5.1 
the role of NLR as a prognostic marker for CRC patients with non-metastatic 
disease undergoing curative resections is determined. Receiver Operating 
Characteristic (ROC) curve analysis was used to identify the optimal value for NLR 
in relation to disease-free and overall survival. In chapter 5.2, the role of NLR in 
predicting survival for patients with CRC undergoing treatments and its utility within 
a CRC surveillance programme was further evaluated through a systematic review 
and metanalysis of the literature. 
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5.1! A Preoperative Neutrophil to Lymphocyte Ratio of 3 Predicts Disease-Free 
Survival After Curative Elective Colorectal Cancer Surgery 
5.1.1! Introduction 
 
There is a need to identify reliable, inexpensive and readily available prognostic 
markers for risk stratification in colorectal cancer treatment, thereby delivering a 
more personalised form of cancer care (Roxburgh, Salmond, Horgan, Oien, & 
McMillan, 2009). A number of inflammation-based scores such as the ‘Modified 
Glasgow Prognostic Score’ (mGPS), ‘Neutrophil to Lymphocyte Ratio’, ‘Platelet to 
Lymphocyte Ratio’, ‘Prognostic Index’, and ‘Prognostic Nutritional Index’ have all 
been compared in their prognostic value in colorectal cancer (Proctor et al., 2011). 
Of these, the neutrophil to lymphocyte ratio (NLR) has gained interest because of its 
performance as well as its ease of calculation from a standard full blood count test 
(that is available in all patients undergoing treatment for colorectal cancer) with no 
additional cost (Proctor et al., 2012). To date, the ability of NLR to act as a 
prognostic marker in colorectal cancer has been studied in three patient groups 
The first group comprises patients with advanced colorectal cancer, where an NLR 
value greater than four has been associated with reduced overall and cancer-specific 
survival in Dukes C and D colorectal cancers (Proctor et al., 2012). An NLR of over 
five has been found to be a predictor of poor prognosis in locally advanced rectal 
cancer patients who receive pre-operative chemoradiotherapy (Carruthers et al., 
2012). The second group includes patients with metastatic liver disease where a 
value greater than five has been associated with poorer overall survival in patients 
undergoing both liver resections with chemotherapy as well as chemotherapy alone 
(Kishi et al., 2009). An NLR greater than five has also been shown to be a predictor 
of outcome in patients undergoing radiofrequency ablation for liver metastases (Y. 
 162 
Zhang et al., 2012). Finally the third area where the use of pre-operative NLR has 
been proposed, is as a predictor of recurrence in patients undergoing curative 
surgery for CRC with no known metastases, where values of above either 3 or 5 
have been associated with poorer overall and disease free survival (Chiang et al., 
2012; Hung et al., 2011; Mallappa et al., 2013; Walsh et al., 2005). In this group it is 
of interest to determine whether adjuvant therapies should be tailored for individual 
patients based not only on pathological prognostic variables but also based upon pre-
treatment inflammatory markers. Limitations of the existing studies include the use 
of heterogeneous patient groups comprising those undergoing emergency surgery, 
palliative or incomplete resections and those receiving pre- or post-operative 
chemotherapy and /or radiotherapy (based on pathological poor prognostic 
indicators). This study aims to evaluate the utility and optimize NLR as a prognostic 
indicator in patients undergoing curative surgery for colorectal cancer who do not 
receive pre-or post-operative therapies of any form and identify a suitable neutrophil 
to lymphocyte ratio that determines differences in disease-free and overall survival. 
 
5.1.2! Patients and Methods 
 
A total of 1177 consecutive patients undergoing colorectal cancer surgery patients at 
St Mark’s Hospital, London between January 2006 and December 2011 were 
identified from a prospective database. Patients with recurrent or metastatic disease 
confirmed preoperatively or at surgery, emergency cases, those receiving neo-
adjuvant/adjuvant chemotherapy and / or radiotherapy, and resections with macro- 
or microscopically positive pathological margins (R1 and R2 resections) were 
excluded. All recorded clinical and pathological data were revalidated from medical 
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and pathology records. Data collected prospectively during the peri-operative period 
(within 30 days of surgery) included age, gender, the American Society of 
Anaesthesiologists (ASA) physical status classification system, surgical approach, 
Enhanced Recovery After Surgery (ERAS), histological grading, TNM stage, presence 
of vascular invasion on histopathology, operation type, and 30 day postoperative 
complications (Clavien-Dindo classification ≥3 considered a major 
complication)(Dindo et al., 2004). Laboratory blood test data collected within the 3 
weeks prior to surgery included pre-operative albumin, neutrophil, and lymphocyte 
count. All patient treatment decisions were discussed and agreed at weekly 
multidisciplinary team (MDT) meetings. Our institution follows a standardised 
surveillance protocol and follows up patients for 5 years with 6-monthly clinical 
assessment intervals for the first 3 years followed by annual surveillance at years 4 
and 5. Postoperative follow-up data included clinical assessment records, laboratory 
tests, radiology results and endoscopic surveillance results. Computerised 
tomography scanning of the chest, abdomen and pelvis is the radiological surveillance 
imaging modality of choice in our institution and is performed, at least, annually. 
Either colonoscopy or CT colonography are used for luminal surveillance. All cause 
mortality data were obtained from the UK Thames Cancer Registry and linked to 
our institutional CRC dataset. Our database is registered with the UK National 
Research Ethics Committee (Reference number: 12/LO/1556) and local ethical 
committee approval was granted for this study (Reference number: 12/088). 
The primary study end point was overall survival, calculated from the date of surgery 
to the date of death. Overall survival (OS) was defined as the time in months from 
the date of surgery to an individuals’ death from any cause.  The secondary end point 
was disease-free survival (DFS), which was defined as the time in months from the 
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date of surgery to the date of identification of disease recurrence either radiological 
or histological.  
Statistics 
We determined the optimal discriminator value for NLR using receiver operating 
characteristic (ROC) curve analysis. At each value, the sensitivity and specificity for 
each outcome under study was plotted, thus generating an ROC curve. The ratio 
closest to the point with maximum sensitivity and specificity was selected as the cut-
off value. [14]. The relationship between NLR and other clinicopathological 
parameters was assessed using non-parametric statistics. Clinical outcomes were 
assessed using survival curves using the Kaplan–Meier method and groups compared 
using the log-rank test. Stepwise multivariate Cox proportion analysis was 
performed. The level of significance permitting multivariate analysis inclusion and the 
statistical significance for all other tests used, was set at p<0.05. All analyses were 
performed using the statistical software, Statistical Package for the Social Sciences, 
version 20.0 (SPSS, Chicago, IL).  
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5.1.3! Results 
 
Of 1177 consecutive patients with CRC diagnosis who underwent surgical resection, 
197 had an emergency operation, 137 had metastatic disease at the time of surgery, 
25 patients had a resection with positive margins and 312 received neo-adjuvant or 
adjuvant therapy. Exclusion of these patients resulted in a sample size of 506 patients 
who had undergone curative elective surgery for colorectal cancer [Figure 5.1.] 
ROC analysis was used to determine NLR cut-off values, above which there is an 
increased risk of an adverse event, that is, the presence of recurrence or death from 
any cause. The cut-off value shown represent a combination of the greatest 
sensitivity and specificity, calculated by the area under the curve (AUC) values. The 
strongest association was observed between a NLR cut-off of 3 and the presence of 
recurrence and death (AUC, 0.789 [0.661-0.917], P =.001). For statistical validation, 
we split the data set into a training data set and a test data set. We retrieved 250 
cases from the data set randomly as a test data set. ROC analyses were done for the 
training data set and the test data set after exclusion of the complicated group. NLR 
of 3 still had the highest sensitivity and specificity. Thereafter, patients were stratified 
into two groups: low NLR (≦3), high NLR (>3). Table 5.1 shows the differences in 
clinicopathological features of the two NLR groups. Overall, 233 (46.1%) patients 
had a low NLR and 273 (53.9 %) patients had a high NLR. A high NLR was 
significantly associated with age, higher T and N stage, presence of micro vascular 
invasion, low preoperative albumin level and ASA status of the patient. It was not 
associated with gender, histological tumour grade, primary tumour site, surgical 
approach, major complication after surgery and ERAS programme participation.  
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To investigate whether the NLR was associated with clinical outcome, univariate and 
multivariate survival analyses for OS and DFS were performed. Median follow-up 
was 45 months (IQR 21-65). Of the 506 patients included in this study, 39 (7.7%) 
developed recurrent disease (32 systemic and 7 loco-regional recurrences), of which 
28 (5.53%) died of their disease. Median time to recurrence was 20.42 months [IQR 
13.7-30.7] for the HNLR group and 32.2 months [IQR 19.8-40.9] for the LNLR 
group (p=0.194). Overall, 118 (23.32%) patients had died by the time of analysis in 
Feb 2013. 30 [76.9 %] of the recurrences and 79 [66.9 %] of all deaths were in the 
high NLR group. Figure 5.3 shows the Kaplan–Meier curves for DFS and Figure 5.4 
shows the Kaplan–Meier curves for OS for patients with high and low NLR. A high 
NLR was a significant poor prognostic factor (P<0.01, log-rank test). 
 Univariate analysis identified age (≤75 versus >75 years), high tumour grade (G3 
versus G1&G2), pathological T and N stage, vascular invasion (V0 versus V1 & V2), 
surgical approach (open versus laparoscopic), ASA score (1+2 versus 3+4), the 
presence of a major complication, and a high NLR as poorer prognostic indicators of 
outcome for patients’ OS, whereas gender (male versus female), pre-operative 
albumin and ERAS participation were not significantly associated with OS. On 
univariate analysis for DFS only age, T stage, N stage, vascular invasion and a high 
NLR were identified as prognostic factors. 
  To determine the independent prognostic significance of NLR on DFS and OS, 
multivariate analysis using a Cox proportional hazards model was performed. 
Multivariate analysis included age, pathological T stage, N stage, high NLR, and the 
presence of vascular invasion. All were independent prognostic factors for DFS. A 
high NLR was associated with a higher recurrence and poorer DFS (OR 2.41, 95% 
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CI 1.12-5.15, P= 0.024) as outlined in Table 2. A high NLR was not identified as an 
independent prognostic factor for OS (OR 1.23, 95% CI (0.80-1.90) P=0.347 as 
outlined in Table 5.3. Age, pathological T stage, N stage, ASA status, and surgical 
approach were identified as independently prognostic for overall survival 
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Figure 5-1 Flow diagram of patients included and excluded in this study 
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Figure 5-2 A.) ROC curve analysis for NLR of all colorectal cancer patients. NLR of 
3 had the highest sensitivity and specificity. (AUC, 0.789 [0.661-0.917], P = 0.001) B.) 
ROC curve analysis for NLR in the training data set. NLR of 3 had the highest 
sensitivity and specificity. (AUC, 0.801 [0.711-0.897], P <0.001) C.) ROC curve 
analysis for NLR in the test data set. NLR03.0 had the highest sensitivity and 
specificity. (AUC, 0.770 [0.749-0.790], P <0.001) 
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Table 5-1 Clinical and pathological features of the high and low NLR patients 
included  
 LNLR 
(n=233), (n, %) 
HNLR 
(n=273), (n, %) 
p-value 
Age (median, IQR) 71(54-88) 76(60-92) 0.010 
Gender  
Male 
Female 
 
132 (56.7) 
101 (43.3) 
 
164(60.1) 
109(39.9) 
0.436 
Primary Cancer 
Site 
Right Colon 
Transverse Colon 
Left Colon 
Sigmoid Colon 
Rectum 
 
 
67 (28.8) 
15 (6.4) 
12 (5.2) 
63 (27) 
76 (32.6) 
 
90 (33) 
19 (7) 
14 (5.1) 
60 (22) 
90 (33) 
0.718  
ASA status 
1+2 
3+4 
 
180 (84.9) 
32 (15.1) 
 
170 (75.2) 
56 (24.8) 
0.012 
Pre-Operative 
Albumin (median, 
IQR) 
 
 
39 (34-44) 
 
38 (32-44) 
0.050 
T stage 
1 
2 
3 
4 
 
43 (18.5) 
59 (25.3) 
106 (45.5) 
25 (10.7) 
 
28 (10.3) 
60 (22) 
154 (56.4) 
31 (11.4) 
0.022 
N stage 
0 
1+2 
 
188 (80.7) 
45 (19.3) 
 
199 (72.9) 
74 (27.1) 
0.039 
V stage 
0 
1+2 
 
187 (80.3) 
46 (19.7) 
 
194 (71.1) 
79 (28.9) 
0.017 
Grade 
Well + moderate 
Poor 
 
175 (88.8) 
22 (11.2) 
 
194 (88.6) 
25 (11.4) 
0.975 
Surgical Approach 
Open 
Laparoscopic 
 
102 (44.7) 
126 (55.3) 
 
119(44.2) 
150 (55.8) 
0.911 
ERAS pathway 
No 
Yes 
 
92 (39.5) 
141 (60.5) 
 
139 (50.9) 
134 (49.1) 
0.100 
Major 
complication  
[CD≥3] 
No 
Yes 
 
200 
33  (14.1%) 
 
231 
42 (15.3%) 
0.756 
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Table 5-2 Univariate and multivariate analysis of clinical and pathological parameters 
for the prediction of disease-free survival in patients with colorectal adenocarcinoma 
(n=506) 
 Univariate 
Analysis 
OR(95%CI) 
P value Multivariate 
Analysis 
OR(95%CI) 
P value 
Age at operation 
years  
    
≤75 years 1(Referent) 0.005 1(Referent) 0.037 
>75 years 2.71 (1.35-5.43)  2.09(1.05 -4.17)  
Gender     
Male 1(Referent) 0.148   
Female 1.63(0.84-3.16)    
Pre-operative 
Albumin 
    
<35 g/L 1 (Referent) 0.93   
≥35 g/L 0.507(0.23-1.12    
T stage     
T1 1(Referent) 0.005 1(Referent) 0.002 
T2 3.16(0.67-14.88)  1.55(0.33-7.30)  
T3 2.11(0.47-9.46)  0.62(0.13-3.01)  
T4 8.25(1.74-38.95)  2.72(1.53-13.99)  
N stage     
N negative 1(Referent) <0.001 1(Referent) 0.009 
N positive 3.64(1.86-7.14)  2.65(1.37-5.49)  
V stage     
V negative 1 (Referent) <0.001 1(Referent) 0.021 
V positive [V1+V2] 4.072 (2.092)  2.45(1.15-5.23)  
Grade     
G1+G2 1(Referent) 0.173   
G3 1.91(0.76-4.81)    
Surgical Approach     
Open 1(Referent) 0.221   
Laparoscopic 0.65(0.34-1.29)    
ERAS pathway     
No 1(Referent) 0.122   
Yes 0.59(0.30-1.15)    
ASA score     
1+2 1(Referent) 0.373   
3+4 1.51(0.61-3.70)    
Major 
Complication 
(CD≥3 in  30 days) 
    
No 1(Referent) 0.262   
Yes 1.6(0.70-3.69)    
Neutrophil–
lymphocyte ratio 
    
≤3 1(Referent) 0.006 1(Referent) 0.024 
>3 2.95(1.36-6.36)  2.41(1.12-5.15)  
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Table 5-3 Univariate and multivariate analysis of clinico pathological parameters for 
the prediction of overall survival in patients with colorectal adenocarcinoma (n=506) 
 Univariate 
Analysis 
OR(95%CI) 
P value Multivariate 
Analysis 
OR(95%CI) 
P value 
Age at operation 
years  
    
≤75 years 1(Referent) <0.001 1(Referent) <0.001 
>75 years 3.59(2.32-5.45)  2.64(1.68-4.15)  
Gender     
Male 1(Referent) 0.784   
Female 0.93(0.62-1.43)    
Pre-Operative 
Albumin 
    
≤35 g/L 1 (Referent) 0.07   
>35 g/L 0.48(0.28-0.82)    
T stage     
T1 1(Referent) <0.001 1(Referent) 0.007 
T2 2.81(1.16-6.84)  2.09(0.85-5.17)  
T3 2.23(0.97-5.16)  1.38(0.56-3.37)  
T4 12.57(4.91-32.21)  3.13(1.20-8.14)  
N stage     
N negative 1(Referent) <0.001 1(Referent) 0.01 
N positive 3.65(2.34-5.71)  2.22(1.41-3.51)  
V stage  <0.001   
V negative 1(Referent)  1(Referent) 0.478 
V positive [V1+V2] 2.37(1.52-3.71)  1.18(0.74-1.90)  
Grade     
G1+G2 1(Referent) 0.002 1(Referent) 0.777 
G3 2.59(1.40-4.80)  0.92(0.52-1.63)  
Surgical Approach     
Open 1(Referent) <0.001 1(Referent) 0.025 
Laparoscopic 0.37(0.24-0.57)  0.62(0.41-0.95)  
ERAS pathway     
No 1(Referent) 0.073   
Yes 0.69(0.45-1.036)    
ASA score     
1+2 1(Referent) <0.001 1(Referent) 0.004 
3+4 3.37(2.03-5.58)  1.88(1.23-2.89)  
Major 
Complication 
(CD≥3 in  30days) 
    
No 1(Referent) <0.001 1(Referent) <0.001 
Yes 3.88(2.32-6.47)  3.53(2.30-5.44)  
Neutrophil–
lymphocyte ratio 
    
≤3 1(Referent) 0.001 1(Referent) 0.347 
>3 2.05(1.33-3.15)  1.23(0.80-1.90)  
 
 
 
 
 
 173 
 
 
Figure 5-3 Kaplan–Meier curves for colorectal carcinoma patients’ DFS based on high 
and low NLR. 
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Figure 5-4 Kaplan–Meier curves for colorectal carcinoma patients’ OS based on high 
and low NLR
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5.1.4! Discussion 
 
The findings of this study support the existing literature on role of NLR as an 
independent predictor of DFS in patients with colorectal cancer. It represents a large 
cohort of consecutive non-metastatic colorectal cancer patients followed up within a 
standardised surveillance programme with complete data. The threshold value for 
NLR in this study was three, which produced a relatively larger ‘high NLR’ group 
with 53.9 % of the patients in it compared to previous studies that have chosen a 
threshold of five (Carruthers et al., 2012; Hung et al., 2011; Kishi et al., 2009; 
Mallappa et al., 2013; Walsh et al., 2005; Y. Zhang et al., 2012). When interpreting 
these results it should be noted that in our study, NLR was not an independent 
predictor of OS, unlike the type of surgical approach (laparoscopic versus open), 30-
day major morbidity, age, tumour stage, and ASA grade. Patients with NLR >3 in our 
study had significantly more advanced tumours with worse micro-vascular invasion, 
were older, and had higher ASA scores. Whilst this study adds to the growing body 
of evidence suggesting that the systemic inflammatory response is related to key 
host and tumour-associated factors influencing clinical outcomes in colorectal cancer 
patients undergoing curative surgery, its findings are not entirely conclusive.   
 
This study has highlighted the potential ability of NLR to act as a prognostic indicator 
in colorectal cancer, but was not designed to provide an explanation for this. 
Halazun et al, have suggested two potential mechanisms through which a high NLR 
may be associated with poorer outcome (Halazun et al., 2008): firstly, patients with 
an elevated NLR are relatively lymphocytopaenic, resulting in a poorer lymphocyte 
mediated immune response to malignancy and therefore an increased potential for 
tumour recurrence (Jass, 1986); secondly, a relatively high neutrophil count may aid 
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in the development and progression of a neoplasm through release of Vascular 
Endothelial Growth Factor (VEGF), a pro-angiogenic factor thought to be integral to 
tumour development (Kusumanto, Dam, Hospers, Meijer, & Mulder, 2003). A high 
circulating neutrophil count producing an elevated NLR may therefore encourage 
metastatic colorectal tumour cells to survive, thereby accounting for a poorer DFS 
and OS (although the latter was not significantly different in our study). Longer 
follow-up may identify differences in OS between NLR groups. Ultimately disease 
progression in malignancy is dependent upon a complex interaction between the 
tumour, its microenvironment and the host immune system. The phenotype of the 
tumour may encourage inflow of inflammatory lymphocytes around the tumour, 
resulting in cell destruction within surrounding tissues, generating a more 
widespread non-specific inflammatory response (Coussens & Werb, 2002). 
 
This study provides some evidence to challenge the NLR threshold of five that has 
been recommended by several groups which was originally extrapolated from a 
Slovakian study of critically ill patients that showed an NLR greater than five was 
associated with a poorer outcome (Zahorec, 2001). If correct, this would mean that 
the number of patients in whom a high NLR predicts poor prognosis might have 
been underestimated. One of the strengths of our study is that it comprises a patient 
group whose management and follow-up is relatively homogenous. Excluding patients 
who received pre- and post-operative chemotherapy or radiotherapy from our study 
was important in removing a potential confounder, as has been done by two other 
groups in the context of NLR. In the first study, an elevated NLR greater than five 
was found to be an independent predictor of OS but not DFS in stage II disease 
(Hung et al in 2011) whereas in the second study (Ding et al in 2010) an elevated 
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NLR greater than four was an independent predictor of DFS and not OS in stage IIA 
disease (P. R. Ding et al., 2010; Hung et al., 2011). Had we adopted an NLR 
threshold of five, only 14 patients that developed disease recurrence would have 
been included in our ‘high’ NLR group compared to the 30 patients we identified 
with NLR >3.  This finding is important to consider in future research on the topic. 
 
Certain limitations in this study merit explanation. Firstly, this was an uncontrolled 
study, despite comprising of a relatively large and homogenous dataset. Secondly, 
patients who underwent an emergency operation, a resection with positive margins 
(macro- or microscopic) or any type of neo-adjuvant treatment were excluded, as 
these interventions can alter preoperative white cell population ratios. Thirdly, 
patients receiving adjuvant chemotherapy were excluded as has been the case in 
other studies evaluating the role of NLR in predicting overall and disease free 
survival from curative surgery for malignancy (Pichler et al., 2013). This is because 
adjuvant chemotherapy treatment modifies the course of the disease (OS and DFS) 
and thus acts as a potential confounder. The reasons for patients not receiving 
adjuvant chemotherapy in our study may have included patient choice, age, co-
morbidity and post-operative complications. The ability of NLR to predict transition 
to and toxicity from adjuvant treatment is of extreme interest and future studies 
should aim to address this. NLR was calculated from laboratory blood test data 
collected within the 3 weeks prior to surgery. For patients that had multiple blood 
tests within this time frame the closest result to the operation date was selected. 
This study was not designed to provide evidence on how the surrogate markers of 
the SIR varied in each patient.  Variability between each patient might exist as SIR is 
also marker of other medical conditions that can lead to background inflammatory 
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response. The fact that in this study NLR was calculated from data closest to the 
surgery date and that these blood tests were part of the elective anaesthetic pre-
assessment reduces the possibility of NLR inconsistency.  The variability of the NLR 
throughout a cancer patient’s pathway is of extreme interest and future studies 
should aim to address this.   
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5.1.5! Conclusion 
 
Routine preoperative NLR measurement in patients undergoing curative treatment 
for CRC may provide a simple and inexpensive means of identifying patients with a 
poorer prognosis and offer assistance in clinical decision-making. Evidence is building 
for the utility of NLR in predicting prognosis yet the optimal ratio that has the 
greatest prognostic significance remains to be established. Whilst oncology trials 
incorporating an NLR >5 within the decision-making process are underway (Pichler 
et al., 2013), we have provided some evidence suggesting this threshold should be 
NLR >3. Although a body of evidence exists suggesting that high NLR is associated 
with both adverse patient-related and pathological factors, to date no specific 
therapies targeting this finding exist. Interventions to modify pre- and post-operative 
inflammatory responses and modulate the immune response may prove beneficial in 
improving long-term outcomes. Further research is required to evaluate the value of 
NLR in other patient groups with colorectal cancer such as those receiving adjuvant 
chemotherapy and neo-adjuvant chemoradiotherapy and attempt independent 
validation of NLR for patient-risk stratification. In a resource-constrained era for 
healthcare where routine assessment of genetic variants of cancer prognosis is 
expensive, NLR >3.0 may play a role in refining stratification of patients to treatment 
and in predicting survival.  
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5.2! The Emerging Role of Neutrophil to Lymphocyte Ratio In Determining 
Colorectal Cancer Treatment Outcomes; A Systematic Review And Meta-
Analysis 
 
5.2.1! Introduction 
 
In patients undergoing treatment for CRC, there are three particular scenarios 
where the role of NLR as a prognostic indicator needs to be clarified. The first is in 
the case of patients undergoing resections of the primary tumour with curative 
intent, where, to date, evidence from individual studies suggests a high NLR is 
associated with poorer disease free survival (DFS). In this group, it is of interest to 
determine whether adjuvant therapies should be tailored for individual patients 
based not only on pathological prognostic variables but also based upon pre-
treatment inflammatory markers. The second scenario is in cases of advanced 
colorectal cancer where in patients receiving palliative chemotherapy, a high NLR 
has been associated with reduced progression-free survival (PFS). Finally, the third 
scenario includes patients with metastatic liver disease where a high NLR is 
associated with poorer DFS in patients undergoing both liver resection and 
radiofrequency ablation with chemotherapy and curative intent. This study aims to 
review systematically the literature and use meta-analytical techniques to evaluate 
the utility of NLR as a prognostic indicator in these three patient groups. It also aims 
to evaluate the performance of NLR as a predictor of DFS or PFS over time during 
follow-up as part of CRC surveillance programmes.  
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5.2.2! Methods 
 
5.2.2.1! Search strategy 
 
 The study was executed and reported in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses (Moher et al.) statement and was 
registered with International Prospective Register of Systematic Reviews 
(PROSPERO), registration number CRD42013004365. All studies published between 
1990 to 2013 (without any language restriction) reporting on NLR and its prognostic 
value in patients undergoing CRC treatment, were identified. Medline, EMBASE, 
Google Scholar and Cochrane databases were searched using the following Medical 
Subject Heading (MESH) terms: “NLR” OR “neutrophil lymphocyte ratio” OR 
“systemic inflammatory response” AND “colorectal cancer” OR “colon cancer”. The 
‘related articles’ function and reference list of each of the identified publications was 
used to further widen the literature search. Any relevant review articles were also 
screened.  
5.2.2.2! Data Extraction 
 
Two reviewers reviewed these publications, independently and the relevant data 
extracted without cross-referencing. A third reviewer before analysis resolved any 
conflicts in data extraction or quality assessment. The inclusion/exclusion criteria and 
outcomes measures are described below. The quality of the included studies was 
assessed according to the Scottish Intercollegiate Guidelines Network 
(SIGN)(Harbour & Miller, 2001) .  
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5.2.2.3! Inclusion & Exclusion Criteria 
 
In order to be included in this analysis studies had to compare survival in CRC 
patients with ‘high’ versus ‘low’ pre-treatment NLR undergoing three types of 
treatment: (i) Resection of the primary CRC; (ii) Palliative chemotherapy for 
advanced CRC; and (iii) Treatment of CRC liver metastases using metastatectomy or 
ablation with curative intent. Studies had to report the outcomes of interest 
mentioned below and comprise an adult patient group (aged 18 or over). Studies 
were excluded if they included patients with other cancers from which the CRC 
group could not be separated or if they reported a previously published dataset (in 
this case the larger or better quality paper was used) 
5.2.2.4! Outcome measures 
 
Disease Free Survival (DFS) was main outcome of interest for studies with patients 
undergoing resection of the primary CRC and treatment of CRC liver metastases 
using metastatectomy or ablation with curative intent. DFS was defined as the 
absence of colorectal cancer throughout the follow-up period. Progression Free 
Survival (PFS) was the main outcome of interest for studies with patients undergoing 
palliative chemotherapy for advanced CRC. PFS was defined as an absence of 
progression and increase in volume of the primary CRC or metastatic disease over 
the follow-up period. 
The following demographics were extracted: study type, number of patients, stage of 
CRC, treatment type, follow up (months), timing of the NLR recorded, and cut-off 
value used to determine ‘high’ versus ‘low’ NLR, the number of patients in each 
group.  
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5.2.2.5! Statistics 
 
The logarithm of the hazard ratio (HR) with 95% confidence intervals (CI) was used 
as the primary summary statistic (Parmar, Torri, & Stewart, 1998). To estimate the 
HR and its variance, this was extracted from the study directly or required additional 
calculation depending on the method of data being presented: annual mortality rates, 
survival curves, number of deaths or percentage freedom from death. Calculation of 
the logarithm of the HRs and their 95% CI was also performed yearly for the first 
three years after treatment (Tierney, Stewart, Ghersi, Burdett, & Sydes, 2007). 
Meta-analysis of data was conducted using a random-effects model. Publication bias 
was explored graphically with funnel plots to detect asymmetry and any outliers. 
Inter-study heterogeneity was assessed using the Chi2-statistic and the I2 value to 
measure the degree of variation not attributable to chance alone. This was graded as 
low (I2<25%), moderate (I2=25-75%) or high (I2>75%). Calculations were performed 
by GM and verified by TA. This study was performed in line with Cochrane 
recommendations and following PRISMA guidelines and using the statistical software 
Review Manager Version 5.1 (The Cochrane Collaboration, Oxford, UK). 
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5.2.3! Results 
 
5.2.3.1! Search Outcomes 
 
After removal of the duplicates, 156 citations were identified during the reported 
systematic literature search. Of these, 120 were excluded through review of 
abstracts, leaving 36 articles. Full text review of these resulted in the identification 
and inclusion of thirteen papers in this analysis (2007-2013), all of which were 
observational cohort studies (evidence grade C based on the SIGN grading 
system)(Absenger et al., 2013; Carruthers et al., 2012; Chua, Charles, Baracos, & 
Clarke, 2011; P. R. Ding et al., 2010; Halazun et al., 2008; He et al., 2013; Hung et al., 
2011; Kaneko et al., 2012; Malietzis, Giacometti, Askari, et al., 2014; Mallappa et al., 
2013; Urrejola et al., 2013; Zeman, Maciejewski, Poltorak, & Kryj, 2013; Y. Zhang et 
al., 2012). A flow chart of the literature search is shown in Figure 5.4.  
The 13 selected studies included 4056 patients with approximately 30% classified as 
having a ‘high’ pre-treatment NLR (HNLR). The cut-off value for HNLR was ≥3 in 
two studies (He et al., 2013; Malietzis, Giacometti, Askari, et al., 2014), ≥ 4 in three 
studies (Absenger et al., 2013; P. R. Ding et al., 2010; Kaneko et al., 2012) and ≥5 in 
eight studies (Carruthers et al., 2012; Chua et al., 2011; Halazun et al., 2008; Hung et 
al., 2011; Mallappa et al., 2013; Urrejola et al., 2013; Zeman et al., 2013; Y. Zhang et 
al., 2012) 14,15,17,19, 22- 25,. One of these was a multicentre database study with 
the remainder being single institution studies (Chua et al., 2011). Seven studies 
reported on patients undergoing resection of the primary CRC (Absenger et al., 
2013; Carruthers et al., 2012; P. R. Ding et al., 2010; Hung et al., 2011; Malietzis, 
Giacometti, Askari, et al., 2014; Mallappa et al., 2013; Urrejola et al., 2013), three 
studies reported on patients undergoing palliative chemotherapy for CRC (Chua et 
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al., 2011; Hung et al., 2011; Kaneko et al., 2012) and three studies reported on 
patients undergoing liver resection or ablation with or without chemotherapy for 
hepatic CRC metastasis (Halazun et al., 2008; Zeman et al., 2013; Y. Zhang et al., 
2012).  A summary of the characteristics of studies included is provided in Table 5.4.  
5.2.3.2! Overall impact of NLR on survival in CRC patients  
 
When considering all thirteen observational studies reporting on pre-treatment NLR 
and DFS or PFS in CRC patients, we found survival to be significantly shorter in the 
HNLR groups using pooled analysis with the generic inverse variance method [HR; 
2.08, 95% CI; 1.64, 2.64, P<0.00001]. The Forest plot for this is shown in figure 5.5, 
and demonstrates moderate heterogeneity [I2=54%, P=0.01].  
5.2.3.3! CRC patients undergoing resection of the primary lesion  
 
DFS amongst the seven studies included in this subgroup analysis showed a 
significant survival disadvantage in the HNLR group [HR; 2.10, 95% CI; 1.50, 2.93, 
P<0.0001]. There was an overall moderate but not statistically significant level of 
heterogeneity between the individual studies [I2=50%, P=0.06]. Figure 5.5 represents 
the Forest plot for this analysis. 
5.2.3.4! Stage IV CRC patients undergoing palliative chemotherapy 
 
PFS was significantly worse in in the HNLR group when considering the three studies 
included in this subgroup with metastatic disease undergoing palliative chemotherapy 
[HR; 1.53, 95% CI; 1.23, 1.90, P=0.0001]. Figure 5.5 represents the Forest plot for 
this analysis. The heterogeneity level between these three studies was low and not 
significant [I2=0%, P=0.83]. 
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5.2.3.5! Stage IV CRC patients undergoing resection or ablation for liver metastases  
 
DFS was significantly poorer in HNLR CRC patients undergoing metastatectomy or 
ablation for liver metastases [HR; 3.91, 95% CI; 2.47, 6.18, P<0.00001]. Figure 5.5 
represents the Forest plot for this analysis and demonstrates a low and not 
statistically level of heterogeneity between the individual studies [I2=0%, P=0.77].   
5.2.3.6! Impact of follow-up duration on HR for survival in CRC patients 
 
With all studies considered, HR for survival of HNLR versus LNLR after the first 
year of follow-up could be calculated for 10 studies, after the second year of follow-
up for 7 studies and after the third year of follow-up for 8 studies. Figure 5.6 
represents the Forest plot for these three time points as well as a cumulative graph 
of these hazard ratios Survival for the first year of follow up was not significantly 
different between groups [HR; 1.47, 95% CI; 0.89, 2.41, P=0.13], however at years 
two [HR; 2.76, 95% CI; 2.06, 3.69, P<0.00001] and three [HR; 2.03, 95% CI; 1.48, 
2.78, P<0.0001] HR for survival was significantly worse for HNLR versus LNLR 
groups. 
5.2.3.7! Sensitivity analyses 
 
In order to uncover the influence of each study’s individual dataset we performed 
sensitivity analyses for the three subgroups mentioned above.  A single study 
involved in the pooled meta-analysis was excluded each time and the corresponding 
HRs were not changed considerably. We also performed the same approach by 
removing the two studies with the NLR threshold of three and again the 
corresponding polled HRs were not materially changed.  
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5.2.3.8! Heterogeneity Assessment: Bias Exploration 
 
Funnel plots were created for combined and the subgroup analysis for DFS or PFS to 
visual assess the publication bias.  They demonstrated symmetry. Exclusion of the 
outliers did not alter the results significantly.  
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Table 5-4 Main characteristics of all the studies included in the meta-analysis 
Reference Study Design Number of 
patients and 
Stage of the 
disease 
Treatment NLR cut-off 
(HNLR/LNLR) 
F-up in 
months 
(median) 
Multivariable Analysis 
(parameters tested) 
Study 
Quality 
 
Patients undergoing surgery for CRC (stage I to stage IV) 
Ding Retrospective 
Cohort study 
141 Stage II CC Curative surgery 4 (20/121) 58 Yes (NLR, lymph node sampling) 2+ 
Hung Retrospective 
Cohort study 
1040 Stage II CC Curative surgery 5 (255/785) 74.5 Yes (age, CEA, grade, tumour size, 
lymph node sampling, T stage, NLR, 
Tumour obstruction or perforation) 
2+ 
Urrejola Retrospective 
Cohort study 
122 Stage II CC Curative surgery 5 (28/94) 73 No 2- 
Absenger Retrospective 
Cohort study 
504 Stage II CC Curative surgery 
+/- Adjuvant 
Chemotherapy 
4 (129/173) 45 Yes (gender, tumour size, lymph node 
sampling, grade, stage, adj 
chemotherapy)  
2- 
Malietzis Retrospective 
Cohort study 
(prospectively 
maintained) 
506 Stage I-III 
CRC 
Curative surgery  3 (273/233) 45 Yes (age, T stage, N stage, V stage, 
NLR) 
2+ 
Carruthers Retrospective 
cohort study 
 
115 Stage I-III RC Neo-adjuvant 
chemoradiation + 
Surgery 
5 (n/a) n/a Yes (resection margins, NLR, Platelet 
count, down staging) 
2+ 
Mallapa Retrospective 
Cohort study 
(prospectively 
maintained) 
297 Stage I-IV 
CRC 
Surgery +/- 
Adjuvant 
Chemotherapy 
 
5 (92/205) 40.2 Yes (age, Jass stage, NLR, tumour 
location) 
2- 
Patients having palliative chemotherapy for Stage IV CRC 
He Retrospective 
Cohort study 
243 Stage IV CRC 
 
Palliative 
chemotherapy 
3 (84/159) 21.87 Yes (age, gender, tumour location, 
NLR, PLR, first and second line 
2- 
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  chemotherapy 
Kaneko Retrospective 
Cohort study 
(prospectively 
maintained) 
 
50 Stage IV CRC 
 
Palliative 
chemotherapy 
 
4 (15/35) 17  Yes (age, gender, tumour location, 
number of metastatic sites, 
performance status,bevazicumab, Hb, 
Platelets count, ALP, albumin, CRP, 
NLR) 
2- 
Chua Retrospective 
multicentre 
Cohort study 
 
379 Stage IV 
Colorectal 
Cancer 
 
Palliative 
chemotherapy 
 
5 (49/120) n/a Yes (age, gender, tumour location, 
number of metastatic sites, 
performance status, Hb, Neutrophil 
and Platelets count, albumin, ALP, 
NLR) 
2+ 
Patients undergoing liver surgical treatment for colorectal liver metastasis (stage IV CRC) 
Halzun Retrospective 
Cohort study 
 
440 Stage IV with 
CRLM 
Liver resection + 
chemotherapy 
5 (78/362) 24 Yes (age, gender, number of tumours, 
tumour size, timing of the tumour, 
number of liver segments removed, 
NLR and resection margins) 
2+ 
Zhang Retrospective 
Cohort study 
 
92 Stage IV CRLM 
 
Liver RF ablation + 
chemotherapy 
 
5 (21/71) 27.1 Yes (NLR, Disease Free interval) 2- 
Zeman Retrospective 
Cohort Study 
 
130 Stage IV 
CRLM 
 
Liver resection or 
RFA +/- adjuvant 
chemo 
 
5 (n/a) 39.3 (mean) Yes (lymph node involvement, tumour 
size, positive margins, NLR)  
2- 
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Figure 5-5 Study Flow diagram 
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Figure 5-6 Forest Plots of survival in pre-treatment HNLR vs LNLR patients  
For: 2a. All studies, 2b. Studies included stage I-IV patients undergoing bowel 
resection demonstrating HNLR vs LNLR patients for overall DFS, 2c Studies 
included stage IV patients undergoing palliative chemotherapy demonstrating HNLR 
vs LNLR patients for overall DFS, 2d Studies included patients undergoing liver 
surgical treatment for colorectal liver metastasis (stage IV CRC) 
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Figure 5-7 Forest plots demonstrating the 1, 2 and 3 years DFS HR for all the studies 
included and linear representation of follow-up yearly trends  
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5.2.4! Discussion 
 
The results of this meta-analysis of thirteen studies suggests that that pre-treatment 
NLR, a systemic inflammation-based prognostic score, can predict DFS in patients 
undergoing primary resections for CRC and in patients undergoing liver 
metastatectomy or ablation (with or without chemotherapy). It also suggests NLR 
has a role to predict PFS in patients undergoing palliative treatments for CRC. HNLR 
was found to be associated with a significantly poorer prognosis when all three 
patient groups were combined, but also during subgroup analysis. Furthermore 
subgroup analysis confirmed these findings in each of the above-mentioned groups 
and resulted a significantly lower heterogeneity, as would be expected. Finally, our 
results have identified a potential role for NLR as a predictor of survival during post-
therapy follow-up, particularly from the 24 months post treatment. This is however 
a preliminary finding that requires further investigation before NLR can be 
recommended as part of CRC surveillance programs. 
To date, there has been one previous meta-analysis examining the role of NLR in 
predicting overall survival and PFS (Li et al., 2014). This current study is importantly 
differentiated from Li et al one in a number of ways: First, it includes a further 3 
studies comprising of 1132 patients, making it significantly more powerful. Second, 
the definitions of overall survival used in the previous study are very inclusive, 
resulting in a significant of heterogeneity in the analyses. By using robust definitions 
of DFS and PFS, we were able to undertake a robust subgroup analysis with no 
significant heterogeneity. Third, the subgroups used by the previous study are less 
well defined according to patient stage. Finally this study has also investigated the 
role of NLR in predicting survival as part of a CRC surveillance program, which is 
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important if this marker is to be used practically in the management of this patient 
group to deliver personalized healthcare. Finally the previously mentioned analysis 
comprised very heterogenous patient groups 
It is important to mention a number of limitations of our study and meta-analytical 
research in general. Firstly, although we classified patients into three broad groups, 
these were still relatively heterogenous in terms of patient demographics, tumour 
characteristics, and treatment types. This could be further addressed by undertaking 
research on NLR that better defines patient subgroups in terms of tumour stage and 
grade of differentiation. It is important to note that randomised controlled research 
is not appropriate in this setting, but that research is required with larger patient 
groups so that a more robust subgroup analysis can be performed. The ease with 
which NLR can be calculated from routine blood tests should make this possible in a 
way that is often challenging for other markers. Second, it is important to note that 
there was heterogeneity in NLR cut-off values used in the included studies, ranging 
from three to five. Whilst it was not our intention to resolve this, combining studies 
with varying NLR thresholds is a source of potential heterogeneity. The point has 
been made in the past that should the threshold be three, there would have been a 
vast under-estimation of the impact of NLR in survival outcomes made by studies 
were the threshold was four or five (Malietzis, Giacometti, Askari, et al., 2014). 
Sensitivity analysis did not provide any additional information to address this 
limitation. Third, many of the studies included patients who underwent an 
emergency operations, a resection with positive margins (macro- or microscopic), 
and variation in the type of neo-adjuvant treatment all of which can alter 
preoperative white cell population ratios. Finally, patients receiving adjuvant 
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chemotherapy were included by many of the studies, which is a source of 
confounding because it modifies the course of the disease (OS and DFS). 
Taken together, our study highlights the importance of systemic inflammation in the 
poor outcome in patients with CRC. The link between carcinogenesis and 
inflammation is generally accepted (Hanahan & Weinberg, 2011). Apart from local 
inflammatory disease cancer patients, frequently present with changes in numerous 
systemic parameters. These include changes in peripheral blood cell numbers, 
phenotypes and gene expression patterns, changes in erythrocyte sedimentation 
rate, and alterations in the level of serum inflammatory cytokines, acute-phase 
proteins and total albumin (Bardou et al., 2013; McMillan, 2009). Body composition 
changes and especially muscle mass depletion has been suggested to be associated 
with the systemic inflammatory response in CRC patients and this relationship might 
begin to explain the mechanism by which sarcopenic patients to worse outcomes 
(Chapter 6) (McMillan, 2009). Therefore, inflammation generates not only cancer-
promoting microenvironment changes but also systemic changes that are favourable 
for cancer progression. We believe that the present results provide good evidence 
of altered systemic inflammatory response, expressed as NLR, acting as a promoter 
in the fatal progression of CRC.  
Moderation of the systemic inflammatory response may be as important a 
therapeutic target as the tumour itself. It has been showed that preoperative 
administration of corticosteroids in patients undergoing surgery for cancer is 
associated with a reduction in postoperative morbidity. This observation may be due 
to the alteration the inflammatory response to surgery (Ramanathan et al., 2013; 
Sato et al., 2002; Schmidt et al., 2007). Also observational, epidemiological studies 
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and clinical trials strongly suggest that NSAIDs have a preventative effect against the 
development and progression of CRC (Chan et al., 2012; Din et al., 2010; Hull, 
2013). NLR is a biomarker that better predicts outcomes of CRC but can it also be 
used to guide clinicians on the dose and duration of NSAIDs on the observed 
benefit; this remains too been seen.    
5.2.5! Conclusion  
 
Routine preoperative NLR measurement in patients undergoing curative treatment 
for CRC may provide a simple and inexpensive means of identifying patients with a 
poorer prognosis and offer assistance in clinical decision-making. Evidence is building 
for the utility of NLR in predicting prognosis yet the optimal ratio that has the 
greatest prognostic significance remains to be established. Although a body of 
evidence exists suggesting that high NLR is associated with both adverse patient-
related and pathological factors, to date, no specific therapies targeting this finding 
exist. Interventions to modify pre- and post-operative inflammatory responses and 
modulate the immune response may prove beneficial in improving long-term 
outcomes. Whether interventions that alter NLR can alter long-term oncological 
outcomes also remains to be established. Further research is required to evaluate 
the value of NLR in other patient groups with colorectal cancer such as those 
receiving adjuvant chemotherapy and neo-adjuvant chemoradiotherapy and attempt 
independent validation of NLR for patient-risk stratification. Finally the ability of NLR 
to predict transition to and toxicity from adjuvant treatment is of extreme interest 
and future studies should aim to address this. 
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Chapter 6 
6! What is the relationship between systemic inflammatory response 
and body composition parameters in patients undergoing surgery for 
CRC?  
 
The biologic underlying mechanisms of SIR in cancer are still unknown. It has been 
suggested that SIR is driven by tumour-derived and is also linked with host related 
factors. Emerging evidence shows that altered SIR is associated with the cardinal 
features of muscle depletion such as decreased quality of life, or increased risk of 
morbidity and mortality but the link between SIR and BC parameters of the CRC 
patient has been remotely investigated. In this chapter CT defined BC parameters 
and their association with the SIR in patients with primary operable CRC is 
examined.  
 
 
 
 
 
  
 198 
6.1! Introduction 
 
Image–based analyses are central to body composition assessment. Cross-sectional 
areas of visceral, subcutaneous and intramuscular adipose tissue, psoas, paraspinal 
muscles and muscles of the abdominal wall on CT at the lumbar level, correlate 
strongly with whole body tissues (Mourtzakis et al., 2008). CT not only precisely 
quantifies muscle mass in vivo but also reliably assesses skeletal muscle fat content. 
To date, research on CTBC quantification techniques suggests that patients with a 
high visceral fat or depleted skeletal muscle mass have poorer functional capacity, 
greater chemotherapy toxicity, more rapid time to cancer progression and higher 
mortality in situations where weight loss and body mass index (BMI) lack predictive 
power (Malietzis, Aziz, et al., 2015; Reisinger et al., 2015).  
Due to the multifactorial character of the condition, neither the time of onset of 
muscle loss or myosteatosis, nor the exact aetiology is known. Inactivity, age-related 
factors, anorexia and unbalanced nutrition are proposed mechanisms that alter 
skeletal muscle (K. Fearon et al., 2013). There is also weak evidence that the 
systemic inflammatory response (SIR), already recognized, as a marker of poor 
prognosis in patients with gastrointestinal cancer, is associated with the cardinal 
features of muscle depletion such as decreased quality of life, or increased risk of 
morbidity and mortality (Richards et al., 2012). NLR is defined as the ratio of 
neutrophil to lymphocyte count and is calculated from a routine laboratory full blood 
count test and has been considered as a predictive prognostic factor for survival 
outcomes in CRC due to its performance and availability. The results of a recent 
meta-analysis indicate that pretreatment NLR can predict disease free survival in 
patients undergoing primary resections for CRC and in patients undergoing liver 
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metastasectomy or ablation. NLR has also a role in predicting progression free 
survival in patients undergoing palliative treatments for CRC(Malietzis, Giacometti, 
Kennedy, et al., 2014). It is thought that a high NLR reflects increased systemic 
inflammatory changes in the host that are cancer promoting and thereby associated 
with a poorer prognosis. Hypoalbuminemia is the result of the combined effects of 
inflammation and inadequate protein and caloric intake in patients with chronic 
disease and has also been used as a marker of SIR (McMillan, 2009).  
Myosteatosis and low muscle mass have emerged as independent risk factors for 
mortality in cancer; however, the characteristics and pathogenesis of these features 
have not been resolved. This study aimed to determine whether CT defined 
myopenia and myosteatosis (LSMI and MA) is associated with SIR expressed as NLR 
and albumin in patients with primary operable colorectal cancer (CRC).  
6.2! Patients and methods 
 
6.2.1! Patient selection 
 
1477 consecutive patients undergoing CRC surgery at St. Mark’s Hospital, London, 
between January 2006 and December 2013 were identified from a prospective 
database. Patients with recorded height data, laboratory blood test data within four 
weeks of the staging CT scan and pre-operative staging CT images stored and 
retrievable in an electronic format suitable for image analysis were included in the 
study. Exclusions were patients with disease recurrence confirmed preoperatively or 
at surgery and emergency cases. All prospectively recorded clinical and pathological 
data were revalidated from medical and pathology records. Data collected 
prospectively during the perioperative period (within 30 days of surgery) included 
age, sex, Body Mass Index (BMI), the American Society of Anaesthesiologists (ASA) 
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physical status classification system, tumour site, histological grading, TNM stage 
(UICC 5 version), the presence of vascular invasion on histopathology. Laboratory 
blood test data collected included preoperative albumin, neutrophil, and lymphocyte 
counts. 
6.2.2! Computed tomography image analysis 
 
Images were retrieved from digital storage in the Picture Archiving and 
Communication System [PACS]. Computed tomography image analysis Slice-O-Matic 
V4.3 software (Tomovision, Montreal, Canada) was performed as described 
previously. Briefly, total skeletal muscle and adipose tissue surface area (cm2) were 
evaluated on a single image at the third lumbar vertebrae (L3) using Hounsfield unit 
(HU) thresholds of -29 to 150 for skeletal muscle, 150 to 50 for visceral adipose 
tissue and 190 to 30 for subcutaneous adipose tissues.  Visceral, subcutaneous fat 
area (VFA, SFA), and skeletal muscle area (SMA) or skeletal muscle index form the 
taxonomies used. The sum of skeletal cross-sectional muscle areas were normalized 
for stature (m2) and reported as LSMI (cm2m-2). Mean Muscle Attenuation [MA] 
(HU) was reported for the whole muscle area at the third lumbar vertebra level. 
Reduced LSMI (myopenia) and low MA (myosteatosis) were defined using predefined 
sex-specific skeletal muscle index cut-points (Martin et al., 2013). The database is 
registered with the UK National Research Ethics Committee (reference number: 
12/LO/1556), and local ethical committee approval was granted for this study 
(reference number: 12/088) 
6.2.3! Statistics 
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SPSS v19.0 (IBM SPSS Statistics, Ontario, Canada) was used for statistical analysis. 
Body Composition parameters are presented as median values and interquartile 
ranges (IQR) and are categorized into sex-specific groups. Grouping of the other 
variables was carried out using standard or previously published thresholds. Mann-
Whitney and Fisher Exact tests were used to test for differences in continuous and 
categorical variables, respectively. Univariate and multivariate logistic regression 
were used to assess the relationship between muscle depletion and myosteatosis and 
multiple categorical variables. 
 
6.3! Results 
 
6.3.1! Patient selection 
 
Of 1477 consecutive patients undergoing surgical resection, 188 cases had a 
preoperative CT scan stored in an paper film form and therefore not suitable for 
analysis, 285 cases did not have blood test data or height data available at the time of 
CT scan and 163 had emergency surgery, 21 had recurrent disease at the time of 
surgery and for 57 the CT analysis was not possible due to poor quality. Exclusion of 
these patients resulted in a sample size of 763 patients who had undergone an 
elective resection for CRC. Baseline clinopathological characteristics of the cohort 
are shown in Table 6.1. Median age was 69 [IQR 60-76] years. The majority of the 
patients (54.7%) had evidence of a preoperative systemic inflammatory response 
expressed as NLR>3. According to WHO BMI classification, 36.2 % of patients were 
normal weight, 38,8% overweight and 25% obese. The operations were carried out 
for rectal cancers in 33% of the cases and for colon cancers in 67%. UICC staging 
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reporting system classified 24.2% of the cancers as Stage I, 32% as stage II, 33% as 
stage III and 10.7% as Stage IV.  
6.3.2! Body composition parameters  
 
The body composition parameters of the patients are shown in Table 6.2. There 
were no differences in BMI between sexes. Females had significantly more 
subcutaneous fat tissue than men expressed as L3 Subcutaneous Fat Index; 79.18 
cm2m-2 versus 53.62 cm2m-2 (p<0.001). Men had significantly more visceral fat 
tissue expressed as L3 visceral Fat Index; 56.12 cm2m-2 versus 33.53 cm2m-2, 
(P<0.001) and more skeletal muscle tissues expressed as LSMI; 46.61 cm2m-2 versus 
37.90 cm2m-2, (P<0.001) than female patients. The median MA value for the male 
group was 30.66 HU whereas the median MA for the female group was significantly 
lower at 27.53 HU (p<0.001). Sex-specific differences were also recorded in the 
VFA/SFA and VFA/SMA ratios. 
6.3.3! Body composition and inflammatory response markers  
 
The relationships of body composition parameters and SIR measures are shown in 
Table 6.3. There were no differences between the SIR expressed as NLR and the L3 
subcutaneous Fat index, L3 Visceral Fat index, VFA/SFA, VFA/SMA ratios and the 
BMI. Patients with NLR>3 had significantly lower LSMI; 42.07 cm2m-2 versus 44.27 
cm2m-2, (P=0.002) and MA; 30.04 HU versus 28.36 HU, (P=0.016) than patients 
with NLR<3. Patients with hypoalbuminaemia had also significantly lower LSMI; 40.24 
cm2m-2 versus 44.17 cm2m-2, (P<0.001), MA; 26.58 HU versus 30.31 HU, 
(P<0.001) and L3 Visceral Index; 43.77 cm2m-2 versus 49.83 cm2m-2, (P=0.03) 
compared to patients with normal albumin levels. To further examine the 
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relationship between SIR and levels of muscularity, sex-specific scatter plots of the 
associations were drawn. Correlations between NLR, albumin and L3 skeletal muscle 
index remained significant.  
6.3.4! Clinical, pathological and inflammatory predictors of myopenia 
 
To investigate whether SIR expressed, as NLR or albumin was associated with 
myopenia, univariate and multivariate logistic regression analysis were performed. Of 
the 763 patients included in this study, 496 (65.0%) were found to have reduced 
muscle mass using criteria from Martin et al. Univariate analysis identified age (>75 
y.o, 65-75 y.o vs <65y.o), ASA status (3+4 vs 1+2), site (colon vs rectum), Stage (IV, 
III, II vs I), NLR (>3 vs <3) and Albumin (<35 g/L vs >35g/L) to be predictors of 
myopenia. To determine the independent prognostic significance of NLR and albumin 
on myopenia status a multivariate logistic regression model analysis was performed.  
Multivariate analysis included age, ASA, UICC stage, Albumin, NLR and tumour site. 
Age, NLR and albumin were independent predictors of myopenia as outlined in 
Table 6.4. A high NLR [OR 1.78, (95% CI 1.29-2.45) (p<0.001)] and low albumin 
levels [OR 1.80 (95%CI 1.17-2.74), p=0.007] were independently associated with 
muscle depletion. 
6.3.5! Clinical, pathological and inflammatory predictors of myosteatosis 
 
A similar analytical approach was performed to investigate whether SIR parameters 
were associated with myosteatosis. 643 (83.7%) patients were found to have 
reduced MA when cut-off values from Martin et al were applied. Univariate analysis 
showed that gender, age, BMI, Site, UICC stage, vascular invasion, NLR and albumin 
were predictors of low MA. Multivariate analysis identified gender (female Vs male), 
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age (>75 y.o, 65-75 y.o vs <65y.o), site (rectum vs colon) and NLR (>3 vs < 3) as 
independent predictors of myosteatosis as outlined in Table 6.5. A high NLR  [(OR= 
1.60 (95%CI 1.03-2.49)] was independently associated with low MA and hence 
myosteatosis.    
 
 
 
 
  
 205 
Table 6-1 Clinicopathological characteristics of patients 
Variable Count 
N=763 
% 
Clinical variables 
Gender Male 457 59.9% 
Female 306 40.1% 
Age Category < 65 y.o 276 36.2% 
65-74 y.o 265 34.7% 
 ≥ 75 y.o 222 29.1% 
ASA Category 1+2 681 89.3% 
3+4 82 10.7% 
BMI 
Categories 
Normal (18.5-25) 276 36.2% 
Overweight (25-30) 296 38.8% 
Obese (>30) 191 25.0% 
Pathological Variables 
Site Colon 511 67.0% 
Rectum 252 33.0% 
Tumour T1 114 14.9% 
T2 122 16.0% 
T3 364 47.7% 
T4 163 21.4% 
Nodes N 0 449 58.8% 
N 1/2 314 41.2% 
Metastasis M 0 681 89.3% 
M 1 82 10.7% 
UICC Stage I 185 24.2% 
II 244 32.0% 
III 252 33.0% 
IV 82 10.7% 
Grade  Well / Moderate 670 87.8% 
Poor 93 12.2% 
Vascular 
invasion 
Absent 500 65.5% 
Present 263 34.5% 
Inflammatory variables 
NLR Category < 3 346 45.3% 
  > 3 417 54.7% 
Albumin < 35 g/L 184 24.1% 
≥ 35 g/L 579 75.9% 
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Table 6-2 Body composition parameters by gender 
 
 
 
 
 
 
 
 
 
Abbreviations: VFA = Visceral Fat Area; SFA = Subcutaneous Fat Area; SMA = Skeletal Muscle Area; HU = Hounsfield Unit 
 IQR = Interquartile Range 
 Bold value indicates statistical significance at p < 0.05 
 
 
 
Parameter Gender  
Male Female p-value 
Median IQR  Median IQR   
Body Mass Index (kg/m2) 26.62      24.00-30.08 26.16 23.45-29.88 0.307 
L3 Subcutaneous Fat Index 53.62 39.78-70.45 79.18 56.61-107.74 <0.001 
L3 Visceral Fat Index 56.12 35.40-79.85 33.53 16.98-55.40 <0.001 
VFA/SFA ratio 0.99 0.66-1.37 0.38 0.23-0.55 <0.001 
VFA/SMA ratio 1.18 0.77-1.63 0.92 0.47-1.41 <0.001 
L3 Skeletal Muscle Index 46.61 41.49-52.82 37.90 33.98-42.39 <0.001 
Muscle Attenuation (HU) 30.66 24.32-36.98  27.53 20.74-33.46  <0.001 
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Table 6-3 Body composition parameters and the systemic inflammatory response 
Abbreviations: HU = Hounsfield Unit; VFA = Visceral Fat Area; SFA = Subcutaneous Fat Area; SMA = Skeletal Muscle Area; HU = Hounsfield Unit, NLR = Neutrophil to Lymphocyte Ratio; 
IQR = Interquartile Range 
Bold value indicates statistical significance at p < 0.05 
 
 
 
 
 NLR Category  Albumin Category  
NLR <3 NLR >3  <35 Hypoalbuminaemia >35 Normal  
Median, IQR Median, IQR p-value Median, IQR Median, IQR p-value 
Body Mass Index 
(kg/m2) 
26.73 [24.22-30.44] 26.23 [23.42-29.43] 0.060 26.45 [24.00-29.09] 26.46 [23.77-30.31] 0.491 
L3 Skeletal Muscle 
Index  (cm2m-2) 
44.27 [38.16-51.15] 42.07 [36.52-48.37] 0.002 40.24 [34.70-45.37] 44.17 [38.29-50.92] <0.001 
Muscle Attenuation 
(HU) 
30.04 [24.17-36.52] 28.36 [22.06-35.75] 0.016 26.58 [19.56-31.69] 30.31 [23.97-37.22] <0.001 
L3 Visceral Fat Index 
(cm2m-2) 
50.34 [27.92-71.60] 44.60 [25.18-67.51] 0.108 43.77 [24.00-64.92] 49.83 [26.72-71.39] 0.030 
L3 Subcutaneous Fat 
Index (cm2m-2) 
64.98 [46.81-88.35] 57.32 [41.23-80.02] 0.080 61.31[42.49-83.78] 61.96 [43.75-86.13] 0.440 
VAF/SAF ratio 0.66 [0.39-1.15] 0.71[0.41-1.12] 0.582 0.67 [0.37-1.06] 0.69 [0.41-1.17] 0.154 
VFA/SMA ratio 1.11 [0.71-1.51] 1.04 [0.59-1.59] 0.662 1.03 [0.62-1.55] 1.08 [0.63-1.55] 0.684 
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Table 6-4  The relationship between myopenia and clinico-pathological parameters 
 
  
 Myopenia Univariate Analysis Multivariate Analysis 
No (267) Yes (496)     
Count % Count % OR 95% CI p-value OR 95% CI p-value 
Gender Male 167 62.5% 290 58.5% 1    
Female 100 37.5% 206 41.5% 0.84 (0.62-1.14) 0.273   
Age Category < 65 years 125 47.2% 151 30.4% 1  1  
65-74 years 94 35.5% 171 34.3% 1.51 (1.07-2.13) 0.020 1.56 (1.09-2.23) 0.016 
≥  75 years 46 17.4% 176 35.3% 3.00 (2.02-4.46) <0.001 2.49 (1.63-3.79) <0.001 
ASA Category 1+2 246 92.8% 435 87.3% 1  1  
3+4 19 7.2% 63 12.7% 1.90 (1.11-3.25) 0.019 1.65 (0.92-2.98) 0.093 
BMI  BMI < 25 98 35.1% 183 36.9% 1    
BMI > 25 173 64.9% 313 63.1% 0.92 (0.63-1.35) 0.675   
Site Colon 165 61.8% 346 69.8% 1  1  
Rectum 102 38.2% 150 30.2% 0.70(0.51-0.96 0.026 0.86(61-1.20) 0.369 
UICC Stage I 72 27.0% 113 22.8% 1  1  
II 67 25.1% 177 35.7% 1.68 (1.11-2.53) 0.012 1.14 (0.92-2.18) 0.117 
III 100 37.5% 152 30.6% 1.09 (0.66-1.43) 0.872 0.78 (0.51-1.18) 0.239 
IV 28 10.5% 54 10.9% 1.23 (0.71-2.12) 0.458 0.95 (0.53-1.69) 0.857 
Grade 
Category 
Well + Moderate 231 86.5% 439 88.5% 1   
Poor 36 13.5% 57 11.5% 0.83 (0.53-1.30) 0.423 
Vascular 
invasion 
Absent 175 65.5% 325 65.5% 1   
Present 92 34.5% 171 34.5% 1.01 (0.73-1.34) 0.996 
NLR Category <3 152 56.9% 194 39.1% 1 <0.001 1  
>3 115 43.1% 302 60.9% 2.06 (1.52-2.79) 1.78 (1.29-2.45) <0.001 
Albumin ≥  35 g/L 216 84.6% 354 71.5% 1  1  
<35g/L 41 15.4% 142 28.5% 2.31 (1.56-3.42) <0.001 1.80 (1.17-2.74) 0.007 
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Table 6-5 The relationship between myosteatosis and clinico-pathological parameters  
 
 Myosteatosis  Univariate Analysis Multivariate Analysis 
No (129) Yes (634)     
Count % Count % OR 95% CI p-value OR 95% CI p-value 
Gender Male 96 74.4% 361 56.9% 1  1  
Female 33 25.6% 273 43.1% 2.20 (1.44-3.37) <0.001 1.91 (1.17-3.10) 0.009 
Age  < 65 y.o 74 57.4% 202 31.9% 1  1  
65-74 y.o 41 31.8% 224 35.3% 2.00 (1.31-3.07) 0.001 2.69 (1.67-4.32) <0.001 
≥ 75 y.o 14 10.9% 208 32.8% 5.44 (2.98-9.95) <0.001 6.14 (3.03-12.42) <0.001 
ASA  1+2 125 92.8% 580 91.5% 1    
3+4 4 7.2% 54 8.5% 1.39 (0.58-2.20) 0.250   
BMI  BMI < 25 32 24.8% 306 40.1% 1  1  
BMI > 25 97 75.2% 328 59.9% 0.49 (0.31-0.78) 0.002 0.98 (0.95-1.04) 0.944 
Site Colon 70 54.3% 441 69.9% 1  1  
Rectum 59 45.7% 193 30.4% 0.52 (0.35-0.76) 0.001 0.58 (0.38-0.91) 0.019 
UICC Stage I 40 31.0% 145 22.9% 1  1  
II 34 26.4% 210 33.1% 1.70 (1.03-2.82) 0.038 1.05 (0.57-1.93) 0.880 
III 46 35.7% 206 32.5% 1.23 (0.77-1.96) 0.382 0.77 (0.42-1.41) 0.389 
IV 9 7.0% 73 11.5% 2.24 (1.03-4.86) 0.042 1.48 (0.52-4.23) 0.456 
Histological 
Grade  
Well + Moderate 109 84.5% 561 88.5% 1   
Poor 20 15.5% 73 11.5% 0.71 (0.41-1.21) 0.208 
Vascular 
invasion 
Absent 97 75.2% 403 63.6% 1  1 
1.47 (0.90-2.42) 
 
0.125 Present 32 24.8% 231 36.4% 1.74 (1.13-2.68) 0.012 
NLR  <3 74 57.4% 266 42.6% 1  
0.001 
1  
>3 55 42.6% 358 57.4% 1.88 (1.28-2.77) 1.60 (1.03-2.49) 0.038 
Albumin ≥ 35 g/L 111 86.0% 459 72.4% 1  1  
<35g/L 18 14.0% 175 27.6% 2.68 (1.52-4.72) 0.001 1.17 (0.57-2.41) 0.661 
 210 
6.4! Discussion 
 
This study has demonstrated an association between myopenia and myosteatosis and 
the presence of an altered SIR, measured as high NLR and low albumin levels, in 
patients with CRC. It represents data from a large cohort of patients operated 
electively for primary cancer. The findings support the hypothesis that host SIR may 
reduce muscularity levels and increase myosteatosis. Furthermore, there were direct 
relationships between age, gender, tumour site and skeletal muscle mass and 
myosteatosis levels. These associations are supported by other publications that 
identify that myopenia is affected by age through accelerated loss of muscle fibres 
mass and function (Demontis, Piccirillo, Goldberg, & Perrimon, 2013). Observational 
studies have also suggested that both intramyocellular and intermuscular fat may 
increase with advancing age (Kuk, Saunders, Davidson, & Ross, 2009). A reduction in 
anabolic stimulation by factors such as sex hormones are known to alter muscle 
mass (Ji et al., 2012; Martin et al., 2013),  as does comorbidity (Martin et al., 2013). In 
addition to disease-related anorexia, polypharmacy, maldigestion, malabsorption and 
dysphagia may contribute to decreased energy intake leading to muscle mass wasting 
(K. Fearon et al., 2013).  
The negative impact of an altered SIR on CRC outcomes has been recorded in 
Chapter 5. The SIR, as defined by a number of inflammation-based prognostic scores 
and in particular, the NLR has been shown to be an independent prognostic marker 
in colorectal cancer. In chapter 5 we demonstrated that for patients with non 
metastatic CRC, a preoperative NLR of more than 3.0 can be an independent 
prognostic factor for disease-free survival (Malietzis, Giacometti, Askari, et al., 2014). 
Routine preoperative NLR measurement in patients undergoing treatment for CRC 
 211 
is a simple and inexpensive means of identifying patients with potentially poorer 
prognosis and may facilitate clinical decision-making. The present study indicates that 
patients with high NLR values and low albumin levels are more likely to have 
myopenia and myosteatosis i.e low muscularity levels and low muscle attenuation. 
Although this study was not designed to provide an explanation for this, the SIR 
involves stimulation of a number of mediators that can directly activate catabolic 
pathways and cause skeletal muscle degradation (Seelaender et al., 2012).  
Statistical significance implies that the difference seen in our study population also 
exists in the generic colorectal cancer population. Clinical significance implies that 
the association between high SIR and muscle depletion in CRC patients in 
effectiveness is clinically important, and it is possible that clinical practice will change. 
The increased awareness of the clinical importance of myopenia has also highlighted 
the need to understand more about its aetiology. Declines in muscle mass and 
strength are expected aspects of aging, alongside a range of age-related changes, for 
example in vascular, endocrine, and neuronal function, but there is significant 
variability between individuals in rates of loss. Some of the variability can be 
explained by factors that are fixed (such as sex, size, heritability, and early life 
environment), but much of the remaining variation is unexplained. This study 
highlights a direct relationship between low muscularity and myosteatosis and the 
presence of altered SIR in CRC treated surgically. This can lead to increasing interest 
in the influence of adult lifestyle, particularly in the effects of modifiable factors such 
as physical activity and diet on muscle mass and function in cancer, with a view to 
identifying intervention opportunities both to prevent and manage myopenia. SIR can 
be used potentially either as a direct target or as a surrogate marker to monitor 
muscle mass changes. Understanding the benefits of maintaining sufficient levels of 
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physical activity and diet quality in cancer patients and also moderating and 
monitoring the SIR is central to considerations of current and future public health 
strategies to promote better physical function and outcomes. 
Certain study caveats are worthy of mention. First, this was an uncontrolled study 
despite comprising a relatively large and homogenous data set. Second, CT body 
composition analysis is a static window into a patient’s BC changes, but as the 
standard pre-treatment staging modality parameters from this type of analysis, has 
proven reliable in previous studies (see Chapter 3). Third, although there is 
heterogeneity in NLR cut-off values used in the literature, ranging from three to five, 
we set the threshold as higher than three as we have previously identified this value 
to be an appropriate threshold in our patients (see Chapter 5). Fourth, electronic 
records of CT scans were not available prior to 2007 as the PACS system was 
introduced in February that year and has contributed to the exclusion from the 
study of a large proportion of the St. Mark’s early cohort.  
Muscle depletion is a common feature of all chronic pathologies but may represent a 
modifiable risk factor in cancer patients. The advent of the concept and application 
“prehabilitation” is relevant to the findings of this study (K. C. Fearon et al., 2013). 
Early identification of low muscularity may permit timely therapeutic intervention 
prior to and after surgery. Appetite regulation and physical activity are the major 
determinants of energy balance and contribute to body composition changes. 
Endurance and resistance-type exercises may be recommended in muscle-depleted 
patients to maintain skeletal muscle mass and function, as well as energy balance. 
Therapeutic interventions using nonselective anti-inflammatory agents, aiming to 
moderate the inflammatory response of the host, have also been explored 
 213 
(Roxburgh & McMillan, 2014). Protein intake may be increased in order to 
counteract the anabolic resistance related to inflammation and inactivity (Guadagni & 
Biolo, 2009). Recent studies have considered the use of (n-3) fatty acids as beneficial 
in improving the attenuation of lean tissue (Murphy, Mourtzakis, Chu, Reiman, & 
Mazurak, 2010).  
6.5! Conclusion 
 
The present study highlights a direct relationship between low muscularity and 
myosteatosis and the presence of altered SIR in patients with primary operable 
colorectal cancer. Further long-term data on this patient group will help 
demonstrate the impact of low muscularity and myosteatosis on overall and disease-
free survival. Finally, early identification of myopenia and myosteatosis through CT 
analysis and SIR biomarkers may allow early therapeutic intervention. Future studies 
should concentrate on metabolic interventions for myopenia and myosteatosis and 
their impact upon clinical outcomes.  
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Chapter 7  
7! Host Body Composition Changes After Elective Colorectal Cancer 
Resection: A Longitudinal Study  
 
Muscle depletion is a poor prognostic indicator in CRC patients (as demonstrated in 
Chapter 3+4) but there are no data assessing comparative temporal body 
composition changes following elective colorectal cancer (CRC) surgery. In Chapter 
7, patient skeletal muscle index trajectories over time after surgery were examined 
and factors that may contribute to those alterations were determined.  
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7.1! Introduction 
 
Colorectal cancer (CRC) remains the fourth most common cause of cancer death 
and the third most common cancer worldwide (Ferlay et al., 2015). Research has 
focused mostly upon tumorigenesis and obtaining an understanding of a cancer’s 
biology whereas the importance of host-related homeostatic factors and more 
specifically, host body composition (BC) has been mostly overlooked. A number of 
BC measurement techniques have been described, addressing all different levels from 
the atomic to the molecular and from the cellular to the tissue level (Thibault & 
Pichard, 2012). For patients with solid tumours, Computer Tomography (CT) BC 
analysis is more relevant as it is routinely employed for disease staging and follow up 
and data can be utilized with minimal additional cost.  
 It is becoming increasingly clear that a variety of BC changes occur in cancer 
patients and that muscle depletion is a common, albeit in most an occult feature. 
Muscle depletion is characterized by reduction in muscle size (myopenia) and an 
increased infiltration by inter- and intramuscular fat, described as myosteatosis (K. 
Fearon, Evans, et al., 2011; Miljkovic & Zmuda, 2010). The incidence of muscle 
depletion varies from 15% to 70% for patients treated for CRC (Malietzis, Aziz, et 
al., 2015).  Evidence also demonstrates also that muscle depletion is associated with 
poorer outcomes in patients treated for cancer (Martin et al., 2013; Prado et al., 
2008). For CRC patients treated surgically, myopenia negatively impacts short-term 
outcomes including mortality, morbidity and functional recovery (Malietzis, Aziz, et 
al., 2015). Muscle depletion, estimated from CTBC analysis, has also been found to 
be a prognostic factor for developing severe toxicity in CRC patients receiving 
chemotherapy (Prado et al., 2007). Finally, emerging data suggests that myopenia can 
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be an independent predictor of poorer survival after CRC treatment. However 
neither the point of onset of muscle depletion nor the patterns of muscle alterations 
over time and their precipitants are known. Therefore, there is a need to identify 
whether BC changes assessible by surveillance imaging after CRC can be related to 
specific clinico-pathological or treatment factors that, once identified, will allow 
muscle depletion to be contained or modified. Conversely, alterations may herald 
eventual systemic disease recurrence prior to identification using well-established 
imaging methods. 
Growth-curve modeling (GCM) is an advanced method for demonstrating within-
person systematic variation and between-person differences in changing outcomes 
across different measurement over time (Shek & Ma, 2011). The GCM approach has 
allowed researches to overcome problems in studies assessing the interindividual 
differences in intraindividual changes over time. Problems mainly based to the 
limitations of more traditional methods examining changes of time such as analysis of 
variance (Della Porta et al.) and analysis of covariance (ANCOVA) that mandate 
accuracy in equal group sizes, condition that is very difficult to meet (Francis, 
Fletcher, Stuebing, Davidson, & Thompson, 1991; Singer & Willett, 2003).   
This study using the GCM approach, aimed not only to examine how patient BC, as 
determined by skeletal muscle index trajectories, varied over time after elective 
surgery for CRC but also to determine specific factors that may contribute to 
alterations over time.  
 
7.2! Patients and Methods 
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7.2.1! Patient Population 
 
1477 consecutive patients undergoing CRC surgery at St. Mark’s Hospital, London, 
between January 2006 and December 2013 were identified from a prospective 
database. Patients with recorded height data, laboratory blood test data within four 
weeks of staging CT scan and pre-operative staging and surveillance CT images 
stored and retrievable in an electronic format suitable for image analysis were 
included in the study. Exclusions were patients with disease recurrence confirmed 
preoperatively or at surgery and emergency operations. All prospectively recorded 
clinical and pathological data were revalidated from medical and histopathology 
records. Data collected prospectively during the perioperative period (within 30 
days of surgery) included age, sex, Body Mass Index (BMI), the American Society of 
Anaesthesiologists (ASA) physical status classification system, tumour site, TNM 
stage (UICC 5 version) and the surgical approach. Laboratory blood test data 
collected included preoperative neutrophil and lymphocyte counts. The Neutrophil 
to Lymphocyte Ratio (NLR) was derived as a valid reflection of the host systemic 
inflammatory response (SIR) (Malietzis, Giacometti, Askari, et al., 2014). 
 
7.2.2! Body Composition Analysis 
 
Serial CT scan images were retrieved from digital storage in the Picture Archiving 
and Communication System [PACS]. CT image analysis Slice-O-Matic V4.3 software 
(Tomovision, Montreal, Canada) was performed as described previously. (Mourtzakis 
et al., 2008) Briefly, total skeletal muscle surface areas (cm2) were evaluated on a 
single image at the third lumbar vertebrae (L3) using Hounsfield unit (HU) thresholds 
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of -29 to 150 for skeletal muscle, -50 to 150 for visceral adipose tissue and -190 to -
30 for subcutaneous adipose tissues. The sum of skeletal cross-sectional muscle 
areas was normalised for stature (m2) and reported as lumbar skeletal muscle 
indexLSMI (cm2m-2).  
 
7.2.3! Data analysis 
 
A non-parametric Mann-Whitney U test was used to determine significant 
differences between the LSMI from baseline demographic and clinico-pathological 
characteristics (p"<"0.05 was regarded as significant). A multi-level mixed effect GCM 
was applied using STATA (version 12.0)(Rabe-Hesketh, Skrondal, & Stata 
Corporation., 2012). GCM are a special case of random-coefficient models where 
the coefficient of time varies randomly between subjects. Growth trajectories can 
take a variety of shapes. A flexible approach to model possible nonlinear growth in 
Yij is to use a p
th degree polynomial function of time tij , Yij =  b1 (von Roon et al.) + 
b2.tij (linear) + b3.t
2
ij (quadratic) +…+ b.p + 1t
p
ij + ξ ij . 
Using the xtmixed command we modeled the shape of trajectories of dependent 
variable (LSMI) over time and how these trajectories varied due to time-level and 
patient-level covariates. There were a number of steps that we considered in 
specifying a repeated measures analysis using a GCM approach as described by Rabe-
Hesketha and Skrondal (Rabe-Hesketh et al., 2012). First, we investigated whether 
there is one or more growth process (ie nonlinear growth) for each covariate of 
interest. Secondly by using polynomial functions we identified the best-fit growth 
trajectory. Third we considered possible subject variable and time interactions that 
might affect individual’s growth curve (two-stage formation). After identifying the 
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best-fit model for each of the covariate of interest we then adjusted the model for 
all the statistical significant interactions found to conclude the final model. Penalized-
likelihood information criteria, such as Akaike's Information Criterion (AIC), the 
Bayesian Information Criterion (BIC) were used for model selection. 
Heteroscedasticity checks were also performed. Heteroscedasticity refers to the 
circumstance in which the observed variance is independent of the variable mean 
(Brehm, Scholtes, Dallmeijer, Twisk, & Harlaar, 2012).  
 
7.3! Results 
 
7.3.1! Study population 
 
The clinico-pathological characteristics of the 856 elective colorectal cancer 
resection cases that fulfilled the selection criteria are provided in Table 7.1. The 
median age at operation was 67 years ((IQR) 58 to 76 years). The majority of 
patients were treated laparoscopically [intention to treat] (63.1% laparoscopic Vs 
36.9% open); two hundred and thirty eight (27.8%) were rectal cancers. A total of 
2236 CT images were analyzed of which 856 (38.2%) were pre-treatment scans. 
Table 7.2 describes the number and timing of CT images included for the analysis. 
7.3.2! Body Composition analysis 
 
The median LSMI was 42.9 (IQR 37.4-49.5) cm2m2. Men had a higher LSMI compared 
with women (P < 0.001). Elderly patients, patients with high ASA or high NLR 
preoperatively or patients with a colon cancer had significantly lower LSMI median 
values compared to patients with patients with age<65 years old (P < 0.001), ASA I 
+II (P < 0.001), NLR<3 (P < 0.001) and patients with rectal cancers (P = 0.016), 
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respectively. There were no differences between the preoperative LSMI and the type 
of surgical approach (Laparoscopic Vs Open; P = 0.710) or the UICC stage (P = 
0.056). The CT-derived LSMI values and their associations with different clinico-
pathological variables are summarized in Table 7.3. 
 
7.3.3! Model fit- Non linear growth 
 
Patient LSMI change was non-linear over time when the observed growth 
trajectories were plotted. As the relationship between LSMI over time was non-
linear, we included a quadratic term for time in our model. Both time terms in this 
model were statistically significant. (If the time2 term had not been statistically 
significant we could only have included a linear term for time in our model). The 
estimated standard deviation (SD) of the random intercept was 8.53 (95% CI 8.09-
9.00) and the estimated SD of the error was 3.22 (95%CI 3.09-3.36). We then 
included a random slope on time, to permit variability between patients in relation 
to overall rates of LSMI change. The standard deviation of the random coefficient on 
time was 0.27 (95% CI: 0.14-0.53), indicating that there is heterogeneity between the 
rates of change in LSMI. Also, the estimated standard deviation of the error term 
decreased from 3.22 to 3.17 indicating a better fit of the model. 
7.3.4! Quadratic growth with random intercept and random slope for patient LSMI 
that includes patient-level covariates 
 
Gender 
At any given time, we estimated that a female patient’s LSMI was 7.95 cm2/m2 (SE= 
0.58 cm2/m2) less than male patient LSMI. The coefficients of both time and time2 
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were significant at the 5% level. Gender did not exert any effect on the slope of the 
curve trajectory as the estimate for gender*time variable was not significant from the 
two-stage model formation.  
Age 
Elderly patients (>65 years old) had a LSMI, on average, 3.79 cm2/m2 (SE= 0.11 
cm2/m2) less than younger patients (<65 years old). The inclusion of the age*time 
variable in a two-stage formation model was not significant and the fact that the AIC 
and BIC values were in favor of the polynomial model; the two-stage formation 
model was omitted.  
Systemic Inflammatory Response  
Elevated SIR expressed as NLR> 3 (HNLR) had a significant effect on the LSMI 
trajectory over time. Patients with HNLR at any given time point had lower LSMI at 
an average of -2.28 cm2/m2 (SE= 0.79 cm2/m2) compare to the patients with NLR < 3 
(LNLR). The two-stage formation model had the best-fit values but NLR did not 
have an impact on the slope of the trajectory.  
ASA  
The two-stage formation model was also the best-fit model when ASA was 
considered as a patient-level covariate. Patients with higher ASA (III+ IV) had 
significantly lower LSMI (estimate= -2.68 cm2/m2 (SE= 0.62 cm2/m2)) than patient 
with ASA of I or II. 
Surgical Approach 
At any given time, we estimated for patients who underwent laparoscopic resection 
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that their LSMI was not statistically different of the LSMI of patients that had an open 
procedure. The coefficients of time2 were significant at the 5% level. Surgical 
approach had an impact on the slope of LSMI trajectory as the estimate for surgical 
approach*time variable was significant from the two-stage model formation. Of 
interest, patients who underwent a laparoscopic procedure had a positive change to 
the slope of their LSMI trajectory compared to the open approach group (estimate= 
+0.15cm2/m2 (SE= 0.06 cm2/m2)). 
Tumour Site 
The two-stage formation model was the best-fit model when tumour location was 
considered as patient-level covariate. Patients who underwent surgery for a rectal 
tumour had a negative change to the slope of their LSMI trajectory compared to the 
colon group (estimate= -0.13 cm2/m2 (SE= 0.05 cm2/m2)). 
UICC stage  
Patients with a higher stage of disease (UICC stage III + IV) had a negative change to 
the slope of their LSMI trajectory compared to patients with UICC stage I + II 
(estimate= -0.20 cm2/m2 (SE= 0.09 cm2/m2)). 
 
7.3.5! Heteroskedasticity  
 
Heteroscedasticity checks were performed for each of the patient-level covariates 
under investigation. No evidence of heteroscedasticity identified.  
Figure 7.1 shows the mean trajectory and 95% range of patient-specific trajectories 
for the different patient-level covariates from the quadratic model. Table 7.4 
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summarizes the maximum likelihood estimates for quadratic models for the patients 
LSMI when the different patient-level factors were investigated.   
7.3.6! Multivariate Quadratic growth with random intercept and random slope for 
patients LSMI  
 
To adjust for all the patient-level covariates and all the statistical significant time-
covariate, interactions were considered for the formulation of the final model. Older 
age, female gende, elevated preoperative SIR and higher ASA were significantly 
associated with lower values of LSMI over time. Laparoscopy and more advanced 
UICC stage had a significant impact on the slope of the LSMI trajectory. Laparoscopy 
offered a positive change on the LSMI slope (estimate = 0.17cm2/m2, SE=0.06 
cm2/m2) whereas UICC stage III+ IV contributed to a negative slope change (estimate 
=- 0.19cm2/m2, SE=0.09 cm2/m2). The coefficients of time and time2 were significant at 
the 5% level. The Log Likelihood and the values for AIC and BIC were also improved 
suggestive of a model of better-fit. Table 5 shows the estimates of the Multivariate 
Quadratic growth with random intercept and random slope for patients LSMI 
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Table 7-1 The clinico-pathological characteristics of the 856 elective colorectal 
cancer resection cases that fulfilled the selection criteria I 
 
  
Baseline Demographics N=856 Count Column N % 
Gender Male 482 56.3% 
Female 374 43.7% 
Age Category <65 y.o 389 45.4% 
>= 65 y.o 467 54.6% 
NLR category Low NLR 318 37.1% 
High NLR 538 62.9% 
ASA status ASA 1+2 711 83.1% 
ASA 3+4 145 16.9% 
Surgical 
Approach 
Open 316 36.9% 
Laparoscopic 540 63.1% 
Tumour Site Colon 618 72.2% 
Rectum 238 27.8% 
UICC stage I 197 23.0% 
II 302 35.3% 
III 283 33.1% 
IV 74 8.6% 
BMI 
Categories 
Underweight BMI<18.5 18 2.2% 
Normal BMI (18.5-25) 276 32.1% 
Overweight BMI (25-30) 349 40.8% 
Obese BMI (>30) 213 24.9% 
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Table 7-2  Number and the timing of CT scans analyzed 
Time point of the CT scan analyzed Frequencies (N) 
Pre-Operatively 856 
0-6 months post-operatively 354 
6-12 months post-operatively 269 
12-18 months post-operatively 234 
18-24 months post-operatively 160 
24-36 months post-operatively 139 
36-42 months post-operatively 58 
42-48 months post-operatively 33 
48-54 months post-operatively 19 
54-60 months post-operatively 14 
Total number of scans analyzed  2236 
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Table 7-3  The LSMI values calculated from the CT analysis and their relationships with the clinico-pathological variables 
 L3 Muscle Index (LSMI) 
Median Percentile 25 Percentile 75 P-Value 
Gender Male 47.16 41.20 54.09  
<0.001 Female 39.20 34.80 43.56 
Age Category <65 y.o 45.42 39.58 51.80  
<0.001 >= 65 y.o 41.55 35.91 47.66 
NLR category Low NLR 44.25 37.57 52.62  
<0.001 High NLR 41.56 36.36 47.47 
ASA status ASA I+II 44.64 38.90 51.13  
<0.001 ASA III+IV 40.52 35.72 45.56 
Surgical 
Approach 
Open 43.12 36.31 51.18  
0.710 Laparoscopic 43.79 37.90 49.68 
Tumour Site Colon 42.81 37.46 49.38  
0.016 Rectum 44.73 38.20 51.76 
UICC stage I 45.26 37.69 52.53  
 
 
0.056 
II 41.90 36.86 49.38 
III 44.36 38.52 50.35 
IV 42.66 37.91 46.88 
Abbreviations: y.o: years old, NLR: Neutrophil to Lymphocyte ratio, ASA: American Society of Anaesthesiologists, UICC: Union for 
International Cancer Control, LSMI : Lumbar 3 Skeletal Muscle Index  
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Table 7-4 Maximum likelihood estimates for quadratic models for the patients LSMI when the different patient-level factors were investigated 
Skeletal Muscle 
Index 
Gender 
Female Vs Male 
Age 
>65 y.o Vs <65 y.o 
NLR 
HNLR Vs LNLR 
ASA 
ASA III + IV Vs      
I + II 
Surgical Approach 
Laparoscopic Vs 
Open 
Tumour Site 
Rectum Vs Colon 
UICC stage 
Stage III+IV 
 Vs I+II 
Best Fit model Two-stage formation Polynomial Two-stage formation Two-stage formation Two-stage formation Two-stage formation Two-stage formation 
Fixed Part 
 
Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) 
 b 1  
[constant] 
47.69 (0.38)* 50.15 (0.99)* 45.68 (0.58)* 49.48 (1.65)* 44.54 (0.62)* 42.17 (0.95)* 44.21 (1.10)* 
 b     
 [variable of 
interest] 
-7.95 (0.58)* -3.79 (0.11)* -2.28 (0.79)* -2.68 (0.62)* -0.32 (0.77) 1.67 (0.09) 0.09 (0.73) 
 b 2  
[time linear] 
0.30 (0.11)* 0.33 (0.11)* 0.30 (0.13)* 0.05 (0.19) 0.21 (0.15) 0.52 (0.16)* 0.64 (0.17)* 
 b 3  
[time quadratic] 
-0.03 (0.01)* -0.03 (0.01)* -0.03 (0.01)* -0.01 (0.02) -0.02 (0.01)* -0.03 (0.01)* -0.03 (0.15)* 
c  
[Variable*time] 
0.13 (0.09)   0.15 (0.10) 0.08 (0.08) 0.15 (0.06)* -0.13 (0.05)* -0.20 (0.09)* 
               
Random Part               
Bp 
 
7.51 (0.22) 8.27 (0.09) 8.82 (0.29) 8.17 (0.29) 8.79 (0.27) 8.44 (0.24) 8.77 (0.27) 
tpij 
 
0.26 (0.10) 0.27 (0.10) 0.31 (0.09) 0.19 (0.16) 0.29 (0.09) 0.26 (0.09) 0.29 (0.09) 
ξ ij   
[constant] 
0.24 (0.23) 0.01 (0.18) 0.05 (0.17) 0.07 (0.29) 0.09 (0.18) 0.11 (0.19) 0.05 (0.16) 
Residual 3.17 (0.08) 3.17 (0.07) 2.93 (0.08) 3.14 (0.09) 3.07 (0.08) 8.44 (0.24) 3.08 (0.08) 
               
Log Likelihood -5983.02 -6045.44 -4123.82 -4332.86 -5055.37 -6064.41 -5148.82 
AIC 11984.02 12106.88 8265.64 8683.71 10118.38 12146.82 10315.64 
BIC 12034.09 12151.38 8312.36 8730.95 10166.87 12196.89 10364.31 
        
Heteroskedastisity  Absent Absent Absent Absent Absent  Absent Absent 
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Table 7-5 Multivariate Quadratic growth with random intercept and random slope 
for patients LSMI 
Skeletal Muscle Index    
 Estimate (SE) P-Value 
Fixed Part    
Gender 
Female Vs Male 
-8.82 (0.88) <0.01 
Age 
>65 y.o Vs <65 y.o 
-3.52 (0.88) <0.01 
NLR 
HNLR Vs LNLR 
-1.89 (0.85) 0.03 
ASA 
ASA III + IV Vs I + II 
-3.53 1.16 <0.01 
Surgical Approach 
Laparoscopic Vs Open 
-0.68 1.20 0.60 
Tumour Site 
Rectum Vs Colon 
-0.91 0.89 0.31 
UICC stage 
Stage III+IV Vs I+II 
0.27 0.86 0.75 
Time*Laparoscopy 0.17 0.06 0.03 
Time*Rectum -0.13 0.11 0.25 
Time*Stage III+ IV -0.19 0.09 0.04 
Time linear 0.75 0.30 0.01 
Time quadratic -0.03 0.01 0.02 
    
Random Part    
Bp 7,41 0.32  
tpij 0.29 0.11  
ξ ij  [constant] 0.13 0.21  
Residual 2.45 0.07  
    
Log Likelihood -3038.85   
AIC 6111.71   
BIC 6195.49   
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Figure 7-1 Mean trajectory and 95% range of patient-specific trajectories of the LSMI 
for the different patient-level covariates from quadratic model 
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7.4! Discussion 
 
This study applied a flexible method to modeling the nonlinear and asymmetric 
relationship between LSMI and time for patients treated surgically for CRC. Using 
the multilevel GCM approach we found that LSMI –time relation followed a 
quadratic trajectory over the follow up period of up to 60 months post-operatively. 
We identified that patients with older age, female gender, high preoperative SIR 
reported as HNLR and high ASA maintain on average low LSMI over time compared 
to their opposite groups. We also showed that laparoscopy offered a positive change 
on the LSMI slope whereas UICC stage III+ IV contributed on a negative slope 
change, over time.  
Skeletal muscle is one of the most modifiable human tissue and changes for 
numerous reasons. Loss of skeletal mass due to aging is a well-recognized process 
but muscle depletion can also be a consequence of chronic diseases such as cancer 
(Biolo et al., 2014). The presence of comorbidities and the effect of the sex 
hormones are again recognized factors that contribute in muscle metabolism (Biolo 
et al., 2007; Ji et al., 2012). However the pattern of muscle changes after treatment 
for cancer has never been examined before.  
We have showed that in patients undergoing CRC surgery, moderate preoperative 
SIR significantly favours maintenance of muscle mass postoperatively. Recent 
advancements in the investigation of the pathophysiology of skeletal muscle 
depletion and cachexia in cancer patients have suggested that inflammation could be 
considered the common denominator (Seelaender et al., 2012). Inflammation plays a 
vital role in the metabolic and BC changes in cancer though five key domains: 
systemic inflammation, central energy balance, control of muscle 
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metabolism/function, control of adipose tissue metabolism/function, and regulation of 
appetite (Tan et al., 2011). An ongoing state of low grade inflammation that involves 
the stimulation of various acute-phase proteins such as C-reactive protein and 
proinflammatory cytokines, which enhance autophagy in skeletal muscle and inhibit 
the synthesis of myofibrillar proteins; may be the background mechanism of the 
effect of systemic inflammation on the muscle trajectory postoperatively (Tan et al., 
2011). Our findings further support the aspect that resolution of the systemic 
inflammation is a potential strong foundation for developing more effective therapies 
against muscle depletion and cancer cachexia.  
Also, we showed that laparoscopy has a positive impact on restoration of the muscle 
postoperatively. Laparoscopy has been confirmed to be equal to open surgery in 
oncological outcomes for colorectal cancer from multiple randomized trials, but also 
benefits from improved cosmesis, decreased LOS decreased postoperative narcotic 
analgesia use, and quicker return of bowel function (Kennedy et al., 2014). We have 
identified that additional benefits after laparoscopic surgery include maintenance and 
restoration of muscle mass. Surgical trauma its associated tissue injuries induce 
immunologic alterations to the patient, which depend on the extent of the injury. 
Laparoscopic as oppose to an open surgical approach is thought to induce less 
systemic inflammatory chances and this may be the driving mechanism (Watt, 
Horgan, & McMillan, 2015). This finding suggests that increasing the adoption of 
laparoscopy for colorectal cancer surgery may have a positive indirect impact upon 
cancer survival. 
GCM is an advanced technique to determine individual growth profiles and to 
address the questions of stability over time with a number of advantages identified.  
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First, it provides a more flexible way to analyse unbalanced data with measurements 
inconsistent over time. Second, it allows investigators to analyse both intra- and 
interindividual differences in the growth parameters (e.g., slopes and intercepts). 
Third, the effects of predictors at higher levels and other predictors on individual 
growth can flexibly be added in the GCM. Finally, the GCM approach is more 
powerful in examining the effects associated with measures over time as it models 
the covariance matrix (i.e., fitting the true covariance structure to the data) rather 
than imposing a certain type of structure as commonly used in traditional univariate 
and multivariate approaches (Shek & Ma, 2011). 
Limitations of this study include, the fact that this was an uncontrolled study despite 
comprising a relatively large and homogenous data set. Electronic records of CT 
scans were not available before 2007 as the Picture Archiving and Communication 
System was introduced in February that year and has contributed to the exclusion 
from the study of a large proportion of the St Mark’s early cohort.  
7.5! Conclusion 
 
In patients undergoing CRC surgery, laparoscopy and moderate SIR significantly 
favours preservation and restoration of muscle mass, postoperatively. These 
emerging data may permit the development of new treatment protocols whereby 
monitoring and modifying body composition has therapeutic potential.    
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Chapter 8 
8! What is the relationship between body composition and immune 
function (DCs) in colorectal cancer patients treated surgically? 
 
8.1! Characterization of the phenotype of circulating DC in patients with CRC 
disease and healthy controls 
CRC results from the accumulation of both genetic and epigenetic alterations of the 
genome (Chapter 1). However, inflammation and the host’s systemic and local 
inflammatory response have been accepted as major factors in tumour development 
and progression (Hanahan & Weinberg, 2011; Mantovani et al., 2008). The changes 
that are observed in the tumour microenvironment but also in the systemic level 
resemble the process associate with chronic inflammation (Whiteside, 2008). 
(Candido & Hagemann, 2013). Similar to other cancer types, CRC antigens induce 
DC recruitment, maturation and cytokine release to cause an effective immune 
response. However the tumours use various mechanisms to escape the 
“immunosurveillance” and more specifically to suppress DC function. The data about 
the phenotype and function of circulating DCs in CRC patients are still very limited. 
In this chapter using circulating blood DCs and flow cytometry analysis we aimed to 
characterize and compare the phenotype of circulating DC in patients with CRC 
disease and healthy controls. 
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8.1.1! Introduction 
The main role of an efficient inflammatory response is to constrain and eliminate 
harmful to the body antigens such as the developing cancer cells. According to this 
judgment, solid tumours that do emerge have either managed to escape detection by 
the various arms of the immune system and/or have been able to avoid the 
immunological killing. Most tumour cells express antigens that can mediate an 
effective CD8+ T –cells reaction by the host (Gajewski, Schreiber, & Fu, 2013).  
DCs are potent APCs and are crucial in initiating and influencing innate and adaptive 
immune responses. They are cable of sampling antigens and initiating cytotoxic T-
lymphocyte response against colorectal cancer cells (Palucka & Banchereau, 2012). 
DCs either boost the immune system (enhancing immunity) or dampen it (leading to 
tolerance). Despite their vital role in generating an immune response, DCs are a 
heterogeneous and rare type of immune cell. Characterization of DC populations in 
humans is challenging due to the low numbers in circulation and the complexity of 
their detection in the tissues and in the blood.  
Peripheral bloods DCs are frequently classified in 2 broad categories (myeloid and 
plasmacytoid) according their haematopoietic precursors (see Chapter 1). DC 
subtypes depend on their localization and differ in phenotype and function. These 
different phenotypes allow the various DC subsets to specifically respond to danger 
signals they encounter and therefore their explicit subset type can influence the 
nature of the immune response (Ueno et al., 2007). The majority of the knowledge 
of DCs biology is based on a DC production method from human monocytes using a 
combination of GM-CSF and interleukin IL-4 (Inaba et al., 1992) (Sallusto & 
Lanzavecchia, 1994). Whether these observations are a true reflection of the real in 
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vivo characteristics of peripheral DCs is still controversial despite the fat that there 
is a shift towards separating monocyte derived DCs and “true” DCs (Guilliams et al., 
2014). In addition to this limitation another methodological problem has to be taken 
into account when the role of DCs is investigated. Flow cytometric analysis for DCs 
relies on negative selection using a large panel of antibodies to remove lineage-
specific cell populations (Chowdhury, Johnson, & Williams, 2010) and this adds to 
the complexity of DC biology.   
Upon recognition of a danger signal though their pathogen associated molecular 
pattern receptors, DCs go through a maturation phase and then they migrate to the 
local lymph nodes where they present antigens to T cells and initiate an antigen- 
specific response by the adaptive immune system (Orsini et al., 2012).  Mature DCs 
increase their capacity to process antigens and express the cytokines and co-
stimulatory molecules such as CD40, CD80, CD83 and CD86 essential for an 
effective immune response. CCR-7 expression on DCs promotes migration in 
response to relevant ligands to the local lymphoid tissues (Clatworthy et al., 2014). 
The role of scavenger receptors has recently been recognized in DC function and it 
has been suggested that immune responses in cancer can be improved by 
manipulating the lipid levels in DCs (Herber et al., 2010). The mDC and pDC 
populations function as APCs following a similar maturation process and they act 
synergistically to induce more effective immune responses (Fricke & Gabrilovich, 
2006). But DCs are not exclusively immunogenic; recent studies suggested that 
depending on the local microenvironment and the type of disease DCs can initiate 
either an immunogenic or a tolorogenic response (Ma et al., 2013). CRC cancer cells 
use different mechanisms to escape the immune surveillance and cause immune 
dysfunction (Yuan et al., 2008).   
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The interactions between tumor cells and DCs are complicated and have yet to be 
fully comprehended. Understanding the interactions between DCs and colorectal 
cancer tumours will lead to better clarification of the tumour immune surveillance 
and escape and ultimately will provide novel therapeutic avenues. This study using 
circulating blood DCs and flow cytometry analysis aimed to characterize and 
compare the phenotype of circulating DC in patients with CRC disease and healthy 
controls.  
8.1.2! Patients and methods 
8.1.2.1! Study population 
 Consecutive patients undergoing colorectal cancer surgery patients at St Mark’s 
Hospital, London between December 2012 and December 2013 were identified 
from a prospective database and considered for inclusion in this registry driven 
prospective study. Patients with recurrent or metastatic disease confirmed 
preoperatively or at surgery, emergency cases, those receiving neo-adjuvant 
chemotherapy and / or radiotherapy, patients with diabetes, smoking and blood 
transfusion, patients not willing to enroll to this study and patients with ASA status > 
3 were excluded. Healthy controls were recruited on the day of the experiment and 
every effort was made to find sex and age-matched controls and with no known 
autoimmune or inflammatory diseases, allergies, diabetes or smoking history.  
All recorded clinical and pathological data for the CRC group were revalidated from 
medical and pathology records. Data collected prospectively during the peri-
operative period (within 30 days of surgery) included age, gender, the American 
Society of Anaesthesiologists (ASA) physical status classification system, surgical 
approach, histological grading, TNM stage, presence of vascular invasion on 
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histopathology, operation type, and 30 day postoperative complications. All patient 
treatment decisions were discussed and agreed at weekly multidisciplinary team 
(MDT) meetings. Our study is registered with the UK National Research Ethics 
Committee (Reference number: 12/LO/1556) and local ethical committee approval 
was granted for this study (Reference number: 12/088). 
8.1.2.2! Blood Samples and processing  
Venous blood (20ml) was obtained from the healthy volunteers and the selected 
CRC patients and collected into heparinized Vacutainers (Becton Dickinson, Oxford, 
UK). Peripheral blood mononuclear cells (PBMC) were obtained by centrifugation of 
human peripheral blood over Ficoll Paque Plus at 800g, for 30 minutes at room 
temperature (RT) and harvesting the buffy coat layer from the interface. The PBMC 
were washed twice (centrifugation 650g, 10 minutes and 450g, 5 minutes) in RPMI 
1640 Dutch modification (Sigma-Aldrich, Dorset, England). The cells were assessed 
for viability by their ability to exclude trypan blue (Sigma, Poole). A minimum of 
200,000 peripheral blood mononuclear cells was used per antibody labeling. 
8.1.2.3! Antibody labeling 
PBMCs were labeled with monoclonal antibody (Oka et al.) at predetermined 
optimal concentrations. Cells were then washed twice in fluorescence activated cell 
sorter (FACS) buffer, which contains phosphate buffered, saline (PBS) with 1 mmol/L 
EDTA and 0.02% sodium azide. Cells were fixed at this point with 1% 
paraformaldehyde (1% PFA). Antibodies to HLA-DR (G46-6), CD40, CD36, CD86, 
CD80 (L307.4), CD83 (HB15e), CD34 (581), CCR7 (2H4) and matching isotype 
control were purchased from BD Pharmingen, Oxford, UK. Antibodies to CD3 
(UCHT-1), CD14 (MIP9), CD16 (B73.1), CD19 (4G7), and CD56 (N901) came from 
 241 
Beckman Coulter, High Wycombe, UK. Antibodies to CD14 (TÜK-4) and CD19 
(SJ25-C1) were obtained from ABD Serotec, Kidlington, UK. Anti-CD11c (clone 
KB90) was purchased from Dako - Alere, Stockport, UK. Biotinylated anti-mouse 
IgM (R6-60.2) and phycoerythrin-conjugated streptavidin obtained from BD 
Pharmingen. Appropriate isotype-matched control for the rest of tested antibodies 
was purchased from the same companies. 
8.1.2.4! Flow Cytometry and data analysis 
Labeled samples were acquired on FACS Canto-II flow cytometer (Becton-
Dickinson, UK) using FACS diva software for partial compensation and creation of 
list mode data files. List mode data files were then analyzed using offline WinListTM 
software (Verity, Topsham, ME). DCs constitute a small proportion of total 
leucocytes from peripheral blood; cells from different tissues emit different levels of 
innate/background auto fluorescence. Therefore compensation was carried out 
separately for every individual experiment. Unlabeled live cells during flow cytometry 
were determined using the forward scatter (FSC) versus the side scatter (SSC) plot 
and were used to set the settings on the machine, based on the cells background or 
auto-fluorescence. For partial online compensation, compensation beads were used 
to adjust the flow cytometer before acquisition of the cells.  
8.1.2.5! Winlist analysis  
Compensation was completed online using compensation toolbox on the WinlistTM 
software program. DCs were identified as HLA-DR+ Lineage − cells where linage 
was a mixture of monoclonal antibodies to CD3, CD14, CD16, CD19 CD34, and 
CD56. The mDC was identified as a CD11c+ subset; plasmacytoid DC were 
CD11c−. To determine expression of other markers, single parameter histogram 
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plots were prepared for gated DC populations. The proportion of cells expressing 
any given surface marker of interest was determined by comparing fluorescence to 
that of an isotype-matched control mAb. Histograms of isotype control labeling 
were subtracted from histograms of specific antibody staining using the Super-
enhanced Dmax normalized subtraction (SED) software option on Winlist. The 
statistical significance of the differences between two histograms (isotype control 
and antibody) were assessed by Kolmogorov and Smirnov (K-S) statistics according 
to the formula: 
Dcrit = Dmax / √ {(n1 + n2) / (n1 x n2)} 
In this equation, Dmax is the maximum difference between cumulative normalized 
histograms of isotype control and antibody labeling, n1 is the number of events in 
the antibody-labeled sample, and n2 is the number of events in the isotype-matched 
control sample. This subtraction results was reported as percentage positive (% 
positive) values. We also calculated the level of staining which was quantified as an 
Intensity ratio (IR). SED analysis uses the cumulative normalized histograms and is 
not equivalent to channel number subtraction. It allows positive cells to be resolved 
in situations where distribution histograms overlap and is an improvement of the 
enhanced normalized subtraction method and reduces errors in estimation of the 
positive fraction.  
8.1.2.6! Statistics 
Statistical analyses were carried out using SPSS v19.0. Pooled data are expressed as 
mean values +/- standard error. Data are presented as mean and standard errors 
(SEM). Non-parametric tests (Mann Whitney Rank-sum tests) were used to analyse 
non-normally distributed data whereas two-way unpaired t-test was used to 
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compare assumed parametric distributed data. P value less than 0.05 was considered 
as the statistically significant level. 
8.1.3! Results 
8.1.3.1! Study population 
After applying the selection criteria 21 patients undergoing surgery for CRC and 21 
healthy control individuals were enroll and consented to the study. The mean age 
was 70 years for the CRC group compared to 65 years for the control group 
(p=0.21). There was no difference between the two groups with regards the BMI 
(28.70 kg/m2 for the CRC Vs 28.21 Kg/m2 for the control; P=0.72) and the gender 
variation (13 males and 8 females for each group). Out of the 21 patients recruited 
for the study, 11 were treated for rectal cancer and 10 for colon cancer. 28.5% 
(n=6) of the CRC group were early tumours T1+T2, whereas 47.6% (n=10) were 
cancers with lymph node metastasis verified on histological examination of the 
specimens. Lymphovascular invasion was present in 6 (28.6%) of the specimens. The 
majority of the CRC tumours included in the study had moderate grade of 
differentiation (n=19). Table 8.1 shows the clinicopathological features for the two 
groups.  
8.1.3.2! DC phenotype characterization  
DCs were identified by multicolor flow cytometry analysis as HLA-DR+ and Linage 
cocktail– cells as shown in the boxed area in Figure 7.1. Within the DCs region, DCs 
were considered as either CD11c+ myeloid DC or CD11c- plasmacytoid DC. An 
example of the subtraction technique used to quantify labeling with anti CCR7 is 
shown in Figure 8.2   
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Table 8-1 Demographics of the colorectal cancer and the control groups 
Demographics CRC Cancer N=21 Healthy Control 
N=21 
 
Mean (SD) N Mean (SD) N P-value 
Age (years) 70 (9.22)  65 (13.66)  0.21 
BMI (Kg/m2) 28.70 (5.02)  28.21 (3.56)  0.72 
Gender Male  13  13  
Female  8  8  
ASA status ASA 2  15  -  
ASA 3  6  -  
Diabetes 
Mellitus  
No  21  21  
Yes  0  0  
Smoking Status No  21  21  
Yes  0  0  
Tumour 
Location 
Rectum  11  
N
ot
 R
el
ev
an
t 
 
Colon  10   
Tumour stage T1  2   
T2  4   
T3  11   
T4  4   
Node stage N negative  11   
N positive  10   
UICC stage Stage I  6   
Stage II  5   
Stage III  10   
Stage IV  0   
Lymph vascular 
Invasion  
Absent  15   
Present   6   
Grade of 
differentiation  
Moderate  19   
Poorly  2   
Abbreviations: BMI= Body Mass Index, ASA= American Society of Anesthesiologists, UICC= Union 
Internationale Contre le Cancer, SD= Standard Deviation, CRC= Colorectal Cancer  
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Figure 8-1 Identification of blood dendritic cells 
First line represents an experiment from a healthy control whereas the second line 
an experiment from a CRC patient. DCs were identified by gating on the polygon-
boxed region on the Forward Scatter versus the Side scatter dot plot and defined as 
HLA-DR+ and lineage- cells 
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Figure 8-2 Identification of blood dendritic cells subtypes. 
Example of the subtraction technique used to quantify labeling with anti CCR7. 
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8.1.3.3! Co-stimulatory markers CD40, CD80, CD83 and CD 86 
A total of 42 (21 CRC vs 21 CTRL) valid experiments were performed for the 
comparison of the CD 40 activation marker. Percentage of blood DC positive for 
activation marker CD40 was increased in CRC compared to the healthy control 
group. The increase was present in all DC [mean % positive, (SED), 31.26 (2.86) Vs 
21.14 (2.77); P-value=0.01], mDC [29.77 (3.13) Vs 20.70 (2.97); P-value=0.04] and 
pDC [35.53 (3.60) Vs 23.55 (3.13)]. A similar pattern was demonstrated for the level 
of staining expressed. Intensity ratio (IR) values were statistically significant higher in 
the CRC population when compared to the healthy individuals in all DC but also in 
the two main subsets, pDC and mDC.    
Differences were also seen for the co-stimulatory marker CD 83. A total of 36 (17 
CRC vs 19 CTRL) experiments were valid for inclusion in the analysis. A total of 6 
experiments were not included due to technical reasons. Activation marker CD 83 
was increased in CRC compared to the healthy control group in all DC [17.78 (4.68) 
Vs 6.16 (1.790; P-value=0.02] and this difference was driven from the mDC 
population [(14.88 (4.02) Vs 5.12 (1.97); P-value=0.03]. With regards the IR values 
differences were seen only for the mDC IR [1.74 (0.41) Vs 0.83(0.29); P-value=0.04].  
The analysis for the CD 80 and CD 86 activation markers did not show any 
statistical significant differences. A trend towards higher % positive values was noted 
for the two markers in all DC and in the two subsets of interest. A total of 36 valid 
experiments were included in the analysis for each marker.  
Table 8.3 summarizes the differences between CRC and control groups with regards 
the DC activation markers. 
 
 248 
Table 8-2 Dendritic Cell Phenotype differences between Colorectal Cancer and Health Controls 
Activation Surface 
Marker of Interest 
Colorectal Cancer Control  
P-Value 
Total 
Exp 
Valid Exp Mean SEM SD Total Exp Valid Exp Mean SEM SD 
            
CD40 all DC %P 21 21 31.26 2.86 13.13 21 21 21.14 2.77 12.71 0.01 
CD40 all DC IR 21 21 4.55 .56 2.58 21 21 2.93 .38 1.73 0.02 
CD40 m DC %P 21 21 29.77 3.13 14.34 21 21 20.70 2.97 13.62 0.04 
CD40 m DC IR 21 21 4.20 .44 2.03 21 21 2.72 .32 1.47 0.01 
CD40 p DC %P 21 21 35.53 3.60 16.49 21 21 23.55 3.13 14.35 0.02 
CD40 p DC IR 21 21 7.84 1.20 5.50 21 21 4.08 .83 3.82 0.01 
            
CD 83 all DC%P 21 17 17.78 4.68 19.29 21 19 6.16 1.79 7.81 0.02 
CD 83 all DC IR 21 17 2.43 1.09 4.49 21 19 1.14 .32 1.37 0.24 
CD 83 m DC %P 21 17 14.88 4.02 16.60 21 19 5.12 1.97 8.58 0.03 
CD 83 m DC IR 21 17 1.74 .41 1.69 21 19 .83 .29 1.25 0.04 
CD 83 p DC %P 21 17 16.72 4.05 16.70 21 19 9.57 3.00 13.09 0.16 
CD 83 p DC IR 21 17 1.53 .24 1.00 21 19 1.08 .25 1.08 0.21 
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CD 86 all DC %P 21 17 50.47 6.56 27.04 21 19 41.75 8.07 35.19 0.41 
CD 86 all DC IR 21 17 3.83 1.16 4.77 21 19 2.51 .89 3.89 0.36 
CD 86 m DC %P 21 17 55.93 6.99 28.81 21 19 44.38 8.46 36.86 0.31 
CD 86 m DC IR 21 17 3.55 .98 4.05 21 19 2.57 .84 3.68 0.45 
CD 86 p DC %P 21 17 44.29 7.54 31.10 21 19 40.88 8.79 38.32 0.77 
CD 86 p DC IR 21 17 2.62 .94 3.88 21 19 3.82 1.83 7.98 0.58 
            
CD 80 all DC %P 21 17 12.82 3.65 15.06 21 19 9.61 2.71 11.80 0.48 
CD 80 all DC IR 21 17 1.73 .32 1.33 21 19 1.51 .33 1.43 0.64 
CD 80 m DC %P 21 17 9.96 3.36 13.84 21 19 8.07 2.62 11.42 0.66 
CD 80 m DC IR 21 17 1.33 .32 1.31 21 19 .89 .26 1.12 0.28 
CD 80 p DC %P 21 17 19.92 4.24 17.47 21 19 15.39 3.71 16.16 0.43 
CD 80 p DC IR 21 17 2.12 .38 1.57 21 19 1.76 .33 1.43 0.47 
 
Abbreviations: CD= Cluster of differentiation; DC = Dendritic Cells, p= plasmacytoid, m= myeloid, %P = percentage positive, IR= Intensity Ratio, SEM= Standard error of mean, SD = 
Standard deviation
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8.1.3.4! Lymph node migration marker CCR 7 
 
Total of 42 (21 from the CRC and 21 from the control group) valid experiments 
were analyzed in order to identify the differences from the CCR 7 marker 
expression on DC. The percentage positive values were higher in the cancer group 
when all DCs were analyzed [45.02 (2.53) Vs 31.37 (4.84); P-value=0.02]. The 
increased expression of CCR 7 in blood DCs was driven from the myeloid subgroup 
[37.92 (2.97) Vs 25.37 (4.26); P-value=0.02]. No differences were found in the 
plasmacytoid subset and also when IR values where compared.  
Scavenger Receptor CD 36 
 A total of 36 (17 CRC Vs 19 CTRL) experiments were valid for inclusion in the 
analysis to identify phenotypic DC differences between the two groups. The analysis 
did not demonstrate any statically significant differences when values for the % 
positive and the level of staining were considered.  
Table 8.3 demonstrates the results for the CCR 7 and CD 36 surface markers.  
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Table 8-3 Dendritic Cell Phenotype differences between Colorectal Cancer and Health Controls 
Surface Marker of 
Interest 
Colorectal Cancer Control  
P-Value Total 
Exp 
Valid 
Exp 
Mean SEM SD Total 
Exp 
Valid 
Exp 
Mean SEM SD 
Migration maker            
CCR7 all DC %P  21 21 45.02 2.53 11.59 21 21 31.37 4.84 22.18 0.02 
CCR7 all DC IR 21 21 5.90 .91 4.18 21 21 4.88 .86 3.95 0.42 
CCR7 m DC %P 21 21 37.92 2.97 13.60 21 21 25.37 4.26 19.52 0.02 
CCR7 m DC IR 21 21 4.62 .84 3.84 21 21 4.01 .77 3.54 0.59 
CCR7 p DC %P 21 21 59.85 4.13 18.95 21 21 47.42 7.45 34.16 0.15 
CCR7 p DC IR 21 21 8.16 1.16 5.30 21 21 8.53 1.62 7.42 0.85 
Scavenger Receptor             
CD 36 all DC %P 21 17 54.00 7.14 29.44 21 19 56.92 5.52 24.06 0.55 
CD 36 all DC IP 21 17 20.91 4.13 17.03 21 19 24.19 3.64 15.86 0.98 
CD 36 m DC %P 21 17 63.11 6.82 28.10 21 19 63.32 5.96 25.96 0.92 
CD 36 m DC IP 21 17 20.22 3.43 14.12 21 19 21.26 3.01 13.12 0.82 
CD 36 p DC %P 21 17 38.35 7.88 32.48 21 19 25.19 7.47 32.56 0.23 
CD 36 p DC IR 21 17 14.81 3.76 15.49 21 19 12.46 4.37 19.04 0.69 
Abbreviations: CD= Cluster of differentiation; DC = Dendritic Cells, p= plasmacytoid, m= myeloid, %P = percentage positive, IR= Intensity Ratio, SEM= Standard error of mean, SD = 
Standard deviation
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8.1.4! Discussion 
In this study we identified through flow cytometry analysis that in these selected 
group of CRC patients the circulating DCs were more activated and potentially 
lymph node homing when compared to healthy controls.  
DCs differentiate mainly during embryonic and postnatal life from bone marrow 
progenitor cells (Geissmann, 2007). From the bone marrow, undifferentiated CD34+ 
precursor cells give rise to two progenitor cell lines, consisting of the “common 
myeloid progenitor cell” and the “common lymphoid progenitor cell”. These cell 
lines generate the mDCs and pDCs respectively. These progenitor cells next seed 
the blood where they differentiate into their respective DC subtype. Newly formed 
DC precursors migrate via the blood circulation to various peripheral sites including 
the majority of the epithelia tissues including the gastrointestinal tract. Once DCs 
are within these mucosal sites, they differentiate to their respective immature 
phenotype.  The differences between a mature and an immature DC are not only 
morphological changes but also are related to the levels of surface major 
histocompatibility complex (MHC) proteins, empty cell-surface class II MHC proteins 
and high intracellular MHC Class II. Also, immature DCs lack co-stimulatory 
molecules rendering them unable to stimulate nai ̈ve T cells. Upon interaction with 
tumour antigens they mature and migrate to the regional lymph node where they 
present to naïve and memory lymphocytes thereby inducing an immune response 
(see Chapter 1).  
The circulating DCs from the CRC group were of a more mature phenotype as seen 
by the increased expression of CD40 and CD83. CD40 is a type 1 membrane 
glycoprotein co-stimulatory molecule that belongs to the tumor necrosis factor 
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superfamily. CD40 is expressed on a variety of immune and non-immune cells, 
including B lymphocytes, macrophages, dendritic cells, epithelial cells and endothelial 
cells (van Kooten & Banchereau, 2000). Upon up-regulation by the CD40-ligand 
pathway, DCs become mature and activated followed by both a strong innate 
immune response and T-cell priming. CD40 ligation enhances the survival of DCs 
and induces the production of anti-tumor cytokines such as IL-8, TNF-α and IL-12, 
which is critical for activation of Th1 response and cytotoxic T-lymphocyte activities 
(Sallusto & Lanzavecchia, 1999). Therefore, CD40/CD40 ligand interaction is key in 
DC maturation, and for effective cell-mediated tumor immunity. This process is 
regulated by expression of the other co-stimulatory molecules such as CD80, CD 83 
and CD86 (Bakdash, Sittig, van Dijk, Figdor, & de Vries, 2013). Few studies in the 
past looked into systemic phenotypic expression profiles in blood DCs for different 
type of cancers. Bellone et al. reported significantly decreased expression of CD40 
on monocyte derived DCs (MoDCs) from patients with pancreatic cancer patients 
compared with healthy individuals (Bellone et al., 2006). Similarly, Hou et al. assessed 
the expression of CD40 on MoDCs in renal cell carcinoma (RCC) there was little or 
no expression of CD40 on MoDCs from RCC patients, and when DC were co-
cultured with TNF-α, the expression of CD40 was significantly lower than that on 
cultured MoDCs from the healthy group (Hou et al., 2010). However studies using 
DCs from PBMC (fresh DCs) instead on MoDCs showed increased expression in 
cancer. Tjomsland et demonstrated a partial maturation of the blood mDCs and 
pDCs in patients with pancreatic adenocarcinoma with significantly enhanced 
expression of CD 83, DC 40 and CCR 7 (Tjomsland et al., 2010). Similarly, Pinzon-
Charry et al. studied DC phenotypes of 120 patients with breast adenocarcinoma at 
various stages, patients with prostate cancer and patients with malignant glioma. In 
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the group of the breast cancer patients, the percentage of DCs expressing CD40 and 
the intensity of staining were significantly higher in the stage IV metastatic group 
compared to healthy controls (Pinzon-Charry, Ho, et al., 2005). This group also 
demonstrated that DCs expressing high CD40 were HLA-DR+ immature cells 
(HLA-DR+, CD11c-, CD123-). These immature cells had lower antigen capture, 
presentation and phenotypic maturation in response to inflammatory mediators, 
suggesting an increased immunodeficiency in cancer disease. Limited data are 
available from studies directly ex-vivo that compare human circulating blood DCs in 
CRC disease. Orsini et al found a significant reduction of the blood circulating DC 
(driven by a reduction in pDC numbers) number in total and advance stage CRC 
patients compared to healthy controls and also a more immunosuppressive profile of 
the mDC subset in CRC with a gating strategy based on the expression of the 
tolorogenic antigen CD85 k (Orsini et al., 2014). In this study total PBMCs were 
gated based on their forward and side scatter and CD33 or CD123 positive cells 
were selected for mDCs and pDCs, respectively. However a study performed by 
Bellik et al. showed a higher percentage of circulating DCs in CRC patients before 
surgical excision, which may be attributable to the different methodology used. 
Negative lineage markers (containing antibodies against CD3-14-16-19-20-56) and 
BDCA+ cells were considered as DCs. BDCA-2 + marker was used for identification 
of pDCs and BDCA-1+ and BDCA-3+ for the mDCs (Bellik et al., 2006). Evidence is 
limited with regards to the phenotypic differences between blood DCs in CRC and 
healthy controls and our study stands upon as the first in the literate to do so.    
The life cycle of a mature DC is understood to be over after the migration and 
interaction with T-cells in the lymphoid tissues. However the findings of our study 
demonstrated the presence of activated circulating blood DCs and this observation 
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generated two possible explanations. Based on our results blood-circulating DC may 
have either a.) interacted with systemic tumour-derived or host factors to become 
activated and lymph node homing or b.) the blood DCs identified may have been 
activated cells that had already been to the lymph nodes and somehow reentered 
the blood circulation.   
Studies showed that malignancies are able to regulate the differentiation and function 
of immune cells by producing a plethora of immunosuppressive factors capable of 
affecting these cells. The changes in blood DC phenotype that we identified, suggest 
that blood DCs may interact with these systemic tumour-derived factors to become 
activated and lymph node homing. Secretion of tumour factors, including cytokines 
such as IL-6, IL-10, IL-12, TNF-α VEGF and inflammatory mediators (gangliosides, 
PGE2) could act as an additional mechanism to impair DC differentiation and 
promote cancer progression (Pinzon-Charry, Maxwell, et al., 2005). However 
reports on the role of the above tumour derived factors on circulating human DC in 
vivo have been slow to emerge and again the knowledge is very limited. It seems 
though that they suggest that elevated production of these factors is associated with 
DC dysfunction and differentiation. Increased levels of IL-6, IL-12, IL -10 and TNF-α 
inhibit DC maturation and these effects are correlated with the disease stage. In our 
cohort of patients we have seen differences between CRC and controls suggesting 
more mature DC phenotype. The fact that only non-metastatic cases were enrolled 
to the study might have been a major contributing factor to these specific phenotypic 
changes.  
To further explore the hypothesis that the DC phenotypic changes are driven by the 
tumour behaviour the phenotypic status of systemic DCs was examined in the 
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postoperative period. Blood samples were obtained from 7 of the CRC group of 
patients pre-operatively and 4 to 6 weeks after operation, prior to chemo or 
radiotherapy. Peripheral blood mononuclear cells were separated and DC identified 
as described above. CD40 expression was decreased on mDC and pDC post-
operatively from 26.32 ± 5.787 % to 14.88 ± 6.024 % (p=0.039). There were no 
significant differences in CCR7 expression on DC between pre and post-operation. 
The postoperative changes in CD 40 demonstrated that removal of colorectal 
tumour alters the phenotype of DC resulting in systemic DC becoming less activated 
and more immature. These findings suggest that the initial increase of CD40 in the 
preoperative period may be due to tumour-derived factors.  
It has been suggested that DCs derived from a peripheral organ or lymph node can 
recirculate back into the blood stream and this phenomenon must be taken into 
account when our results are discussed. Our study showed the presence of a more 
mature and lymph node homing DC phenotype in the CRC group whereas the 
classical paradigm of DC life span prompts the scenario that activated DCs should 
not be present in the blood stream once they have migrated and presented the 
antigen at the lymph node level. Mechanisms to reenter the blood circulation include 
either the direct exodus across the vascular endothelium at the lymphatics or 
through the thoracic duct after they enter the efferent lymphatic duct (Randolph et 
al., 2008). If this hypothesis is verified in patients with cancer, this observation could 
have a major impact on DC immunobiology and immunotherapy. Recirculating 
activated DCs can be serving as Trojan horses and such trafficking might facilitate the 
failure of the immune system to produce an efficient immune response to cancer. 
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In order to understand further the systemic DC characteristics such as the 
differences in expression of phenotypic markers there is a need for further work 
based on functional analysis.  Intracellular cytokine production and DC capacity to 
stimulate T cells need to be determined in disease (CRC) group and compared with 
healthy controls. Additionally, the role of circulating serum cytokine levels on the 
systemic DC microenvironment needs also clarification. DCs are able to recognize 
antigens from necrotic tumour cells and undergo maturation. They can then drain 
into the lymph nodes activating both CD8+ and CD4+ T cells resulting in production 
of antigen-specific cytotoxic T cells (CTL). However, growing tumour cells “escape” 
this process and advance into metastatic cancer. Early research investigating this 
phenomenon concentrated on the impaired function of DCs in stimulating 
immunogenic response against cancer cells, mainly their inability to express MHC 
class II and co-stimulatory molecules. However, tumour-mediated DC dysfunction is 
most likely to be multifactorial, where evidence of “escape” mechanism may occur at 
an earlier stage of DC differentiation due to systemic effect of tumour-derived 
factors. Tumour-derived factors have been suggested as the main cause of defective 
DC differentiation. Our results justify further work where DC are conditioned with 
serum from heathy or cancer individuals and their ability of T Cells stimulation is 
observed (mixed leucocyte reaction). Conclusions from such studies will enable us 
to understand further how cancer is able to escape the ‘immunosurveillance” phase 
and propose possible solutions to it.   
This study has limitations and merit explanations. Firstly, patents with metastatic 
disease, emergency cases, those receiving neo-adjuvant chemotherapy and / or 
radiotherapy, patients with diabetes, smoking and blood transfusion, were excluded, 
as these interventions can alter the preoperative systemic immune profile. The 
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selection criteria and the prospective character of this study’s design, contributed in 
minimising the effect of the confounding elements and also restricting the selection 
bias. As we can see from table 8.1 there were no differences in age, gender and BMI 
between the CRC and the control group, minimizing the confounding effect of these 
factors.  The nature of the study design, the cost and the complexity of the 
experiments limited the number of participants. The small numbers in this study 
carry a risk of introducing a type II error to the analysis of the results hence bigger 
numbers are needed to secure conclusions.  
8.1.5! Conclusion 
In conclusion this study identified that in CRC, circulating DC are activated (CD 40 
and CD 83 high) and potentially lymph node homing (CCR7 high). Such changes may 
be due to systemic tumour-derived factors or recirculation of gut-activated DC 
through lymph nodes in CRC. Further studies are warranted to identify the cause, 
which may identify novel therapeutic pathways for CRC treatment.  
 259 
8.2! The relationship of BC anthropometric parameters and tumour characteristics 
on DC phenotype in patients with CRC  
DCs are the most potent antigen presenting cells, capable of sampling antigens and 
initiating cytotoxic T-lymphocyte response against cancer cells (see Chapter 1). 
Colorectal tumor antigens induce DC recruitment, maturation, and cytokine release 
in order to generate effective T cell immune response (Legitimo et al., 2014). 
Despite their crucial role in generating an immune response, DCs are a 
heterogeneous and rare type of immune cell. Their diverse phenotypes and subtypes 
allow the DCs to specifically respond to danger signals they encounter but this is 
mainly regulated by exogenous factors. In cancer tumour derived factors appear to 
exploit this by producing a variety of immunosuppressive factors capable of affecting 
DC. As mentioned previously (see 8.1) certain cancer disease characteristics such as 
stage may have an impact on the function and the DCs phenotype but again the 
evidence is limited. Associations between the TNM stage, the grade, the location, 
the presence of lymph vascular invasion or features of the tumour host – the patient 
such as the Body Composition (BC) and the DCs profiles have rarely been explored. 
In this study the relationship of BC anthropometric parameters and tumor 
characteristics on DC phenotype in patients with CRC is examined.   
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8.2.1! Introduction 
 
BC describes the percentages of fat, bone and muscle in human bodies. BC changes 
have been documented in patients with malignant disease; however, associated 
metabolic and immune changes developing during disease and its legacy are less 
clear, particularly in CRC (Bardou et al., 2013). 
Herber et al. gave another explanation on how the host immune system can be 
compromised during cancer; an increase in lipid content of dendritic cells (DCs) 
diminishes their capacity to present antigens from tumour cells and to activate 
effector T cells. The authors demonstrate that normalization of lipid levels in DCs in 
mice could enhance the effect of cancer vaccine (Herber et al., 2010). O’Shea et al 
studying the susceptibility to viral infection observed in severe obesity also showed 
that obesity negatively impacts the ability of systemic DC’s to mature and elicit 
appropriate T-Cell responses to a general stimulus (O'Shea et al., 2013).  
The interactions between tumor cells and DCs are complicated and have yet to be 
fully comprehended. Also, very few data are available on how other factors such as 
the tumour characteristics, parameters of BC like myopenia, myosteatosis or 
myopenic and visceral obesity influence the immune system and DCs phenotype and 
function. Understanding the links between DCs, colorectal cancer tumours and BC 
profiles will lead to better understating of the immune surveillance and escape 
mechanisms and ultimately will provide novel therapeutic targets. Here, using 
circulating blood DCs and flow cytometry analysis we aimed to identify the 
relationship of BC anthropometric parameters and tumor characteristics on DC 
phenotype in patients with CRC.   
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8.2.2! Patients and methods 
8.2.2.1! Study population and DC phenotype experiments  
Peripheral blood mononuclear cells were obtained from CRC patients before any 
surgical intervention with the same selection criteria as described in paragraph 7.1.3 
(n=21). DC identified as HLA-DR positive and lineage (anti-CD3, CD14, CD16, 
CD19, CD34 and CD56) negative cells. DCs were further classified as CD11c+ 
myeloid (mDC) or CD11c- putative plasmacytoid. CD40, CD83, CD86, CD36 and 
CCR7 expression was determined on DC by flow-cytometry (see paragraph 8.1.3.2).  
8.2.2.2! Image analysis 
The preoperative CT images were retrieved from digital storage in the Picture 
Archiving and Communication System [PACS]. CT image analysis Slice-O-Matic V4.3 
software (Tomovision, Montreal, Canada) was performed as described previously 
(see chapter 3).  
8.2.2.3! Statistics 
 Relationships between continuous BC variables and DCs phenotype profile values 
were examined using Pearson correlation coefficients (r) as appropriate. The 
relationship between DC phenotype profile values and BC profile and other 
clinicopathological parameters was assessed using with two-tailed unpaired Student’s 
t-tests. P values of less than 0.05 were considered statistically significant.   
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8.2.3! Results 
8.2.3.1! Study population 
After applying the selection criteria 21 patients undergoing surgery for CRC and 21 
healthy control individuals were enroll and consented to the study. Table 8.1 
describes the demographics and the clinicopathological characteristics of these CRC 
group. 
8.2.3.2! Body Composition Parameters  
The BC parameters of the included patients are shown in Table 8.4.  The mean LSMI 
was 38.65 cm2/m2 with standard deviation (SD) of 9.10 cm2/m2 and the mean HU 
value for the skeletal muscle demarcated was 30.74 HU with a SD of 9.64 HU. To 
allow a better generalization of the adipose tissue from the CTBC analysis the total 
adipose area was calculated by adding the VAT with the SAT. Out of the 21 patients 
CRC patients included in the study 8 (38.1%) were obese as defined by BMI > 30 
kg/m2, 14 (66.7%) had visceral obesity, 14 (66.7%) were myopenic and 4 (19%) were 
myopenic obese patients. 13 (61.9%) patients had myosteatosis from analysis of their 
CT images were analyzed.  
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Table 8-4 Body Composition parameters for the Cancer Patients included in the 
study 
 Mean Standard 
Deviation 
Skeletal Muscle Area (cm2) 117.30 32.42 
Mean Hounsfield Units 30.74 9.64 
Visceral Fat Area (cm2) 197.93 138.23 
Subcutaneous Fat Area (cm2) 233.73 115.53 
Total Fat Tissue Area (cm2) 439.19 190.20 
L3 Skeletal Muscle Index (cm2/m2) 38.65 9.10 
Total Adipose Tissue Index (cm2/m2) 155.77 58.84 
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8.2.3.3! Body composition and Dendritic Cells phenotype profiles  
The relationship of BC parameters and measures of the % positive or intensity ratio 
for the different DC surface markets studied in patients with operable CRC fulfilling 
the selection criteria are shown in Table 8.5.  
There was no significant correlation between the CD 40, CD 80, CD 83, CD 86, 
CCR 7 and CD 36 expression on DCs and the L3 VFA, SFA and total fat tissue 
index. However there was a statistically significant positive correlation of the 
expression of CD 40 in all DCS and LSMI (r=+0.45, P-value = 0.04). The mean HU 
were also significantly correlated with levels of CCR 7 expression in all DCs (r=-
0.46, P=0.03). This association is again showed when CCR 7 is examined as a marker 
of local immune response in chapter 8.   
A significant correlation between the mean HU values and both the expression of 
CD 83 and CD 36 was found. For the CD 83 the association was a negative one [all 
DCs (r=-0.63; p=0.01) and mDCs (r=-0.75; p<0.01)] whereas for the CD 36 was a 
positive correlation [all DCS (r=0.60; p=0.01) and mDCs (r=0.63; p<0.01)]. To 
graphically present the significant correlations described above, scatter plots of the 
associations were drawn (Fig.8.3).  
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Table 8-5 Correlations between Body Composition parameters and DCs 
phenotypes 
 
Abbreviations: CD= Cluster of differentiation; DC = Dendritic Cells, p= plasmacytoid, m= myeloid, %P = 
percentage positive, IR= Intensity Ratio, SEM= Standard error of mean, SD = Standard deviation 
 
  
 L3 Skeletal Muscle 
Index 
Mean Hounsfield 
Units 
CD 40 All DC %P 
Correlation Coefficient 
 Sig. (2-tailed) 
 
0.45 
0.04 
 
CCR 7 All DC %P 
Correlation Coefficient 
 Sig. (2-tailed) 
 
 
 
-0.46 
0.03 
CD 36 All DC %P 
Correlation Coefficient 
 Sig. (2-tailed) 
  
0.60 
0.01 
CD 36 m DC %P 
Correlation Coefficient 
 Sig. (2-tailed) 
  
0.63 
0.01 
CD 83 All DC %P 
Correlation Coefficient 
 Sig. (2-tailed) 
  
-0.63 
0.01 
CD 83 m DC %P 
Correlation Coefficient 
 Sig. (2-tailed) 
  
-0.75 
<0.01 
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Figure 8-3 Scatterplots of the major significant associations between DCs phenotype 
and BC parameters. 
A.) CD 40 % positive All DCs Vs L3 Skeletal Muscle Index, B.) CCR7 All DC % 
positive Vs Mean Hounsfield Units, C.) CD 83 All DC % positive Vs Mean Hounsfield 
Units, and D.) CD 36 All DC % positive Vs Mean Hounsfield Units   
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8.2.3.4! Dendritic Cells and pathological parameters 
The relationship between DCs phenotype and the tumour parameters listed in table 
8.1 were assessed. Here, only statistical significant relationships are reported.  
T stage 
CD 40 % positive at both all DC and the pDCs subset were significantly associated 
with lower T stage. The mean CD 40 % positive expression on All DCs was 37.29 
for the T 1+2 tumours compared to 28.85 for the T 3+4 (p<0.01) whereas for the 
pDCs was 45.50 for T1+2 compared to 31.58 for T3+4 (p<0.05).   
N stage 
Patients with positive lymph nodes on their resection specimen had significantly 
increased CD 86 expression in all DC (66.29 Vs 36.40; p<0.01), mDC (71.09 Vs 
42.45; P<0.01) and p DC (66.52 Vs 24.53; P<0.01) compared to the patients where 
the there was no lymph node metastasis.  A significant difference was seen between 
the lymph node metastasis positive Vs the lymph node metastasis negative group 
when the expression of the CCR 7 surface marker was analysed. Higher values of 
the mean % positive expression of CCR 7 on all DCs and p DCs were found in 
patients with N negative stage compare to the N positive patients  (51.58 VS 38.13; 
P<0.01 for all DCs and 68.12 Vs 50.72; P<0.05).  
Grade 
Two patients were found to have a poorly differentiated colorectal tumour and in 
these patients the DCs CD 40 expression was increased. The mean % positive for 
the CD 40 marker in all DC was 50.00 compared to 29.29 for the moderate 
differentiated tumours (P<0.05). The difference was still present when the m DC 
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subsets were analysed. For the m DCs the poorly differentiated group had a mean % 
positive value of 54.50 compared to 27.17 for the poorly differentiate group 
(P<0.01).  
There were no significant differences between the expression of CD 40, CD 80, CD 
83, CD 86, CCR 7 and CD 36 when lymphovascular invasion and tumour location 
categories were considered.  
Table 8.6 demonstrates the significant differences between DC phenotypes and 
tumour related factors in the group of patients with CRC who had been treated 
surgically. 
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Table 8-6 Significant differences between DC phenotypes and tumour related factors 
 T category N stage Grade 
T 1+2 T 3+4 N negative N positive Moderate Poorly 
Mean Mean Mean Mean Mean Mean 
CD 40 All DC %P       
CD 40 m DC %P       
CD 40 p DC %P       
CD 40 p DC IR       
CCR7 All DC %P       
CCR7 p DC %P       
CD 86 All Dc %P       
CD 86 m DC %P       
CD 86 p DC %P       
 
Abbreviations: CD= Cluster of differentiation; DC = Dendritic Cells, p= plasmacytoid, m= myeloid, %P = 
percentage positive, IR= Intensity Ratio, SEM= Standard error of mean, SD = Standard deviation 
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8.2.4! Discussion 
In this study, through flow cytometry analysis in a selected group of CRC patients, 
we identified associations between the DC phenotype and the disease and host’s BC 
characteristics. The expression on peripheral DCs of the activation marker CD 40 
was positively correlated with the muscle mass expressed as LSMI of the host. 
Negative correlations were seen with the DC expression of the co-stimulatory 
molecule CD83 and the migration marker CCR7 with the myosteatosis status of the 
host expressed as mean MA.  Also T, N stage and grade of differentiation of the 
CRC tumour were associated with significant differences between DC phenotypes.  
Obesity is known to alter the immune system and its impact on the cells of the 
adaptive immunes system has also been explored but the DCs are probably the least 
explored subset (Mraz & Haluzik, 2014). Macia et al reported that DCs from obese 
mice showed are less potent in stimulation of allogenic T cells in vitro and that this 
impaired functionality was linked with the secretion of immunosuppressive cytokines 
such as TGF-beta. The obese mice were also found to have minimum levels of 
functional leptin, a key adipokine linking nutrition, metabolism, and immune functions 
(Macia et al., 2006). In another study diet induced obese mice showed distorted and 
inefficient T-cell responses to influenza infection, attributed to upregulation of 
immunosuppressive cytokines from lung DCs (Smith, Sheridan, Tseng, Sheridan, & 
Beck, 2009). DCs from obese individuals expressed significantly lower levels of 
CD86 and CD83 compared to DCs form lean patients in a study form O’shea et al 
looking at the susceptibility to viral infection observed in severe obesity (O'Shea et 
al., 2013).   
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This study is amongst the first to report correlations between DCs phenotype and 
CT defined BC parameters such as LSMI, MA, VAT and SFA. Muscle depleted 
patients treated surgically for CRC appear to have a more “immature” DC 
phenotype as seen by the positive correlation between CD40 expression and LSMI. 
Also this study demonstrated that high levels of CCR7 and CD83 expression on all 
DCs were correlated with low levels of MA and hence myosteatosis. However the 
correlation between CD36 expression and MA was of a positive change. Thus, DCs 
might be directly sensitive to BCs profiles such as myopenia and myosteatosis, 
providing a partial explanation of the immunodeficiency associated with CRC. If we 
relate the findings of this study with the fact that muscle depleted CRC patients have 
worse survival outcomes as showed in Chapter 4 then we can speculate that DCs 
efficient activation is of paramount importance.  
To convey muscle depletion, obesity, and declining immunity in cancer, we can 
assume that these conditions are linked processes, which are controlled by adipose 
tissue derived and skeletal muscle-derived cytokines, known as adipokines and 
myokines, respectively. Evidence suggests that as adipose tissue increases the 
amount of the anti-inflammatory cytokine decreases whereas there is an increase in 
the level of the pro-inflammatory molecules such as leptin, TNF-a, IL-1 and IL-6 
(Stefanyk & Dyck, 2010). These pro-inflammatory cytokines produced by especially 
visceral fat, negatively regulate muscle and muscle negatively regulates adipose tissue 
via IL-15 and other myokines (Lutz & Quinn, 2012). Skeletal muscle tissue produces 
very high levels of IL-15 and levels of IL-15 are reported to increase rapidly 
immediately following resistance and aerobic exercise (Quinn, 2008; Riechman, 
Balasekaran, Roth, & Ferrell, 2004). IL!15 is required for DC development and 
survival, whereas inflammatory cytokines such as TNF!α and IL!6 shorten DC cell 
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survival. IL-15 is an immunostimulatory cytokine that has an impact on DC 
differentiation and has been showed to increase the T-cell stimulatory capacity of the 
DCs and also with an increase tumoricidal activity and capacity to harness NK cell 
function against tumour (Anguille et al., 2013).  In cancer, muscle mass and quality 
diminishes and this may influence also the production of the IL-15 and other 
myokines and therefore these changes might impact negatively the ability of DCs to 
“fight” the cancer insult.  
Changes in the blood DCs may be attributed to factors produced by the tumour. 
Here, we have shown that expression of CD40 in all DCs was higher in patients with 
T1+T2 CRC tumours compared to T3 +T4 and this difference was driven by the 
plasmacytoid subset. Our findings indicate that, in CRC patients, the loss of DC 
activation correlates with tumour burden (suggesting a possible correlation between 
a more aggressive course of the disease). Different pattern was noticed with regards 
the CD40 expression and the grade of differentiation; patients with poorly 
differentiated tumours had higher levels of CD 40 expression in all and m DCs 
compared to patients with tumours of moderate grade. The complexity of the 
interplay between the pathological features of a colorectal carcinoma and the DCs 
and also the power of the study might have been some of the reasons behind the 
different relationships identified.    
Our data confirmed that in CRC patients with lymph node metastasis, 
preoperatively, peripheral blood DCs displayed a phenotype with lower levels of 
accessory signals for lymph node migration such as CCR7 suggesting a possible 
connection between the loss of the DCs ability to migrate to lymph nodes and 
disease stage. However the CRC patients with positive lymph nodes metastasis were 
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found to have higher levels of the co-stimulatory molecule CD86 compared to the 
DCs phenotype form CRC patients with N negative. Although the directions of the 
relationships are difficult to explain, there is a significant correlation between the 
tumour pathologic characteristics and the phenotype of DCs reflecting on their 
ability to get activated and migrate successfully to the lymph nodes. The experiments 
that have been performed are only representative of a “static window” and the time 
has not been accounted for i.e the changes in phenotype are dynamic events and 
secure conclusions are very difficult to be drawn.       
 
8.2.5! Conclusion 
The findings of the above study suggest that in CRC patients there are a phenotypic 
differences of peripheral blood DCs compartment possibly related to the 
pathological characteristics and also to the host’s BC profile. These preliminary 
reports indicate that the association of BC parameters and DCs are synergistic, and 
may be particularly attractive from a clinical point of view. Further studies are 
necessary to better clarify the contribution of BC to DC impairment and to explore 
and optimize treatment modalities such as DCs targeted immunotherapy.  
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Chapter 9 
9! The relationship of Local Inflammatory Response with BC and its 
prognostic utility for CRC outcomes 
 
9.1! Introduction 
 
Virchow first described the link between cancer and inflammation, suggesting that 
the “lymphoreticular infiltrate” at sites of chronic inflammation reflected the origin 
of cancer.(Mantovani et al., 2008) The local tumor microenvironment plays an 
important role in carcinogenesis including, cell growth; invasion and metastasis and 
these effects are mediated via host-derived stromal cells and cytokines. Jass first, in 
1986 proposed that infiltration of immune cells can act as an independent prognostic 
factor in CRC, and since then the local inflammatory response (LIR) has been 
accepted as a major factor in the pathogenesis of cancer. (Jass, 1986).  A number of 
studies followed that demonstrated that infiltration of inflammatory cells in CRC is 
associated with improved survival, regardless of the stage of the disease (Roxburgh & 
McMillan, 2012). Despite the potential of a prognostic tool, there is no agreement as 
to which individual cell type is most important due to the heterogeneity of the 
different cellular subtypes and the inconsistency between the regions of interest on 
the specimen reported.   
Klintrop et al tried to simplify the assessment of inflammatory cell infiltrate in CRC 
with a robust grading system (KM grade) of the inflammatory infiltrates on routine 
haematoxylin and eosin (H&E) stained sections (Klintrup et al., 2005). Galon et al 
also attempted to improve the reporting of the LIR using more sophisticated 
techniques such as tissue microarrays and focusing on the intratumoral immune 
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infiltrates in the center of the tumour and in the invasive margin (Mlecnik et al., 
2011). However the mechanisms by which a local immune response improves 
outcomes in CRC are not known and its is still unclear whether host’s related 
factors such as BC parameters, surrogate markers of global health such as age or 
pathological features of the tumour are related to the LIR.     
Originally, chemokines and their receptors were reported to mediate different pro- 
and anti-inflammatory responses.(Zlotnik & Yoshie, 2000) LIR depends on the ability 
of immune cells to actively migrate in and out of tissue, and chemokines are 
established regulators of immune cell migration and survival. Two essential 
chemokines involved in cell movement during homeostasis are CC-chemokine ligand 
19 (CCL-19) and 21 (CCL-21), that are ligands for the CC-chemokine receptor 7 
(CCR-7).  CCR7 is expressed on naıve T cells, memory T cells, B cells, and mature 
dendritic cells, and is considered to play an important role in lymphocyte cell 
trafficking and homing to lymph nodes. (Forster, Davalos-Misslitz, & Rot, 2008) In 
cancer, CCR7 expression on immune cells regulates homing of lymphocytes into 
secondary lymphoid organs and may also be involved in the lymphatic spread of solid 
tumors. (Grivennikov, Greten, & Karin, 2010). In Chapter 7 we identified that in 
CRC, circulating DC are activated and potentially lymph node homing (CCR7 high). 
Evidence also suggests that assessment of the CCR7 expression on CRCs specimens 
might improve prediction not only of the survival outcome but also of lymph node 
spread. (Mei et al., 2014) 
The aim of the present study was a.) to examine the relationships between the LIR 
assessed by the KM grade, BC parameters and pathological factors in patients 
undergoing curative resection for CRC b.) to determine the expression of CCR7 on 
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tumour infiltrating cells in primary CRC and investigate its impact on disease 
progression and survival and finally c.) to correlate the expression of CCR7 with the 
patients’ clinical and pathological parameters (including their body composition).  
9.2! Patients and methods 
 
9.2.1! Study population 
 
A total of 242 consecutive patients with primary CRC who underwent elective 
resection at St Mark’s Hospital between January 2009 and December 2011 were 
identified from a prospective database. Patients with recurrent or metastatic disease 
confirmed preoperatively or at surgery, emergency cases, those receiving 
neoadjuvant chemotherapy and/or radiotherapy, and those with a non-available pre-
operative CT were excluded. All recorded clinical and pathological data were 
revalidated from medical and pathology records. Data collected prospectively during 
the perioperative period included age, sex, Body Mass Index (BMI), histological 
grading, TNM stage (UICC 5 version), the presence of vascular invasion and 
histopathological grade of differentiation. 
9.2.2! Tissue Samples  
 
Colorectal cancer paraffin embedded tissue blocks were obtained from all the 
patients meeting the selection criteria.   
9.2.3! Immunohistochemical Analysis 
 
Preparation of sections from paraffin blocks was performed by standard methods. 
Immunohistochemical analysis of CCR7 was performed using a mouse monoclonal 
antibody against human CCR7 (CCR7 MAb (Clone 150503) Cat# MAB197). 
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Immunohistochemical staining of CCR7 was performed using an automated 
procedure (Automated Immunostaining Ventana Benchmark®XT XT ultraView 
DAB), according to the manufacturer's protocol. Briefly, the 4-µm paraffin-
embedded tissue sections were subjected to deparaffinization and rehydration prior 
to be immersed in 0.01 M citric buffer (pH 6.0). The mouse monoclonal antibody 
against human CCR7 (Clone 150503 Cat# MAB197) was diluted (Antibody 
Conc=0.25mg/ml @ 1:50 (Dako S2022 Diluent) = 5ugml) and filled into a Ventana 
antibody dispenser. Trials of different dilutions were also considered and the final 
dilution was chosen after careful review of the slides.  The Ventana staining 
procedure included pre-treatment with Cell Conditioner 2 (pH 6) for 60 min 
(standard), followed by incubation with 1:50 diluted antibody clone at 37 °C for 32 
min. Upon antibody incubation Ventana standard signal amplification was performed 
with ultraWash, countering with one drop of Hematoxylin for 8 min and one drop 
of bluing reagent for 8 min. For chromogenic detection ultraView Universal DAB 
Detection Kit (Ventana) was used. This kit provides synthetic, non-endogenous 
haptens per primary antibody, and subsequently delivers the sensitivity needed to 
visualize even low expressing antigens. Slides were removed from stainer, washed in 
water with a drop of dishwashing detergent and mount. As negative control the first 
monoclonal antibody was replaced by an isotype control antibody in the same 
dilution. Using this technique, no staining of the colon tissue was detectable. Lymph 
node tissue was used as a positive control stained with same conditions. Figure 9-1. 
Negative and positive controls slides 
9.2.4! Image Analysis 
 
Images of immunostained slides were digitized at 40X magnification using the Leica 
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SCN400F. For digital quantification, image analysis software (Tissue Studio v.3.5; 
Definiens AG, Munich, Germany) was used to distinguish the CCR7+ cells. We 
focused on three main regions of interest (tumor margin, tumor stroma and 
tumour). Two independent assessors graphically mapped these regions using the 
image software. Cells were considered to either positive (+) or negative (-) 
according to presence of clearly defined positively stained cytoplasm in a granular 
distribution. Faint ill-defined staining was considered to represent an artifact and 
considered negative. The image analysis software was calibrated accordingly. The cell 
density defined as the percentage of the area containing CCR7+ cells (summed area 
with CCR7+ cells / total measured area x 100) was calculated for each slide.  Figure 
9-2 shows an example of the Immunohistochemical staining with CCR7 
9.2.5! Immune score 
 
In an attempt to directly relate CCR7 expression with LIR, a previously proposed 
method for assessing the LIR in CRC, the Klitrup-Makinen (KM) grade was applied 
(Klintrup et al., 2005). Using the corresponding H&E-stained sections of the study 
population, inflammatory cell infiltration at the invasive margin was graded using a 
four-point scale and subsequently classified as low grade (no increase or mild/patchy 
increase in inflammatory cells) or high grade (prominent inflammatory reaction 
forming a band at the invasive margin, or florid cup-like infiltrate at the invasive edge 
with destruction of cancer cell islands), by two independent assessors. An 
independent third reviewer resolved any discrepancies. Table 9-1 summarizes the 
KM grading system 
9.2.6! Body Composition Analysis 
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Images were retrieved from digital storage in the Picture Archiving and 
Communication System [PACS]. CT image analysis Slice-O-Matic V4.3 software 
(Tomovision, Montreal, Canada) was performed as described Chapter 4. 
 The sum of skeletal cross-sectional muscle areas was normalised for stature (m2) 
and reported as LSMI (cm2m-2). Mean Muscle Attenuation [MA] (HU) was reported 
for the whole muscle area at the third lumbar vertebra level. Reduced L3 skeletal 
muscle index (myopenia) and low MA (myosteatosis) were defined using predefined 
sex-specific skeletal muscle index cut-points. (Martin et al., 2013) Increased visceral 
adipose tissue area (visceral obesity) was also described by using gender-specific and 
pathologically relevant cut-off values. (Doyle et al., 2013) 
9.2.7! Statistical Analysis 
 
The relationship between CCR7 expression and other clinicopathological 
parameters was assessed using nonparametric statistics. Clinical outcomes were 
assessed using the Kaplan-Meier survival curves, and the groups were compared 
using the log-rank test. Stepwise multivariate Cox proportion analysis was 
performed. The level of significance permitting multivariate analysis inclusion and the 
statistical significance for all other tests used was set at P < 0.05. All analyses were 
performed using the statistical software, Statistical Package for the Social Sciences, 
version 20.0 (SPSS, Inc, Chicago, IL).  
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Figure 9-1 Negative and positive controls slides 
  
 281 
 
 
 
Figure 9-2 Original example of Immunohistochemical staining with CCR7  
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Table 9-1 Klintrup-Makinen grading system.  
Low inflammatory reaction was defined as Grade 0 or 1 whereas High inflammatory 
reaction was defined as Grade 2 or 3. 
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9.3! Results  
 
9.3.1! Patient Selection 
 
Of 242 consecutive patients undergoing surgical resection, 42 cases had a 
preoperative CT scan stored in a paper film form and, therefore, unsuitable for 
analysis, 27 had had emergency surgery, 30 had recurrent or metastatic disease at 
the time of surgery, 9 received neo-adjuvant treatment, and for 18 the CT analysis 
was not possible due to poor image acquisition quality. Exclusion of these patients 
resulted in a sample size of 116 patients who had undergone elective resection for 
CRC. 
9.3.2! KM score and clinical and pathological parameters 
 
After assessing the corresponding H&E-stained sections, 38% (n=54) of the study 
population had high KM grade. The presence of high KM grade was only significant 
associated with the grade of differentiation. Poorly differentiated tumours had higher 
KM grade compared to well and moderate differentiated tumours (p=0.023). There 
was no significant association between KM grade with age, gender, BMI, site of 
tumor, lymph node metastasis, lymphovascular invasion, or any CT BC parameter. 
 
9.3.3! Distribution of CCR7+ cells in CRC  
 
Staining was achieved in all 116 specimens with the majority showing homogeneous 
staining and, different intensities were frequently observed. Staining expression of 
CCR7 was observed mainly at the tumour margin, and stroma but also in the 
primary tumour. Image software analysis from all the specimens revealed a median 
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tumor infiltrating CCR7+ cell density of 15.85 % (Inter Quartile Range (IQR) 10.02-
21.83 %) in the tumor stroma, and 7.17 % (IQR 3.90-12.37 %) at the tumor margin. 
CCR7+ cell density of the two areas correlated positively (Spearman r = 0.77; 
p<0.001). The median CCR7+ cell density for the tumour cells was 16.78 % (IQR 
7.28-22.76).  We divided the cases into high and low CCR7+ groups according to 
the median value of CCR7 + cell density. Figure 9-2 demonstrates the distribution of 
CCR7+ cells in CRC.  
9.3.4! CCR7+ cells and clinical and pathological parameters 
 
High CCR7+ cell density at both the tumor center and the margin was significantly 
associated with older age, higher tumor stage, lymph node metastasis and the 
presence of myosteatosis. High CCR7+ cell density at the tumor margin was also 
significantly associated with female sex and the presence of lymphovascular invasion. 
There was no significant association between CCR7+ cell density either at the 
margin or within an intra-tumoral location with BMI, site of tumor, grade of 
differentiation, myopenia or visceral adiposity.  A high KM grade was identified in 38 
% of the cases studies and this was significantly associated with the CCR7+ cell 
density at the tumour margin but not in the stroma. High density of CCR7+ tumour 
cells was significantly associated with higher tumor stage, lymph node metastasis and 
the presence of lymphovascular invasion. Table 9.2 demonstrates the correlation 
between tumor-infiltrating CCR7+ cell density and clinicopathological factors in 
patients with CRC who had been treated surgically. 
9.3.5! CCR7+ cells and Clinical Outcome of Colorectal Cancer 
 
Among the 116 patients, there were 13 recurrences and 18 deaths during a median 
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40-month follow-up (IQR 15-50 months). Kaplan–Meier analysis demonstrated that 
high CCR7+ cell density at the tumor margin was significantly associated with 
shorter disease-free and overall survival (log-rank test, p=0.031 and p=0.022; 
respectively). Figure 9.3 demonstrates the Kaplan-Meier graphs of CRC overall 
survival (OS) and disease free survival (DFS) after resection for CRC according to 
CCR7+ cell density at the tumor margin and the stroma. 
To determine the independent prognostic significance of CCR7+ cell density on DFS 
and OS, multivariate analysis using a Cox proportional hazards model was 
performed. High CCR7+ cell density at the tumor margin was significantly associated 
with shorter DFS and OS in multivariate regression analysis (HR=8.87; 95%CI (2.51-
31.3); p<0.01 for OS and HR=4.72; 95%CI (1.24-12.9) p=0.02 for DFS) as outlined in 
Table 9.3. However, a high CCR7+ cell density in the tumor stroma or in the 
tumour cells was not an independent prognostic factor for DFS or OS in this study. 
Lymph node metastasis and grade of differentiation were identified as being 
independently prognostic factors for OS and grade of differentiation was also an 
independent prognostic factor for DFS. 
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Figure 9-3 CCR 7 cell immunohistochemistry  
Shows high (A,C) and low (B,D) infiltration of CCR7+ cells in the stroma (A,B) and 
the tumour periphery (C,D). 
 287 
 
 
 
 Cell Density of CCR7 positive cells in the tumour 
periphery 
 Cell Density of CCR7 positive cells in the 
tumour stroma 
 
High Low P-
value 
High Low P-
value No of cases Row N % No of cases Row N % No of 
cases 
Row N 
% 
No of 
cases 
Row N 
% 
Gender Male 30 41.7% 42 58.3%  34 47.2% 38 52.8%  
Female 29 65.9% 15 34.1% 0.011 26 59.1% 18 40.9% 0.215 
Age Categories <70 years 26 41.3% 37 58.7%  27 42.9% 36 57.1%  
>=70years 32 62.7% 19 37.3% 0.023 32 62.7% 19 37.3% 0.035 
BMI Categories <25 15 53.6% 13 46.4%  15 53.6% 13 46.4%  
>25 40 48.2% 43 51.8% 0.623 41 49.4% 42 50.6% 0.702 
Site Colon 40 54.8% 33 45.2%  42 57.5% 31 42.5%  
Rectum 19 44.2% 24 55.8% 0.270 18 41.9% 25 58.1% 0.103 
T stage T1+T2 15 35.7% 27 64.3%  15 35.7% 27 64.3%  
T3+T4 44 58.7% 31 41.3% 0.017 45 60.0% 30 40.0% 0.012 
Lymph Node 
Metastasis 
Absent 32 40.5% 47 59.5%  35 44.3% 44 55.7%  
Present 27 71.1% 11 28.9% 0.002 25 65.8% 13 34.2% 0.029 
Lymphovascular 
Invasion 
Absent 36 43.9% 46 56.1%  41 50.0% 41 50.0%  
Present 23 65.7% 12 34.3% 0.031 19 54.3% 16 45.7% 0.671 
Grade of 
Differentiation 
Well + 
Moderate 
52 49.5% 53 50.5%  53 50.5% 52 49.5%  
Poor 7 58.3% 5 41.7% 0.563 7 58.3% 5 41.7% 0.606 
 
K-M grade 
Low 29 40.3% 29 59.7%  33 45.8% 39 54.2%  
High 29 65.9% 15 34.1% 0.007 26 59.1% 18 40.9% 0.166 
Myosteatosis No 11 30.6% 25 69.4%  11 30.6% 25 69.4%  
Yes 47 58.8% 33 41.2% 0.005 48 60.0% 32 40.0% 0.003 
Myopenic obesity No 46 47.9% 50 52.1%  47 49.0% 49 51.0%  
Yes 9 52.9% 8 47.1% 0.702 10 58.8% 7 41.2% 0.453 
Myopenia No 29 55.8% 23 44.2%  28 53.8% 24 46.2%  
Yes 30 46.2% 35 53.8% 0.301 32 49.2% 33 50.8% 0.559 
Visceral Obesity No 20 46.5% 23 53.5%  24 55.8% 19 44.2%  
Yes 39 52.7% 35 47.3% 0.518 36 48.6% 38 51.4% 0.455 
Table 9-2 Correlation between tumour-infiltrating CCR7-positive cell density and clinic-pathological factors in patients with CRC treated 
surgically  
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Table 9-3 Tumour-infiltrating CCR7-positive cell density in Colorectal Cancer and Patient outcomes 
  Overall Survival Disease Free Survival 
  Univariate Multivariate Univariate Multivariate 
      
 OR; 95%CI P-value OR; 95%CI P-value OR; 95%CI P-value OR; 95%CI P-value 
CCR7 + cell density 
in tumour periphery 
Low 1  1  1  1  
High 3.17 (1.12-8.94) 0.03 8.87 (2.51-31.3) <0.01 3.77 (1.03-13.7) 0.04 4.72 (1.24-12.9) 0.02 
CCR7 + cell density 
in tumour stroma 
Low 1    1    
High 2.51 (0.93-6.75) 0.07   1.63 (0.53-5.04) 0.38   
CCR7 + cell density 
in tumour cells 
Low  1    1    
High 3.37 (0.89-9.52) 0.08   4.13 (0.83- 15.1) 0.06   
Gender Male 1    1    
Female 0.60 (0.21-1.71) 0.34   0.51 (0.14-1.89) 0.31   
Age Categories <70 years 1  1  1    
>=70years  2.31 (1.09-6.54) 0.04 1.39 (0.48-4.00) 0.54 0.56 (0.17-1.87) 0.35   
BMI Categories <25 1    1    
>25 0.61 (0.22-1.68) 0.34   0.60 (0.20-2.26) 0.53   
Site Colon 1    1    
Rectum 1.40 (0.54-3.64)    1.49 (0.48-4.63) 0.49   
T stage T1+T2 1    1    
T3+T4 0.87 (0.23-1.98) 0.23   1.31 (0.40-4.27) 0.65   
Lymph Node 
Metastasis 
Absent 1  1  1  1  
Present 3.17 (1.23-8.28) 0.02 4.07 (1.14-14.5) 0.03 2.13 (1.02-5.97) 0.04 1.99 (0.59-6.62) 0.26 
Lymphovascular 
Invasion 
Absent 1  1  1    
Present 2.57 (1.01-6.53) 0.04 1.46 (0.42-5.01) 0.54 2.28 (0.77-6.81) 0.14   
Grade of 
Differentiation 
Well + Moderate 1  1  1  1  
Poor 5.43 (2.10-14.0) <0.01 4.91 (1.68-14.3) <0.01 5.10 (1.56-16.6) 0.01 4.19 (1.18-14.8) 0.03 
K-M grade Low 1    1    
High 2.07 (0.81-5.27) 0.12   1.32 (0.44-3.92) 0.62   
Myosteatosis No 1    1    
Yes 0.93 (0.34-2.67) 0.89   1.01 (0.31-3.26) 0.98   
Myopenia No 1    1    
Yes 2.83 (0.93-8.65) 0.07   1.41 (0.46-4.30) 0.55   
Visceral Obesity No 1    1    
Yes 0.80 (0.32-2.04) 0.64   0.58 (0.19-1.73) 0.33   
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Figure 9-4 Kaplan-Meier graphs of colorectal cancer overall survival (OS) and 
Disease free Survival (DFS) after resection for CRC according to CCR7+ cell density 
at the tumour periphery (a,c) and stroma (b,d). 
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9.4! Discussion 
 
This study demonstrated that a high density of tumor-infiltrating CCR7+ cells was 
significantly associated with age, histological invasion, higher tumor stage, lymph 
node metastasis, high grade of inflammatory response (KM score), and myosteatosis 
that are adverse prognostic factors in CRC. Moreover, high CCR7+ cell density in 
the tumor margin was significantly associated with shorter DFS and OS. Our findings 
suggest that tumor-infiltrating CCR7+ cells are associated with a more aggressive 
cancer.  
The mechanisms by which LIR affects prognosis in patients with CRC are not clear. 
The present study did not demonstrate any association between the grade of LIR 
and surrogate markers of global health such as age or host’s characteristic such as 
BC. However, the present study found an association between infiltration of CCR7+ 
cells, at the tumor margin and within the tumor stroma, with some of the 
clinicopathological variables examined. In particular, high CCR7 density in the tumor 
margin and stroma were directly correlated with adverse prognostic factors such as 
increased age, advanced T and N stage and the presence of myosteatosis.  These 
findings may therefore suggest a model whereby the stimulus for the local immune 
cell response is not only induced by the tumor but also influenced by host-related 
factors. In Chapter 6, we have demonstrated an association between myosteatosis 
and the presence of an altered systemic inflammatory response in patients treated 
for CRC. Also in Chapter 8 a negative correlation was described with the DC 
expression of the migration marker CCR7 with the myosteatosis status of the host 
expressed as mean MA. We have now identified that myosteatosis is additionally 
related to an adverse local inflammatory response as measured by a high CCR7 
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density. To our knowledge these findings are novel and may support the hypothesis 
not only the host SIR but also the LIR may influence the development and 
persistence of myosteatosis. 
Retrospective studies on various cancers have shown that tumor cells express 
CCR7, including breast, (Muller et al., 2001) melanoma, (Takeuchi et al., 2004) 
oesophageal, (Y. Ding et al., 2003) lung, (Takanami, 2003) head and neck (Mburu et 
al., 2012) and CRC.(Gunther et al., 2005). Ongoing oncogenic mutagenesis within 
the tumor can lead to increased expression of chemokine receptors including CCR7, 
but also tumor-derived factors such as VEGF and PGE2 may contribute to this over-
expression.(Chuang, Pan, Hou, & Hung, 2013; A. Issa, Le, Shoushtari, Shields, & 
Swartz, 2009; D. Wang & DuBois, 2013) Therefore, increased expression of CCR7 
on immune cells infiltrating the tumor mass can be attributed to this tumor behavior. 
Increased on-going chemokine production by the tumor will attract immune cells 
and up-regulate the expression of CCR7. (F. R. Balkwill, 2012) In our study, we have 
specifically focused on the critical interface between tumor and the stroma and the 
margin excluding tumor tissue itself. Therefore, CCR7+ cells from our study will 
mainly consist of immune cells known to express CCR7, such as T cells, antigen 
presenting cells and stroma cells. This is further supported by the observation that 
high expression of CCR7 at the tumour margin was strongly associated with high 
grade of inflammatory response measured with the KM score. 
The impact of CCR7+ non-tumor cells on CRC outcomes has been recorded 
previously, but the results were controversial: Gunther et al. studied the expression 
of CCR7 on paraffin-embedded tumor specimens of 99 all stages CRC patients and 
concluded that increased CCR7 expression at the invasion margin was associated 
 292 
with worse OS. (Gunther et al., 2005) Similarly, Schimanski et al. studied the 
expression of CCR7 and another chemokine receptor, CXCR4, on tumor specimens 
of 96 CRC patients of all stages. (Schimanski et al., 2005) However, only increased 
CXCR4 expression was associated with poorer outcome, not CCR7 expression. 
Correale et al. studied the expression of CCR7 on tumor-infiltrating T cells in 76 
patients with metastatic CRC. The results demonstrated that high expression of 
CCR7 positive tumor infiltrating lymphocyte, specifically CD8+ CCR7+ cells, was 
predictive of good outcome in patients with advanced CRC. (Correale et al., 2012) 
Previous studies have shown a beneficial role of infiltrating CD8+ cells in outcome in 
CRC. (Naito et al., 1998),(Pages et al., 2009),(Ling, Edin, Wikberg, Oberg, & 
Palmqvist, 2014) Therefore, expression of CCR7 on CD8+ cells in CRC could 
correlate with improved outcome, especially in advanced CRC. In the present study, 
on a population of 116 patients with non-metastatic CRC, multivariate analyses 
demonstrated that high CCR7+ cell density at the tumor margin is significantly 
associated with shorter DFS and OS. Our results suggest that CCR7+ cell density at 
the tumor margin may be a novel prognostic biomarker to predict outcomes in 
patients with early CRC.  
Our analyses showed that in the tumor periphery, high CCR7+ cell density was 
associated with high KM score. A recent study reported that high KM score 
correlated with markers of infiltrated peritumoural inflammatory cells (CD3, CD8, 
CD68 and FoxP3 cells), but no association was identified with DC density 
determined using CD1a+ cells. (Vayrynen et al., 2013) Therefore, it is possible to 
infer that CCR7 positivity in our study was mainly due to expression on the 
inflammatory cells described above. Our results also suggest that despite increased 
LIR in the tumor peripheries (demonstrated by high KM score), high expression of 
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CCR7 in these immune cells may have an impact and key role for the development 
of an efficient immune response. This highlights the importance of determining the 
characteristics of tumor infiltrating inflammatory cells, rather than only the density 
or count of inflammatory cells determined by KM score. 
This study has a number of limitations. The identification and classification of specific 
cell types expressing CCR7 was not performed. However, the main aim of this work 
was to investigate the overall stromal expression of CCR7 in the tumor margin and 
the stroma of the colorectal tissues and whether this expression is an indicator of 
undesirable prognosis in patients with CRC. Results were encouraging and pave the 
way to assess the prognostic value of the expression of CCR7 on particular cell 
types, which will be the subject of future work. Although CCR7 expression was 
observed on the tumour cells we focused only on the tumor margin and stroma. The 
primary reason for this approach is that the tumor stroma and margin represent a 
vital compartment of the tumor microenvironment that reflects LIR, affects tumor 
progression and metastasis (Quail & Joyce, 2013) and also because the expression of 
CCR7 on tumor cells has been previously reported.  
9.5! Conclusion 
 
In summary, the results of the above study, give additional support to the prognostic 
significance of the LIR in CRC. Moreover, our results suggest that CCR7 positive cell 
density at the tumor margin may be a novel prognostic biomarker to predict 
outcomes in patients with CRC.  
Acknowledgement: Source BioScience, Nottingham, UK, performed the 
immunohistochemical staining for this study. The optimization of the staining was 
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Chapter 10 
10! General Discussion 
 
At the outset of this period of research it was recognized that disease progression in 
CRC patients is determined not only on pathological stage but also on complex 
interactions between tumour and host –related factors. Emerging body of evidence 
suggested that the chronic presence of a low grade SIR could have an important 
prognostic utility in patients treated for CRC. Similarly, local immune response and 
specific inflammatory infiltrates were related to CRC progression. Such inflammatory 
responses are key components of both the innate and the adaptive immune system. 
DCs play a key role against carcinogenesis and cancer progression, as they are 
decision makers determining whether the adaptive arm of the immune system should 
or should not be turned on. Despite this knowledge the drivers for an ongoing SIR 
and an effective local immune cell reaction remained unclear but was hypothesized 
to be either tumour related or host burden.  
In cancer, inflammation and decreased physical activity are key characteristic 
features. Although bed rest alone can result in approximately 5% loss of lean body 
mass in healthy volunteers, the effects of severe stress combined with muscle 
unloading can be two to three fold greater. The SIR involves stimulation of 
numerous mediators (mainly cortisol and proinflammatory cytokines), which directly 
can activate autophagy in skeletal muscle as well as inhibit synthesis of myofibrillar 
proteins and has been proposed as contributing factor to the development of muscle 
depletion. These changes are enhanced by factors including sex hormones and insulin 
like growth factor-1 and glucocorticoid therapy. In cancer, chemotherapy-related 
toxicity and side effects are more prevalent in muscle-depleted patients and muscle 
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mass appears to predict the risk of toxicity better than body surface area. In 
addition, muscle loss is associated with poorer patient recovery and survival 
following cancer treatment. It has also been reported that BMI obesity confers a 
survival advantage in patients treated for cancer although the basis of this 
observation has been widely criticized. (see Chapter 1)Therefore, the view is 
evolving that BC profiles of the host is regarded as one of the major contributors to 
negative outcomes of cancer, including loss of autonomy and impaired quality of life.  
A number BC measurement have been proposed methods including assessments at 
the atomic, molecular, cellular, tissue-system and whole-body levels exist. 
Techniques include bioelectrical impedance analysis, dilution techniques, air 
displacement plethysmography, and image-based approaches; dual energy X-ray, 
magnetic resonance imaging, and computer tomography (CT). CTBC imaging is 
particularly relevant in patients with solid cancers such as CRC as it is routinely 
employed for disease staging and therefore can be assessed with little increase in 
healthcare costs. Skeletal muscle and adipose tissue areas at the lumbar vertebral 
landmark (L3) have been shown to correspond to whole-body tissue quantities in 
nonmalignant populations as well as in cancer patients. It is also feasible using 
Hounsfield Unit disparity in skeletal muscle tissue to determine intramyocellular lipid 
accumulation; a term called myosteatosis; related to pain, functional decline, obesity 
and insulin resistance. The majority of the studies in this field had concentrated on 
BMI obesity and very few investigated the potential role of other BC profiles on 
CRC outcomes. Moreover, hardly any study tried to link the systemic and local 
immune response observed in CRC patients with CT BC parameters.  
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As an extension to the above work Chapter 3 systematically reviewed the literature 
to evaluate the role of CTBC analysis in relation to the short-term, oncological, and 
long-term outcomes for CRC patients. Also the current limitations for this 
methodology were examined and areas of improvement were identified. The 
evidence strongly suggested that skeletal muscle and visceral adipose mass might 
have prognostic significance. The distribution of skeletal muscle is lower at a higher 
degree of adiposity especially in men who store more adipose tissue at the trunk 
compared to women who proportionally store more adipose tissue at the limbs 
hence using sex specific cut-off values to report on BC profiles has an advantage. 
Due to the heterogeneity in protocols and the limited study populations used by the 
current evidence, data aggregation was not possible. Such inconsistencies contribute 
to a great variety in prevalence estimates and limit comparative evaluation of 
interventions directed against BC profiles. Similarities in the pathology, overlapping 
etiology and consequences justify a unique definition and diagnostics of myopenia and 
visceral obesity in cancer. Potential future research should focus on a careful 
statistical modeling based on age, gender, adipose mass and disease specific 
characteristics and meta –analytic approaches so as to optimize CTBC analysis and 
influence clinical practice.   
 The prevalence of different CT defined BC profiles including visceral obesity, 
myopenia, myosteatosis, their impact on short outcomes and their prognostic utility 
on short and long term outcomes in patients treated surgically for CRC were 
evaluated in Chapter 4. To date, this is the first study to have tested various CTBC 
profiles and concluded that myopenia and not BMI, is an independent prognostic 
factor for poorer OS and DFS after CRC surgery; promoting the view that the 
analysis of cross-sectional imaging is a more accurate way to quantify BC in patients 
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with cancer. The presence of myosteatosis was related to prolonged LOS and obese 
patients with myopenia undergoing surgery had increased rate of major 
postoperative complications and more deaths than those who were not categorized 
with myopenic obesity. These observations may reflect a slow functional recovery 
inherent in these patients and also a poor physiological state directly related to 
muscle depletion rather than the adiposity, prone to develop surgical and septic 
complications. In the past, people being treated for chronic disease, including cancer 
were often advised by their physician to rest and reduce their physical activity. This 
is suitable advice if movement causes pain, cardiac or respiratory distress. These 
results support a concept whereby early identification of these muscle depleted 
patients and prompt interventions such as exercise and nutritional support can 
improve their physically function, quality of life and cancer outcomes. 
Chapter 5 attempted to determine the role of SIR and more specifically the neutrophil 
to lymphocyte ratio (NLR) as a prognostic marker for patients with CRC undergoing 
curative resection and to gain insight into the patient factors associated with systemic 
inflammation in patients with CRC. A ROC analysis identified the value of 3 as the 
optimal value for NLR in relation to DFS and OS. The results demonstrated that a 
preoperative NLR of more than 3 was an independent predictor of CRC survival 
outcomes.  A high NLR was significantly associated with age, higher T and N stage, 
presence of micro vascular invasion, low preoperative albumin level and ASA status 
of the patient but not related with gender, histological tumour grade, primary 
tumour site, surgical approach and major complication after surgery. These 
relationships raised the possibility that altered SIR was a result of disease 
aggressiveness or host related drivers. The role of NLR in predicting survival for 
patients with CRC undergoing treatments and its utility within a CRC surveillance 
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programme was further established through a systematic review and metanalysis of 
the literature. Nonetheless, the results of this Chapter highlighted the importance of 
SIR in the poor outcome in patients with CRC inflammation and support the 
hypothesis that SIR generates not only cancer-promoting microenvironment changes 
but also systemic changes that are favourable for cancer progression. In relation to 
future work, it would be considerable interest to focus on the moderation of the SIR 
as a therapeutic target in cancer patients. Aiming at the SIR, the administration of 
aspirin, statins or NSAIDs drugs can offer potential therapeutic strategies.  
Chapter 6 examined the influence of SIR on the BC of patients undergoing surgery 
for CRC. The results proved a strong association between low skeletal muscle mass 
and myosteatosis with the presence of an altered SIR in patients with primary 
operable colorectal cancer. It was of interest that tumour characteristics such as 
stage, grade of differentiation and lymphovascular invasion and other clinical factors 
such as BMI and ASA were not directly related to the presence of myopenia or 
myosteatosis; a result which suggests the muscle depletion in cancer cachexia is 
driven not by tumour biology or physiological features but rather through the host 
SIR. Traditionally, controlling the progress of the cancer has been viewed as an 
appropriate method to contain loss of muscle. However the results of this study 
support the foundations of targeting the SIR as a therapeutic intervention to maintain 
and restore muscle mass and ultimately too improve outcomes.  
One of the limitations of the CT analysis as a valid and convenient approach for 
determining BC synthesis is the fact that is a “ snapshot”, a static window of the 
patient’s pathway. Moreover neither the point of onset of muscle depletion nor the 
patterns of muscle alterations over time and their precipitants are known. Chapter 7 
 300 
sought to explore patient skeletal muscle index trajectories over time after surgery and 
identify factors that may contribute to those alterations. Results demonstrated that 
patients with older age, female gender, high preoperative SIR and high ASA maintain on 
average low LSMI over time compared to their opposite groups. Also showed that 
laparoscopy offered a positive change on the LSMI slope whereas UICC stage III+ IV 
contributed on a negative slope change, over time. This analysis represents the first 
documented link between SIR and maintenance of low levels of muscle mass in patients 
with colorectal cancer at the postoperative phase. Also for the first time it was 
demonstrated that laparoscopy can have a positive impact on restoration of the muscle 
postoperatively. These emerging data may permit the development of new treatment 
protocols targeting the SIR and the adoption of laparoscopy to modify and restore the 
host’s BC that may have a positive impact upon CRC survival.  
Previous work had established that an increase in lipid content of DCs diminishes 
their capacity to present antigens from tumour cells and to activate effector T cells 
and also that clinical obesity negatively impacts the ability of systemic DCs to mature 
and elicit an appropriate immune response. These suspected links between DC 
dysfunction in cancer at the cellular and tissue BC level led to the aims of chapter 8. 
This study using circulating blood DCs and flow Cytometry analysis aimed to 
characterize and compare the phenotype of circulating DC in patients with CRC disease 
and healthy controls. The possible links between the peripheral blood DCs 
phenotype, BC parameters and pathological characteristics of the tumour were also 
studied. Methods established in our laboratory have allowed us to identify and 
phenotype freshly isolated human circulating DCs from CRC patients and healthy 
individuals. Monoclonal antibody labeling and flow cytometry were used for DC 
analysis and this approach has enabled to characterise DC.  
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Evidence is limited with regards the phenotypic differences between blood DCs in 
CRC and healthy controls and this study stands upon the first to do so. The 
circulating DCs from the CRC group were of a more mature phenotype as seen by 
the increased expression of the surface molecules CD40 and CD83 and potentially 
lymph node homing as seen by the increased expression of CCR7.  We hypothesized 
that these differences may partly due to the interaction with tumour-derived factors 
or due to host parameters such as BC. Moreover, questions were raised with 
regards the life cycle of a mature DC since the current theory suggests that DCs die 
after the interaction with the T-cells in the lymphoid tissues. To explain our findings 
i.e the presence of systemic mature and lymph node homing DCs in cancer patients 
the theory of recirculation was also argued. Phenotypic postoperative changes were 
also studies demonstrating that CD 40 levels on blood DCs are reducing after the 
removal of the tumour supporting the theory that the driver for the immunological 
differences is tumour-derived factors. Further studies are needed to explain the 
mechanisms through these changes in DC immunobiology occur.  
The expression on peripheral DCs of the activation marker CD 40 was positively 
correlated with the muscle mass of the host. Negative correlations were seen with 
the DC expression of the co-stimulatory molecule CD83 and the migration marker 
CCR7 with the myosteatosis status of the host. Disease pathological features such, 
as T, N stage and grade of differentiation of the CRC tumour were associated with 
significant differences between DC phenotypes. To link muscle depletion, obesity, 
and changing immunity in cancer, we assumed that these conditions are related 
processes, which are controlled by adipose tissue derived and skeletal muscle-
derived cytokines. It has been suggested that pro-inflammatory molecules that 
account for the chronic presence of SIR in cancer such as TNF-a, IL-6 and IL-1 can 
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negatively regulate muscle and cause DCs dysfunction. This study is amongst the first 
to provide evidence that muscle tissue is linked with phenotypic changes in DCs and 
to pave the way for better understanding of the host impact on immune function. 
The time sequence of the development of SIR, muscle depletion and immune 
dysfunction still remains unknown and it will be very difficult to answer. Prospective 
registry driven studies that account for measuring SIR, BC and immune cells 
phenotype and function at different time points before and after the removal of a 
CRC tumour might provide us with a better understanding. 
The results from Chapter 8 and especially the phenotypic differences in CD 40 
between CRC and healthy controls and the correlation to patient’s muscle mass can 
provide additional evidence in support of agonistic anti-CD40 monoclonal antibodies 
in CRC immunotherapy. Recent trials on anti-CD40 mAbs rarely comment on 
human studies on CD40 expression on DCs in cancer and they are mainly based on 
animal studies, despite innate differences in blood and tissue DC types between mice 
and humans (Lee et al., 2014). Our results on expression of CD40 on DCs in CRC 
may provide insight into how different BC profiles influence DC phenotype and 
function and may provide valuable information on selecting patients that may be 
more suitable for therapeutic use of anti-CD40 mAbs. 
In Chapter 9 a more detailed analysis of the local immune response in CRC tumours 
was performed. First we sought to identify relationships between BC parameters and 
pathological factors using a simple and inexpensive way to grade inflammatory cell 
density on routinely stained sections of CRC, the KM grade. The study did not 
demonstrate any association between the grade of LIR and surrogate markers of 
global health such as age or host’s characteristic such as BC but KM was only 
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associated with the grade of the tumour. When a different approach was implement 
i.e instead of commenting at the cell infiltration pattern, the characteristics of the 
tumour infiltrating cells determined at this instant with the expression of the CCR-7 
surface marker significant relationships were demonstrated. The results showed an 
association between infiltration of CCR7+ cells, at the tumor margin and within the 
tumor stroma, with adverse prognostic factors such as increased age, advanced T 
and N stage and the presence of myosteatosis. These striking findings may therefore 
suggest that the presence of a LIR is not only influenced from tumour characteristics 
but also by the patient’s BC. A survival analysis was performed and despite the 
limited follow up and small number of patients, the presence of CCR7+ at the 
critical interface of the tumour margin was amongst the strongest survival prognostic 
factors. Additional work in this should continue in two fronts. First, efforts must be 
made to achieve consensus on the grading of the LIR in CRC patients and advances 
in the digital image analysis of the pathological sections may play a key role. Second , 
additional consideration must also be given to the underlying factors influencing the 
production of an effective immune response. One possibility is that modifying and 
restoring the mass and quality of the muscle may allow the balance between pro and 
anti – inflammatory tumour – derived cytokines, ease the SIR and enable a 
competent tumour “immunosurveillance”.  
In summary the work presented in this thesis results made apparent that cancer 
associated changes in patient’s BC and immune and inflammatory responses are 
complex. Muscle alongside with fat tissue may reflect an emerging and potentially 
modifiable factor that can improve outcome in CRC. 
Skeletal muscle is one of the most modifiable human tissues. Changes in skeletal 
muscle occur for numerous reasons combining physiological and metabolic 
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conditions. Although researchers and clinicians all use individual terminology to 
describe skeletal muscle mass depletion there is an overlap in the underlying 
multifactorial pathophysiology of these phenotype descriptions. To indicate the 
presence of clinically relevant muscle wasting irrespective of illness and age, Fearon 
proposed the term myopenia (mys in Greek is muscle) in 2011(K. Fearon, Evans, et 
al., 2011). Myopenia is clinically relevant muscle wasting that is associated either with 
impaired functional capacity and/or with increased morbidity or mortality risk. The 
precise cut-off points to define myopenia may be specific to a particular disease or 
condition. This thesis supports that myopenia is the term that fits reasonably in 
today’s medical terminology and through its clear definition can be used to raise 
awareness of its presence.  
Traditionally, controlling the progress of the cancer has been viewed as an 
appropriate method to contain myopenia. However the emerging possibilities of 
measuring the muscle tissue before and after treatment as this thesis showed, will 
stimulate the development of new treatment protocols. Appetite regulation and the 
level of physical activity are the major determinants of energy balance and BC 
changes.  It has been suggested that inflammatory mediators play a vital role in 
appetite regulation. In the majority of the patients, systemic inflammation leads to 
anorexia and fat loss in combination with myopenia. In others, appetite is sustained, 
despite activation of systemic inflammation, leading to the association of myopenia 
with increased BMI; a condition described as myopenic obesity. This broad 
phenotypic variability within the same disease needs careful tailoring of nutritional 
intervention. Protein intake should be increased in order to counteract the anabolic 
resistance associated with inflammation and inactivity (Guadagni & Biolo, 2009). Both 
endurance and resistance-type exercises are recommended especially in myopenic 
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obese patients to maintain skeletal muscle mass and functions. Rehabilitation 
medicine, with its focus on optimizing function despite a patient’s symptoms or 
impairments, involves strategies that may be beneficial in myopenic patients. 
However, it seems reasonable that obtaining optimal physical improvement before 
cancer treatment (prehabilitation) might produce better outcomes (K. C. Fearon et 
al., 2013). Aerobic and repetitive muscular exercise in patients has been proven to 
increase endurance capacity, improve muscle strength and range of motion in a 
number of joints. Studies on prehabilitation programmes show results in obtaining 
moderate gain in muscle reserve after a minimum time period of 3 weeks and this 
looks promising, being within time limitations of a cancer treatment protocol and 
targets (Valkenet et al., 2011).  
No commonly approved drug for the management of cancer myopenia is currently 
available. However, studies have suggested that steroid hormones can be effective in 
stimulating appetite with corticosteroids being more efficient. Cyclooxygenase 
inhibitors, including ibuprofen and indomethacin, moderate the SIR of the host and 
have been also tested with promising results in severely malnourished patients. 
Recent studies have identified (n-3) fatty acids (known to be competitive antagonists 
of arachidonic acid) as beneficial in improving the attenuation of lean body mass 
tissue. Thalidomide (TNF-a inhibitor), insulin or metformin  (decrease of the 
catabolic phase) are amongst other drugs gaining interest from an antimyopenia 
viewpoint.(K. Fearon et al., 2013)  
Results form this thesis made it clear that a variety of BC changes occur in CRC and 
that myopenia is a common and for most an occult feature. Myopenia is a 
multidimensional condition imposing a significant economic burden on healthcare but 
currently we not only have reliable diagnostic tools for its identification but also 
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promising new treatments to modify it. Cancer care is shifting from disease-focused 
management to a more patient–centred approach. Measuring and reporting quality of 
care drives refinement and an ideal quality improvement framework should be 
primarily based on the structure, process and outcome of care, an updated cancer 
pathway that considers muscle monitoring is therefore important.  
 
This thesis suggests that the maintenance of muscle mass in addition to the excess of 
adiposity needs to be targeted as a relevant endpoint of health recommendations. To 
implement optimal multimodal management of myopenia in cancer patients the 
following items are required: first, awareness about the impact of muscle deficits; 
second, expertise to recognize and monitor relevant defects; third, knowledge about 
the relevant treatment options; and, fourth, an ability to implement treatment 
options. The development of a multimodal package incorporating novel therapeutics 
promises to bring a new era in the holistic care of cancer patients.  
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